reference_id,authors,title,journal,year,volume,citation_footer,citation_type,citation,urls,pubmed_id,doi,header,reference_type,study_id,exclusion_reason,PUBMED_ID_TITLE_AUTHORS,PUBMED_ID_TITLE,PUBMED_ID_S2,N_CITATIONS,S2_PDF_LINK,CORE_PDF_LINK,PUBMED_ID
CD010254-bib-0001,"Agouridis AP, Tsimihodimos V, Filippatos TD, Dimitriou AA, Tellis Costantinos C, Elisaf MS, et al. ",The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia, Expert Opinion on Pharmacotherapy ,2011,12,    ,['citation-journal']," Agouridis AP, Tsimihodimos V, Filippatos TD, Dimitriou AA, Tellis Costantinos C, Elisaf MS, et al. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.  Expert Opinion on Pharmacotherapy 2011;12(17):2605‐11. [MEDLINE: 21714585]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1517/14656566.2011.591383', 'https://www.ncbi.nlm.nih.gov/pubmed/21714585', 'https://scholar.google.com/scholar_lookup?title=The+effects+of+rosuvastatin+alone+or+in+combination+with+fenofibrate+or+omega+3+fatty+acids+on+inflammation+and+oxidative+stress+in+patients+with+mixed+dyslipidemia+&author=AP+Agouridis&author=V+Tsimihodimos&author=TD+Filippatos&author=AA+Dimitriou&author=C+TellisCostantinos&author=MS+Elisaf&publication_year=2011&hl=en']",21714585,https://doi.org/10.1517/14656566.2011.591383, Agouridis 2011 {published data only}  ,included,CD010254-bbs2-0001,,,,21714585,32.0,,,21714585
CD010254-bib-0002,"Agouridis AP, Tsimihodimos V, Filippatos TD, Tselepis AD, Elisaf MS. ",High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n‐3 fatty acids in mixed dyslipidemia, Lipids ,2011,46,    ,['citation-journal']," Agouridis AP, Tsimihodimos V, Filippatos TD, Tselepis AD, Elisaf MS. High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n‐3 fatty acids in mixed dyslipidemia.  Lipids 2011;46(6):521‐8. [MEDLINE: 21327725]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1007/s11745-011-3538-0', 'https://www.ncbi.nlm.nih.gov/pubmed/21327725', 'https://scholar.google.com/scholar_lookup?title=High+doses+of+rosuvastatin+are+superior+to+low+doses+of+rosuvastatin+plus+fenofibrate+or+n‐3+fatty+acids+in+mixed+dyslipidemia+&author=AP+Agouridis&author=V+Tsimihodimos&author=TD+Filippatos&author=AD+Tselepis&author=MS+Elisaf&publication_year=2011&hl=en']",21327725,https://doi.org/10.1007/s11745-011-3538-0, Agouridis 2011 {published data only}  ,included,CD010254-bbs2-0001,,21714585,,21327725,21.0,,,21327725
CD010254-bib-0003,"Andreou I, Tousoulis D, Miliou A, Tentolouris C, Zisimos K, Gounari P, et al. ",Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: A randomized placebo‐controlled study, Atherosclerosis ,2010,210,    ,['citation-journal']," Andreou I, Tousoulis D, Miliou A, Tentolouris C, Zisimos K, Gounari P, et al. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: A randomized placebo‐controlled study.  Atherosclerosis 2010;210(1):194‐8. [MEDLINE: 19962701]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.atherosclerosis.2009.10.046', 'https://www.ncbi.nlm.nih.gov/pubmed/19962701', 'https://scholar.google.com/scholar_lookup?title=Effects+of+rosuvastatin+on+myeloperoxidase+levels+in+patients+with+chronic+heart+failure:+A+randomized+placebo‐controlled+study+&author=I+Andreou&author=D+Tousoulis&author=A+Miliou&author=C+Tentolouris&author=K+Zisimos&author=P+Gounari&publication_year=2010&hl=en']",19962701,https://doi.org/10.1016/j.atherosclerosis.2009.10.046, Andreou 2010 {published data only}  ,included,CD010254-bbs2-0002,,,19962701,19962701,57.0,,,19962701
CD010254-bib-0004,"Tousoulis D, Andreou I, Tentolouris C, Antoniades C, Papageorgiou N, Gounari P, et al. ",Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure, International Journal of Cardiology ,2010,145,    ,['citation-journal']," Tousoulis D, Andreou I, Tentolouris C, Antoniades C, Papageorgiou N, Gounari P, et al. Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure.  International Journal of Cardiology 2010;145(3):438‐43. [MEDLINE: 19539384]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ijcard.2009.05.051', 'https://www.ncbi.nlm.nih.gov/pubmed/19539384', 'https://scholar.google.com/scholar_lookup?title=Comparative+effects+of+rosuvastatin+and+allopurinol+on+circulating+levels+of+matrix+metalloproteinases+and+tissue+inhibitors+of+metalloproteinases+in+patients+with+chronic+heart+failure+&author=D+Tousoulis&author=I+Andreou&author=C+Tentolouris&author=C+Antoniades&author=N+Papageorgiou&author=P+Gounari&publication_year=2010&hl=en']",19539384,https://doi.org/10.1016/j.ijcard.2009.05.051, Andreou 2010 {published data only}  ,included,CD010254-bbs2-0002,,,19539384,19539384,21.0,,,19539384
CD010254-bib-0005,"Tousoulis D, Andreou I, Tsiatas M, Miliou A, Tentolouris C, Siasos G, et al. ",Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: The impact of inflammatory process and oxidative stress, Atherosclerosis ,2011,214,    ,['citation-journal']," Tousoulis D, Andreou I, Tsiatas M, Miliou A, Tentolouris C, Siasos G, et al. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: The impact of inflammatory process and oxidative stress.  Atherosclerosis 2011;214(1):151‐7. [MEDLINE: 21122851]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.atherosclerosis.2010.11.002', 'https://www.ncbi.nlm.nih.gov/pubmed/21122851', 'https://scholar.google.com/scholar_lookup?title=Effects+of+rosuvastatin+and+allopurinol+on+circulating+endothelial+progenitor+cells+in+patients+with+congestive+heart+failure:+The+impact+of+inflammatory+process+and+oxidative+stress+&author=D+Tousoulis&author=I+Andreou&author=M+Tsiatas&author=A+Miliou&author=C+Tentolouris&author=G+Siasos&publication_year=2011&hl=en']",21122851,https://doi.org/10.1016/j.atherosclerosis.2010.11.002, Andreou 2010 {published data only}  ,included,CD010254-bbs2-0002,,,21122851,21122851,73.0,,,21122851
CD010254-bib-0006,"Betteridge DJ, Gibson J, Sager PT. ",Comparison of effectiveness of Rosuvastatin versus Atorvastatin on the achievement of combined c‐reactive protein (< 2 mg/L) and low‐density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes Mellitus (from the ANDROMEDA study), American Journal of Cardiology ,2007,100,    ,['citation-journal']," Betteridge DJ, Gibson J, Sager PT. Comparison of effectiveness of Rosuvastatin versus Atorvastatin on the achievement of combined c‐reactive protein (< 2 mg/L) and low‐density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes Mellitus (from the ANDROMEDA study).  American Journal of Cardiology 2007;100(8):1245‐8. [MEDLINE: 17920365]CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/17920365', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+effectiveness+of+Rosuvastatin+versus+Atorvastatin+on+the+achievement+of+combined+c‐reactive+protein+(<+2+mg/L)+and+low‐density+lipoprotein+cholesterol+(<+70+mg/dl)+targets+in+patients+with+type+2+diabetes+Mellitus+(from+the+ANDROMEDA+study)+&author=DJ+Betteridge&author=J+Gibson&author=PT+Sager&publication_year=2007&hl=en']",17920365,, ANDROMEDA 2007 {published data only}  ,included,CD010254-bbs2-0003,,17920365,17920365,,,,,17920365
CD010254-bib-0007,"Betteridge DJ, Gibson JM. ","Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes", Diabetic Medicine ,2007,24,    ,['citation-journal']," Betteridge DJ, Gibson JM. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.  Diabetic Medicine 2007;24(5):541‐9. [MEDLINE: 17367312]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1111/j.1464-5491.2007.02095.x', 'https://www.ncbi.nlm.nih.gov/pubmed/17367312', 'https://scholar.google.com/scholar_lookup?title=Effects+of+rosuvastatin+on+lipids,+lipoproteins+and+apolipoproteins+in+the+dyslipidaemia+of+diabetes+&author=DJ+Betteridge&author=JM+Gibson&publication_year=2007&hl=en']",17367312,https://doi.org/10.1111/j.1464-5491.2007.02095.x, ANDROMEDA 2007 {published data only}  ,included,CD010254-bbs2-0003,,17367312,,17367312,42,,,17367312
CD010254-bib-0008,AstraZeneca. ,"A 6‐week, randomized, open‐label, comparative study to evaluate the efficacy and safety of rosuvastatin versus atorvastatin in the treatment of hypercholesterolaemia in African American subjects. (ARIES)",,,,   ,['citation-other']," AstraZeneca. A 6‐week, randomized, open‐label, comparative study to evaluate the efficacy and safety of rosuvastatin versus atorvastatin in the treatment of hypercholesterolaemia in African American subjects. (ARIES). http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/D3560L00022 (accessed 07 July 2004). [Study code D3560L00022/4522US0002]CENTRAL    ",[''],,, ARIES 2006 {published data only}  ,included,CD010254-bbs2-0004,,,,,,,,
CD010254-bib-0009,"Ferdinand KC, Clark LT, Watson KE, Neal RC, Brown CD, Kong BW, et al. ",Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African‐American patients in a six‐week trial, American Journal of Cardiology ,2006,97,    ,['citation-journal']," Ferdinand KC, Clark LT, Watson KE, Neal RC, Brown CD, Kong BW, et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African‐American patients in a six‐week trial.  American Journal of Cardiology 2006;97(2):229‐35. [MEDLINE: 16442368]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.amjcard.2005.08.026', 'https://www.ncbi.nlm.nih.gov/pubmed/16442368', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+efficacy+and+safety+of+rosuvastatin+versus+atorvastatin+in+African‐American+patients+in+a+six‐week+trial+&author=KC+Ferdinand&author=LT+Clark&author=KE+Watson&author=RC+Neal&author=CD+Brown&author=BW+Kong&publication_year=2006&hl=en']",16442368,https://doi.org/10.1016/j.amjcard.2005.08.026, ARIES 2006 {published data only}  ,included,CD010254-bbs2-0004,,,,16442368,73,,,16442368
CD010254-bib-0010,"Fonseca FA, Izar MCO, Silva MA, Karapanos A, Schuster H, Singh D. ",Rosuvastatin may be more effective than atorvastatin in African‐Americans with hypercholesterolemia, Evidence‐based Cardiovascular Medicine ,2006,10,    ,['citation-journal']," Fonseca FA, Izar MCO, Silva MA, Karapanos A, Schuster H, Singh D. Rosuvastatin may be more effective than atorvastatin in African‐Americans with hypercholesterolemia.  Evidence‐based Cardiovascular Medicine 2006;10(2):96‐100. [MEDLINE: 16753506]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ebcm.2006.04.017', 'https://www.ncbi.nlm.nih.gov/pubmed/16753506', 'https://scholar.google.com/scholar_lookup?title=Rosuvastatin+may+be+more+effective+than+atorvastatin+in+African‐Americans+with+hypercholesterolemia&author=FA+Fonseca&author=MCO+Izar&author=MA+Silva&author=A+Karapanos&author=H+Schuster&author=D+Singh&publication_year=2006&hl=en']",16753506,https://doi.org/10.1016/j.ebcm.2006.04.017, ARIES 2006 {published data only}  ,included,CD010254-bbs2-0004,,16753506,16753506,16753506,1,,,16753506
CD010254-bib-0011,AstraZeneca. ,"A randomised, double‐blind trial to compare the efficacy of rosuvastatin 5 and 10 mg to atorvastatin 10 mg in the treatment of high risk patients with hypercholesterolemia followed by an open label treatment period with rosuvastatin up‐titrated to the maximum dose of 20 mg for those patients who do not achieve goal",,,,   ,['citation-other']," AstraZeneca. A randomised, double‐blind trial to compare the efficacy of rosuvastatin 5 and 10 mg to atorvastatin 10 mg in the treatment of high risk patients with hypercholesterolemia followed by an open label treatment period with rosuvastatin up‐titrated to the maximum dose of 20 mg for those patients who do not achieve goal. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/D356FC00007 (accessed 02 June 2010). [Study code D356FC00007]CENTRAL    ",[''],,, AstraZeneca 2010a {published data only}  ,included,CD010254-bbs2-0005,,,,,,,,
CD010254-bib-0012,ClinicalTrials.gov. ,Compare the efficacy of rosuvastatin to atorvastatin in high risk patients with yypercholesterolemia,,,,   ,['citation-other'], ClinicalTrials.gov. Compare the efficacy of rosuvastatin to atorvastatin in high risk patients with yypercholesterolemia. http://www.clinicaltrials.gov/ct2/show/results/NCT00683618?term‐D356FC00007&rank=1&sect=X0125#all (accessed 09 July 2010). [Study code NCT00683618]CENTRAL    ,[''],,, AstraZeneca 2010a {published data only}  ,included,CD010254-bbs2-0005,,28836458,,,,,,28836458
CD010254-bib-0013,AstraZeneca. ,"A double blind, double dummy, phase IV, randomized, multicenter, parallel group, placebo control trial to evaluate the effect of rosuvastatin on triglycerides levels in Mexican hypertriglyceridemic patients",,,,   ,['citation-other']," AstraZeneca. A double blind, double dummy, phase IV, randomized, multicenter, parallel group, placebo control trial to evaluate the effect of rosuvastatin on triglycerides levels in Mexican hypertriglyceridemic patients. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/D3560L00075 (accessed 28 March 2010). [Study code DM‐CRESTOR‐0002/D3560L00075]CENTRAL    ",[''],,, AstraZeneca 2010b {published data only}  ,included,CD010254-bbs2-0006,,,,,,,,
CD010254-bib-0014,ClinicalTrials.gov. ,Effect of rosuvastatin on triglyceride levels in Mexican hypertriglyceridemic patients,,,,   ,['citation-other'], ClinicalTrials.gov. Effect of rosuvastatin on triglyceride levels in Mexican hypertriglyceridemic patients. http://clinicaltrials.gov/ct2/show/results/NCT00473655?sect=X43da987601 (accessed 10 May 2010). [ Study code NCT00473655]CENTRAL    ,[''],,, AstraZeneca 2010b {published data only}  ,included,CD010254-bbs2-0006,,23323877,,,,,,23323877
CD010254-bib-0015,"Yamazaki T, Kurabayashi M, ASTRO‐2 Study Group. ",A randomized controlled study to compare the effect of rosuvastatin 5mg with atorvastatin 10mg on plasma lipids in Japanese patients with hypercholesterolemia (ASTRO‐2), Annals of Vascular Diseases ,2009,2,    ,['citation-journal']," Yamazaki T, Kurabayashi M, ASTRO‐2 Study Group. A randomized controlled study to compare the effect of rosuvastatin 5mg with atorvastatin 10mg on plasma lipids in Japanese patients with hypercholesterolemia (ASTRO‐2).  Annals of Vascular Diseases 2009;2(3):159‐73. [PUBMED: 23555376]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.3400/avd.oa090019', 'https://www.ncbi.nlm.nih.gov/pubmed/23555376', 'https://scholar.google.com/scholar_lookup?title=A+randomized+controlled+study+to+compare+the+effect+of+rosuvastatin+5mg+with+atorvastatin+10mg+on+plasma+lipids+in+Japanese+patients+with+hypercholesterolemia+(ASTRO‐2)+&author=T+Yamazaki&author=M+Kurabayashi&publication_year=2009&hl=en']",23555376,https://doi.org/10.3400/avd.oa090019, ASTRO‐2 2009 {published data only}  ,included,CD010254-bbs2-0007,,,,,,,,23555376
CD010254-bib-0016,"Capoulade R, Clavel MA, Dumesnil JG, Chan KL, Teo KK, Tam JW, et al. ",Impact of metabolic syndrome on progression of aortic stenosis: influence of age and statin therapy, Journal of the American College of Cardiology ,2012,60,    ,['citation-journal']," Capoulade R, Clavel MA, Dumesnil JG, Chan KL, Teo KK, Tam JW, et al. Impact of metabolic syndrome on progression of aortic stenosis: influence of age and statin therapy.  Journal of the American College of Cardiology 2012;60(3):216‐23. [MEDLINE: 22789885]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.jacc.2012.03.052', 'https://www.ncbi.nlm.nih.gov/pubmed/22789885', 'https://scholar.google.com/scholar_lookup?title=Impact+of+metabolic+syndrome+on+progression+of+aortic+stenosis:+influence+of+age+and+statin+therapy+&author=R+Capoulade&author=MA+Clavel&author=JG+Dumesnil&author=KL+Chan&author=KK+Teo&author=JW+Tam&publication_year=2012&hl=en']",22789885,https://doi.org/10.1016/j.jacc.2012.03.052, ASTRONOMER 2010 {published data only}  ,included,CD010254-bbs2-0008,,,22789885,22789885,114,https://doi.org/10.1016/j.jacc.2012.03.052,,22789885
CD010254-bib-0017,"Capoulade R, Clavel MA, Dumesnil JG, Chan KL, Teo KK, Tam JW, et al. ",Insulin resistance and LVH progression in patients with calcific aortic stenosis: a substudy of the ASTRONOMER trial, JACC. Cardiovascular Imaging ,2013,6,    ,['citation-journal']," Capoulade R, Clavel MA, Dumesnil JG, Chan KL, Teo KK, Tam JW, et al. Insulin resistance and LVH progression in patients with calcific aortic stenosis: a substudy of the ASTRONOMER trial.  JACC. Cardiovascular Imaging 2013;6(2):165‐74. [MEDLINE: 23489530]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.jcmg.2012.11.004', 'https://www.ncbi.nlm.nih.gov/pubmed/23489530', 'https://scholar.google.com/scholar_lookup?title=Insulin+resistance+and+LVH+progression+in+patients+with+calcific+aortic+stenosis:+a+substudy+of+the+ASTRONOMER+trial+&author=R+Capoulade&author=MA+Clavel&author=JG+Dumesnil&author=KL+Chan&author=KK+Teo&author=JW+Tam&publication_year=2013&hl=en']",23489530,https://doi.org/10.1016/j.jcmg.2012.11.004, ASTRONOMER 2010 {published data only}  ,included,CD010254-bbs2-0008,,,23489530,,38,https://doi.org/10.1016/j.jcmg.2012.11.004,,23489530
CD010254-bib-0018,"Chan K‐L, Teo K, Tam J, Dumesnil JG. ","Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis. The Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial", American Heart Journal ,2007,153,    ,['citation-journal']," Chan K‐L, Teo K, Tam J, Dumesnil JG. Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis. The Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial.  American Heart Journal 2007;153(6):925‐31. [MEDLINE: 17540192]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ahj.2007.03.011', 'https://www.ncbi.nlm.nih.gov/pubmed/17540192', 'https://scholar.google.com/scholar_lookup?title=Rationale,+design,+and+baseline+characteristics+of+a+randomized+trial+to+assess+the+effect+of+cholesterol+lowering+on+the+progression+of+aortic+stenosis.+The+Aortic+Stenosis+Progression+Observation:+Measuring+Effects+of+Rosuvastatin+(ASTRONOMER)+trial+&author=K‐L+Chan&author=K+Teo&author=J+Tam&author=JG+Dumesnil&publication_year=2007&hl=en']",17540192,https://doi.org/10.1016/j.ahj.2007.03.011, ASTRONOMER 2010 {published data only}  ,included,CD010254-bbs2-0008,,17540192,17540192,17540192,55,,,17540192
CD010254-bib-0019,"Chan KL, Dumesnil JG, Tam J, Ni A, Teo K. ",Effect of rosuvastatin on C‐reactive protein and progression of aortic stenosis, American Heart Journal ,2011,161,    ,['citation-journal']," Chan KL, Dumesnil JG, Tam J, Ni A, Teo K. Effect of rosuvastatin on C‐reactive protein and progression of aortic stenosis.  American Heart Journal 2011;161(6):1133‐9. [MEDLINE: 21641360]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ahj.2011.03.016', 'https://www.ncbi.nlm.nih.gov/pubmed/21641360', 'https://scholar.google.com/scholar_lookup?title=Effect+of+rosuvastatin+on+C‐reactive+protein+and+progression+of+aortic+stenosis&author=KL+Chan&author=JG+Dumesnil&author=J+Tam&author=A+Ni&author=K+Teo&publication_year=2011&hl=en']",21641360,https://doi.org/10.1016/j.ahj.2011.03.016, ASTRONOMER 2010 {published data only}  ,included,CD010254-bbs2-0008,,21641360,21641360,21641360,23,,,21641360
CD010254-bib-0020,"Chan KL, Teo K, Dumesnil JG, Ni A, ASTRONOMER Study Group. ",Effect of lipid lowering with rosuvastatin on progression of aortic stenosis results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial, Circulation ,2010,121,    ,['citation-journal']," Chan KL, Teo K, Dumesnil JG, Ni A, ASTRONOMER Study Group. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial.  Circulation 2010;121(2):306‐14. [MEDLINE: 20048204]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1161/CIRCULATIONAHA.109.900027', 'https://www.ncbi.nlm.nih.gov/pubmed/20048204', 'https://scholar.google.com/scholar_lookup?title=Effect+of+lipid+lowering+with+rosuvastatin+on+progression+of+aortic+stenosis+results+of+the+Aortic+Stenosis+Progression+Observation:+Measuring+Effects+of+Rosuvastatin+(ASTRONOMER)+Trial+&author=KL+Chan&author=K+Teo&author=JG+Dumesnil&author=A+Ni&publication_year=2010&hl=en']",20048204,https://doi.org/10.1161/CIRCULATIONAHA.109.900027, ASTRONOMER 2010 {published data only}  ,included,CD010254-bbs2-0008,,,,20048204,747,https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.109.900027,,20048204
CD010254-bib-0021,ClinicalTrials.gov. ,Effect of cholesterol lowering on the progression of aortic stenosis in patients with mild to moderate aortic stenosis (ASTRONOMER) Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin and the sub‐study protocol,,,,   ,['citation-other'], ClinicalTrials.gov. Effect of cholesterol lowering on the progression of aortic stenosis in patients with mild to moderate aortic stenosis (ASTRONOMER) Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin and the sub‐study protocol. http://clinicaltrials.gov/show/NCT00800800 (accessed 25 November 2008). [ Study code NCT00800800]CENTRAL    ,[''],,, ASTRONOMER 2010 {published data only}  ,included,CD010254-bbs2-0008,,,,,,,,
CD010254-bib-0022,"Jassal DS, Bhagirath KM, Karlstedt E, Zeglinski M, Dumesnil JG, Teo KK, et al. ",Evaluating the effectiveness of rosuvastatin in preventing the progression of diastolic dysfunction in aortic stenosis: A substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study, Cardiovascular Ultrasound ,2011,9,    ,['citation-journal']," Jassal DS, Bhagirath KM, Karlstedt E, Zeglinski M, Dumesnil JG, Teo KK, et al. Evaluating the effectiveness of rosuvastatin in preventing the progression of diastolic dysfunction in aortic stenosis: A substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study.  Cardiovascular Ultrasound 2011;9(1):5. [MEDLINE: 21299902]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1186/1476-7120-9-5', 'https://www.ncbi.nlm.nih.gov/pubmed/21299902', 'https://scholar.google.com/scholar_lookup?title=Evaluating+the+effectiveness+of+rosuvastatin+in+preventing+the+progression+of+diastolic+dysfunction+in+aortic+stenosis:+A+substudy+of+the+aortic+stenosis+progression+observation+measuring+effects+of+rosuvastatin+(ASTRONOMER)+study+&author=DS+Jassal&author=KM+Bhagirath&author=E+Karlstedt&author=M+Zeglinski&author=JG+Dumesnil&author=KK+Teo&publication_year=2011&hl=en']",21299902,https://doi.org/10.1186/1476-7120-9-5, ASTRONOMER 2010 {published data only}  ,included,CD010254-bbs2-0008,,,21299902,21299902,3,https://cardiovascularultrasound.biomedcentral.com/counter/pdf/10.1186/1476-7120-9-5,,21299902
CD010254-bib-0023,"Jassal DS, Bhagirath KM, Tam JW, Sochowski RA, Dumesnil JG, Giannoccaro PJ, et al. ",Association of bicuspid aortic valve morphology and aortic root dimensions: A substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study, Echocardiography ,2010,27,    ,['citation-journal']," Jassal DS, Bhagirath KM, Tam JW, Sochowski RA, Dumesnil JG, Giannoccaro PJ, et al. Association of bicuspid aortic valve morphology and aortic root dimensions: A substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study.  Echocardiography 2010;27(2):174‐9. [MEDLINE: 19725842]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1111/j.1540-8175.2009.00993.x', 'https://www.ncbi.nlm.nih.gov/pubmed/19725842', 'https://scholar.google.com/scholar_lookup?title=Association+of+bicuspid+aortic+valve+morphology+and+aortic+root+dimensions:+A+substudy+of+the+aortic+stenosis+progression+observation+measuring+effects+of+rosuvastatin+(ASTRONOMER)+study+&author=DS+Jassal&author=KM+Bhagirath&author=JW+Tam&author=RA+Sochowski&author=JG+Dumesnil&author=PJ+Giannoccaro&publication_year=2010&hl=en']",19725842,https://doi.org/10.1111/j.1540-8175.2009.00993.x, ASTRONOMER 2010 {published data only}  ,included,CD010254-bbs2-0008,,,19725842,19725842,30,https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1540-8175.2009.00993.x,,19725842
CD010254-bib-0024,"Jassal DS, Tam JW, Dumesnil JG, Giannoccaro PJ, Jue J, Pandey AS, et al. ",Clinical usefulness of tissue doppler imaging in patients with mild to moderate aortic stenosis: a substudy of the aortic stenosis progression observation measuring effects of rosuvastatin study, Journal of the American Society of Echocardiography ,2008,21,    ,['citation-journal']," Jassal DS, Tam JW, Dumesnil JG, Giannoccaro PJ, Jue J, Pandey AS, et al. Clinical usefulness of tissue doppler imaging in patients with mild to moderate aortic stenosis: a substudy of the aortic stenosis progression observation measuring effects of rosuvastatin study.  Journal of the American Society of Echocardiography 2008;21(9):1023‐7. [MEDLINE: 18406575]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.echo.2008.02.014', 'https://www.ncbi.nlm.nih.gov/pubmed/18406575', 'https://scholar.google.com/scholar_lookup?title=Clinical+usefulness+of+tissue+doppler+imaging+in+patients+with+mild+to+moderate+aortic+stenosis:+a+substudy+of+the+aortic+stenosis+progression+observation+measuring+effects+of+rosuvastatin+study+&author=DS+Jassal&author=JW+Tam&author=JG+Dumesnil&author=PJ+Giannoccaro&author=J+Jue&author=AS+Pandey&publication_year=2008&hl=en']",18406575,https://doi.org/10.1016/j.echo.2008.02.014, ASTRONOMER 2010 {published data only}  ,included,CD010254-bbs2-0008,,,18406575,18406575,21,,,18406575
CD010254-bib-0025,"Jassal Davinder S, Tam James W, Bhagirath Kapil M, Gaboury Isabelle, Sochowski Randall A, Dumesnil Jean G, et al. ",Association of mitral annular calcification and aortic valve morphology: a substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study, European Heart Journal ,2008,29,    ,['citation-journal']," Jassal Davinder S, Tam James W, Bhagirath Kapil M, Gaboury Isabelle, Sochowski Randall A, Dumesnil Jean G, et al. Association of mitral annular calcification and aortic valve morphology: a substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study.  European Heart Journal 2008;29(12):1542‐7. [MEDLINE: 18443031]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1093/eurheartj/ehn172', 'https://www.ncbi.nlm.nih.gov/pubmed/18443031', 'https://scholar.google.com/scholar_lookup?title=Association+of+mitral+annular+calcification+and+aortic+valve+morphology:+a+substudy+of+the+aortic+stenosis+progression+observation+measuring+effects+of+rosuvastatin+(ASTRONOMER)+study+&author=S+JassalDavinder&author=W+TamJames&author=M+BhagirathKapil&author=Isabelle+Gaboury&author=A+SochowskiRandall&author=G+DumesnilJean&publication_year=2008&hl=en']",18443031,https://doi.org/10.1093/eurheartj/ehn172, ASTRONOMER 2010 {published data only}  ,included,CD010254-bbs2-0008,,,,18443031,52,https://academic.oup.com/eurheartj/article-pdf/29/12/1542/1793123/ehn172.pdf,,18443031
CD010254-bib-0026,"Page A, Dumesnil JG, Clavel MA, Chan KL, Teo KK, Tam JW, ASTRONOMER Study Group. ",Metabolic syndrome is associated with more pronounced impairment of left ventricle geometry and function in patients with calcific aortic stenosis: a substudy of the ASTRONOMER (Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin), Journal of the American College of Cardiology ,2010,55,    ,['citation-journal']," Page A, Dumesnil JG, Clavel MA, Chan KL, Teo KK, Tam JW, ASTRONOMER Study Group. Metabolic syndrome is associated with more pronounced impairment of left ventricle geometry and function in patients with calcific aortic stenosis: a substudy of the ASTRONOMER (Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin).  Journal of the American College of Cardiology 2010;55(17):1867‐74. [MEDLINE: 20413039]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.jacc.2009.11.083', 'https://www.ncbi.nlm.nih.gov/pubmed/20413039', 'https://scholar.google.com/scholar_lookup?title=Metabolic+syndrome+is+associated+with+more+pronounced+impairment+of+left+ventricle+geometry+and+function+in+patients+with+calcific+aortic+stenosis:+a+substudy+of+the+ASTRONOMER+(Aortic+Stenosis+Progression+Observation+Measuring+Effects+of+Rosuvastatin)+&author=A+Page&author=JG+Dumesnil&author=MA+Clavel&author=KL+Chan&author=KK+Teo&author=JW+Tam&publication_year=2010&hl=en']",20413039,https://doi.org/10.1016/j.jacc.2009.11.083, ASTRONOMER 2010 {published data only}  ,included,CD010254-bbs2-0008,,,20413039,20413039,103,https://doi.org/10.1016/j.jacc.2009.11.083,,20413039
CD010254-bib-0027,"Milionis HJ, Rizos E, Kostapanos M, Filippatos TD, Elisaf MS. ",Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study), Current Medical Research & Opinion ,2006,22,    ,['citation-journal']," Milionis HJ, Rizos E, Kostapanos M, Filippatos TD, Elisaf MS. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study).  Current Medical Research & Opinion 2006;22(6):1123‐31. [MEDLINE: 16846545]CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1185/030079906X112462', 'https://scholar.google.com/scholar_lookup?title=Treating+to+target+patients+with+primary+hyperlipidaemia:+comparison+of+the+effects+of+ATOrvastatin+and+ROSuvastatin+(the+ATOROS+study)+&author=HJ+Milionis&author=E+Rizos&author=M+Kostapanos&author=TD+Filippatos&author=MS+Elisaf&publication_year=2006&hl=en']",,https://doi.org/10.1185/030079906X112462, ATOROS 2006 {published data only}  ,included,CD010254-bbs2-0009,,16846545,16846545,16846545,74,,,16846545
CD010254-bib-0028,"Ballantyne CM, Stein EA, Paoletti R, Southworth H, Blasetto JW, Barter P, et al. ",Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome, American Journal of Cardiology ,2003,91 Suppl 1,    ,['citation-journal']," Ballantyne CM, Stein EA, Paoletti R, Southworth H, Blasetto JW, Barter P, et al. Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome.  American Journal of Cardiology 2003;91 Suppl 1(5):25C‐28C. [MEDLINE: 12646342]CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/S0002-9149(03)00006-7', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+rosuvastatin+10+mg+in+patients+with+the+metabolic+syndrome&author=CM+Ballantyne&author=EA+Stein&author=R+Paoletti&author=H+Southworth&author=JW+Blasetto&author=P+Barter&publication_year=2003&hl=en']",,https://doi.org/10.1016/S0002-9149(03)00006-7, Ballantyne 2003 {published data only}  ,included,CD010254-bbs2-0010,,,,12646342,45,,,12646342
CD010254-bib-0029,"Ballantyne CM, Miller E, Chitra R. ","Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: A randomized, open‐label, multicenter trial", Clinical Therapeutics ,2004,26,    ,['citation-journal']," Ballantyne CM, Miller E, Chitra R. Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: A randomized, open‐label, multicenter trial.  Clinical Therapeutics 2004;26(11):1855‐64. [MEDLINE: 15639697]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.clinthera.2004.11.001', 'https://www.ncbi.nlm.nih.gov/pubmed/15639697', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+rosuvastatin+alone+and+in+combination+with+cholestyramine+in+patients+with+severe+hypercholesterolemia:+A+randomized,+open‐label,+multicenter+trial+&author=CM+Ballantyne&author=E+Miller&author=R+Chitra&publication_year=2004&hl=en']",15639697,https://doi.org/10.1016/j.clinthera.2004.11.001, Ballantyne 2004 {published data only}  ,included,CD010254-bbs2-0011,,15639697,15639697,15639697,26,,,15639697
CD010254-bib-0030,"Bellia A, Rizza S, Galli A, Fabiano R, Donadel G, Lombardo MF, et al. ",Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes, Atherosclerosis ,2010,210,    ,['citation-journal']," Bellia A, Rizza S, Galli A, Fabiano R, Donadel G, Lombardo MF, et al. Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes.  Atherosclerosis 2010;210(1):199‐201. [MEDLINE: 20018286]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.atherosclerosis.2009.11.021', 'https://www.ncbi.nlm.nih.gov/pubmed/20018286', 'https://scholar.google.com/scholar_lookup?title=Early+vascular+and+metabolic+effects+of+rosuvastatin+compared+with+simvastatin+in+patients+with+type+2+diabetes+&author=A+Bellia&author=S+Rizza&author=A+Galli&author=R+Fabiano&author=G+Donadel&author=MF+Lombardo&publication_year=2010&hl=en']",20018286,https://doi.org/10.1016/j.atherosclerosis.2009.11.021, Bellia 2010 {published data only}  ,included,CD010254-bbs2-0012,,,20018286,20018286,43,,,20018286
CD010254-bib-0031,"Briseno GG, Mino‐Leon D. ",Cost‐effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico, Current Medical Research and Opinion ,2010,26,    ,['citation-journal']," Briseno GG, Mino‐Leon D. Cost‐effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico.  Current Medical Research and Opinion 2010;26(5):1075‐81. [MEDLINE: 20225991]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1185/03007991003694498', 'https://www.ncbi.nlm.nih.gov/pubmed/20225991', 'https://scholar.google.com/scholar_lookup?title=Cost‐effectiveness+of+rosuvastatin+versus+ezetimibe/simvastatin+in+managing+dyslipidemic+patients+in+Mexico+&author=GG+Briseno&author=D+Mino‐Leon&publication_year=2010&hl=en']",20225991,https://doi.org/10.1185/03007991003694498, Briseno 2010 {published data only}  ,included,CD010254-bbs2-0013,,20225991,20225991,20225991,4,,,20225991
CD010254-bib-0032,AstraZeneca. ,"A randomized, double‐blind, multicenter trial to compare the short‐term and long‐term efficacy and safety of ZD4522 5 and 10 mg, simvastatin 20 mg, and pravastatin 20 mg in the treatment of subjects with hypercholesterolemia",,,,   ,['citation-other']," AstraZeneca. A randomized, double‐blind, multicenter trial to compare the short‐term and long‐term efficacy and safety of ZD4522 5 and 10 mg, simvastatin 20 mg, and pravastatin 20 mg in the treatment of subjects with hypercholesterolemia. http://astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/9256721 (accessed 30 March 2001). [ Study code 4522IL/0028]CENTRAL    ",[''],,, Brown 2002 {published data only}  ,included,CD010254-bbs2-0014,,,,,,,,
CD010254-bib-0033,"Benner JS, Smith TW, Klingman D, Tierce JC, Mullins CD, Pethick N, et al. ",Cost‐effectiveness of rosuvastatin compared with other statins from a managed care perspective,,2005,,    ,['citation-other']," Benner JS, Smith TW, Klingman D, Tierce JC, Mullins CD, Pethick N, et al. Cost‐effectiveness of rosuvastatin compared with other statins from a managed care perspective. Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research. United States: ValueMedics Research, LLC, Arlington, VA, and University of Maryland, Baltimore, MD, USA. [email protected], 2005; Vol. 8, issue 6:618‐28. [MEDLINE: 16283862]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Cost‐effectiveness+of+rosuvastatin+compared+with+other+statins+from+a+managed+care+perspective+&author=JS+Benner&author=TW+Smith&author=D+Klingman&author=JC+Tierce&author=CD+Mullins&author=N+Pethick&publication_year=2005&hl=en']",,, Brown 2002 {published data only}  ,included,CD010254-bbs2-0014,,,16283862,,,,,16283862
CD010254-bib-0034,"Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A. ",Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups,,2003,,    ,['citation-other']," Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. American Journal of Cardiology. United States: AstraZeneca LP, Wilmington, Delaware 19850, USA. [email protected], 2003; Vol. 91, issue 5A:3C‐10C. [MEDLINE: 12646336]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+rosuvastatin+compared+with+other+statins+at+selected+starting+doses+in+hypercholesterolemic+patients+and+in+special+population+groups+&author=JW+Blasetto&author=EA+Stein&author=WV+Brown&author=R+Chitra&author=A+Raza&publication_year=2003&hl=en']",,, Brown 2002 {published data only}  ,included,CD010254-bbs2-0014,,12646336,12646336,,,,,12646336
CD010254-bib-0035,Brown VW. ,A 52‐week trial of rosuvastatin versus pravastatin and simvastatin in patients with primary hypercholesterolemia, International Journal of Clinical Practice ,2002,Suppl 124,    ,['citation-journal'], Brown VW. A 52‐week trial of rosuvastatin versus pravastatin and simvastatin in patients with primary hypercholesterolemia.  International Journal of Clinical Practice 2002;Suppl 124:12. [CENTRAL: CN‐00858312 NEW]CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=A+52‐week+trial+of+rosuvastatin+versus+pravastatin+and+simvastatin+in+patients+with+primary+hypercholesterolemia+&author=VW+Brown&publication_year=2002&hl=en']",,, Brown 2002 {published data only}  ,included,CD010254-bbs2-0014,,,,,,,,
CD010254-bib-0036,"Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson H, et al. ","Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double‐blind, 52‐week trial", American Heart Journal ,2002,144,    ,['citation-journal']," Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson H, et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double‐blind, 52‐week trial.  American Heart Journal 2002;144(6):1036‐43. [MEDLINE: 12486428]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1067/mhj.2002.129312', 'https://www.ncbi.nlm.nih.gov/pubmed/12486428', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+rosuvastatin+compared+with+pravastatin+and+simvastatin+in+patients+with+hypercholesterolemia:+A+randomized,+double‐blind,+52‐week+trial+&author=WV+Brown&author=HE+Bays&author=DR+Hassman&author=J+McKenney&author=R+Chitra&author=H+Hutchinson&publication_year=2002&hl=en']",12486428,https://doi.org/10.1067/mhj.2002.129312, Brown 2002 {published data only}  ,included,CD010254-bbs2-0014,,,12486428,12486428,164,,,12486428
CD010254-bib-0037,AstraZeneca. ,Evaluation of the efficacy and safety of rosuvastatin 5 mg versus pravastatin 40 mg and atorvastatin 10 mg in type IIa and IIb hypercholesterolaemic patients,,,,   ,['citation-other'], AstraZeneca. Evaluation of the efficacy and safety of rosuvastatin 5 mg versus pravastatin 40 mg and atorvastatin 10 mg in type IIa and IIb hypercholesterolaemic patients. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/D3560L00068 (accessed 16 September 2009). [Study code D3560L00068/NCT00631189]CENTRAL    ,[''],,, CAP‐Chol 2009 {published data only}  ,included,CD010254-bbs2-0015,,,,,,,,
CD010254-bib-0038,"Capuzzi DM, Morgan JM, Weiss RJ, Chitra RR, Hutchinson HG, Cressman MD. ",Beneficial effects of rosuvastatin alone and in combination with extended‐release niacin in patients with a combined hyperlipidemia and low high‐density lipoprotein cholesterol levels, American Journal of Cardiology ,2003,91,    ,['citation-journal']," Capuzzi DM, Morgan JM, Weiss RJ, Chitra RR, Hutchinson HG, Cressman MD. Beneficial effects of rosuvastatin alone and in combination with extended‐release niacin in patients with a combined hyperlipidemia and low high‐density lipoprotein cholesterol levels.  American Journal of Cardiology 2003;91(11):1304‐10. [MEDLINE: 2767421]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0002-9149(03)00318-7', 'https://www.ncbi.nlm.nih.gov/pubmed/12767421', 'https://scholar.google.com/scholar_lookup?title=Beneficial+effects+of+rosuvastatin+alone+and+in+combination+with+extended‐release+niacin+in+patients+with+a+combined+hyperlipidemia+and+low+high‐density+lipoprotein+cholesterol+levels+&author=DM+Capuzzi&author=JM+Morgan&author=RJ+Weiss&author=RR+Chitra&author=HG+Hutchinson&author=MD+Cressman&publication_year=2003&hl=en']",12767421,https://doi.org/10.1016/S0002-9149(03)00318-7, Capuzzi 2003 {published data only}  ,included,CD010254-bbs2-0016,,12767421,12767421,12767421,72,,,12767421
CD010254-bib-0039,"Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, et al. ",Lipid‐altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients, Current Medical Research and Opinion ,2006,22,    ,['citation-journal']," Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, et al. Lipid‐altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.  Current Medical Research and Opinion 2006;22(10):2041‐53. [MEDLINE: 17022864]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1185/030079906X132721', 'https://www.ncbi.nlm.nih.gov/pubmed/17022864', 'https://scholar.google.com/scholar_lookup?title=Lipid‐altering+efficacy+of+the+ezetimibe/simvastatin+single+tablet+versus+rosuvastatin+in+hypercholesterolemic+patients+&author=AL+Catapano&author=MH+Davidson&author=CM+Ballantyne&author=WE+Brady&author=RA+Gazzara&author=JE+Tomassini&publication_year=2006&hl=en']",17022864,https://doi.org/10.1185/030079906X132721, Catapano 2006 {published data only}  ,included,CD010254-bbs2-0017,,,17022864,17022864,110,,,17022864
CD010254-bib-0040,ClinicalTrials.gov. ,"A multicenter, randomized, double‐blind study to evaluate the lipid‐altering efficacy and safety of the ezetimibe/simvastatin combination tablet versus rosuvastatin in patients with primary hypercholesterolemia",,,,   ,['citation-other']," ClinicalTrials.gov. A multicenter, randomized, double‐blind study to evaluate the lipid‐altering efficacy and safety of the ezetimibe/simvastatin combination tablet versus rosuvastatin in patients with primary hypercholesterolemia. http://clinicaltrials.gov/show/NCT00090298 (accessed 24 May 2013). [Study code NCT00090298]CENTRAL    ",[''],,, Catapano 2006 {published data only}  ,included,CD010254-bbs2-0017,,,,,,,,
CD010254-bib-0041,"Davidson MH, Abate N, Ballantyne CM, Catapano AL, Xu X, Lin J, et al. ","Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL‐C and each of five other emerging risk factors for coronary heart disease: Non‐HDL‐cholesterol, TC/HDL‐C, apolipoprotein B, apo‐B/apo‐A‐I, or C‐reactive protein", Journal of Clinical Lipidology ,2008,2,    ,['citation-journal']," Davidson MH, Abate N, Ballantyne CM, Catapano AL, Xu X, Lin J, et al. Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL‐C and each of five other emerging risk factors for coronary heart disease: Non‐HDL‐cholesterol, TC/HDL‐C, apolipoprotein B, apo‐B/apo‐A‐I, or C‐reactive protein.  Journal of Clinical Lipidology 2008;2(6):436‐46. [EMBASE: 2008584795]CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/21291777', 'https://scholar.google.com/scholar_lookup?title=Ezetimibe/simvastatin\xa0compared\xa0with\xa0atorvastatin\xa0or\xa0rosuvastatin\xa0in\xa0lowering\xa0to\xa0specified\xa0levels\xa0both+LDL‐C\xa0and\xa0each\xa0of\xa0five\xa0other\xa0emerging\xa0risk\xa0factors\xa0for+coronary+heart+disease:+Non‐HDL‐cholesterol,+TC/HDL‐C,+apolipoprotein+B,+apo‐B/apo‐A‐I,+or+C‐reactive+protein+&author=MH+Davidson&author=N+Abate&author=CM+Ballantyne&author=AL+Catapano&author=X+Xu&author=J+Lin&publication_year=2008&hl=en']",21291777,, Catapano 2006 {published data only}  ,included,CD010254-bbs2-0017,,,,,,,,21291777
CD010254-bib-0042,"Celik O, Acbay O. ",Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance, Journal of Endocrinological Investigation ,2012,35,    ,['citation-journal']," Celik O, Acbay O. Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance.  Journal of Endocrinological Investigation 2012;35(10):905‐10. [MEDLINE: 22522778]CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/22522778', 'https://scholar.google.com/scholar_lookup?title=Effects+of+metformin+plus+rosuvastatin+on+hyperandrogenism+in+polycystic+ovary+syndrome+patients+with+hyperlipidemia+and+impaired+glucose+tolerance+&author=O+Celik&author=O+Acbay&publication_year=2012&hl=en']",22522778,, Celik 2012 {published data only}  ,included,CD010254-bbs2-0018,,22522778,22522778,,,,,22522778
CD010254-bib-0043,"Chiang CE, Huang SS, Sung SH. ",Efficacy and safety of rosuvastatin in Taiwanese patients, Journal of the Chinese Medical Association: JCMA ,2008,71,    ,['citation-journal']," Chiang CE, Huang SS, Sung SH. Efficacy and safety of rosuvastatin in Taiwanese patients.  Journal of the Chinese Medical Association: JCMA 2008;71(3):113‐8. [EMBASE: 2008210915]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S1726-4901(08)70001-7', 'https://www.ncbi.nlm.nih.gov/pubmed/18364261', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+rosuvastatin+in+Taiwanese+patients&author=CE+Chiang&author=SS+Huang&author=SH+Sung&publication_year=2008&hl=en']",18364261,https://doi.org/10.1016/S1726-4901(08)70001-7, Chiang 2008 {published data only}  ,included,CD010254-bbs2-0019,,18364261,18364261,18364261,7,https://doi.org/10.1016/s1726-4901(08)70001-7,,18364261
CD010254-bib-0044,"Coban E, Afacan B. ",The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment, Platelets ,2008,19,    ,['citation-journal']," Coban E, Afacan B. The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment.  Platelets 2008;19(2):111‐4. [MEDLINE: 17852772]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1080/09537100701230444', 'https://www.ncbi.nlm.nih.gov/pubmed/17852772', 'https://scholar.google.com/scholar_lookup?title=The+effect+of+rosuvastatin+treatment+on+the+mean+platelet+volume+in+patients+with+uncontrolled+primary+dyslipidemia+with+hypolipidemic+diet+treatment+&author=E+Coban&author=B+Afacan&publication_year=2008&hl=en']",17852772,https://doi.org/10.1080/09537100701230444, Coban 2008 {published data only}  ,included,CD010254-bbs2-0020,,17852772,17852772,17852772,91,,,17852772
CD010254-bib-0045,ClinicalTrials.gov. ,Phase 4 clinical trial to examine the role of rosuvastatin and exercise treatment in modulating inflammatory response in hypercholesterolemic subjects,,,,   ,['citation-other'], ClinicalTrials.gov. Phase 4 clinical trial to examine the role of rosuvastatin and exercise treatment in modulating inflammatory response in hypercholesterolemic subjects. http://clinicaltrials.gov/show/NCT00295373 (accessed 19 April 2007). [Study code NCT00295373]CENTRAL    ,[''],,, Coen 2009 {published data only}  ,included,CD010254-bbs2-0021,,,,,,,,
CD010254-bib-0048,Coen PM. ,Statin treatment and exercise: Is there an additive anti‐inflammatory effect?,,2008,,    ,['citation-other'], Coen PM. Statin treatment and exercise: Is there an additive anti‐inflammatory effect?. ProQuest Dissertations and Theses2008. [DOI: 3330211]CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Statin+treatment+and+exercise:+Is+there+an+additive+anti‐inflammatory+effect?&author=PM+Coen&publication_year=2008&hl=en']",,, Coen 2009 {published data only}  ,included,CD010254-bbs2-0021,,20580035,,,,,,20580035
CD010254-bib-0046,"Coen PM, Flynn MG, Markofski MM, Pence BD, Hannemann RE. ","Adding exercise to rosuvastatin treatment: influence on C‐reactive protein, monocyte toll‐like receptor 4 expression, and inflammatory monocyte (CD14+CD16+) population",,2010,,    ,['citation-other']," Coen PM, Flynn MG, Markofski MM, Pence BD, Hannemann RE. Adding exercise to rosuvastatin treatment: influence on C‐reactive protein, monocyte toll‐like receptor 4 expression, and inflammatory monocyte (CD14+CD16+) population. Metabolism: Clinical and Experimental2010; Vol. 59, issue 12:1775‐83. [MEDLINE: 20580035]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Adding+exercise+to+rosuvastatin+treatment:+influence+on+C‐reactive+protein,+monocyte+toll‐like+receptor+4+expression,+and+inflammatory+monocyte+(CD14+CD16+)+population+&author=PM+Coen&author=MG+Flynn&author=MM+Markofski&author=BD+Pence&author=RE+Hannemann&publication_year=2010&hl=en']",,, Coen 2009 {published data only}  ,included,CD010254-bbs2-0021,,20580035,20580035,,,,,20580035
CD010254-bib-0047,"Coen PM, Flynn MG, Markofski MM, Pence BD, Hannemann RE. ",Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage, Metabolism: Clinical and Experimental ,2009,58,    ,['citation-journal']," Coen PM, Flynn MG, Markofski MM, Pence BD, Hannemann RE. Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage.  Metabolism: Clinical and Experimental 2009;58(7):1030‐8. [MEDLINE: 19411087]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.metabol.2009.03.006', 'https://www.ncbi.nlm.nih.gov/pubmed/19411087', 'https://scholar.google.com/scholar_lookup?title=Adding+exercise+training+to+rosuvastatin+treatment:+influence+on+serum+lipids+and+biomarkers+of+muscle+and+liver+damage+&author=PM+Coen&author=MG+Flynn&author=MM+Markofski&author=BD+Pence&author=RE+Hannemann&publication_year=2009&hl=en']",19411087,https://doi.org/10.1016/j.metabol.2009.03.006, Coen 2009 {published data only}  ,included,CD010254-bbs2-0021,,19411087,19411087,19411087,36,,,19411087
CD010254-bib-0049,ClinicalTrials.gov. ,"A 12 week randomized, double‐blind, force‐titration, parallel group, multi centre, phase IIIb study to compare the efficacy of rosuvastatin with atorvastatin and placebo in the treatment of non‐diabetic, non‐atheroscleric, metabolic syndrome subjects with raised LDL‐C and a 10 year risk of CHD >10%",,,,   ,['citation-other']," ClinicalTrials.gov. A 12 week randomized, double‐blind, force‐titration, parallel group, multi centre, phase IIIb study to compare the efficacy of rosuvastatin with atorvastatin and placebo in the treatment of non‐diabetic, non‐atheroscleric, metabolic syndrome subjects with raised LDL‐C and a 10 year risk of CHD >10%. http://clinicaltrials.gov/show/NCT00654485 (accessed 13 March 2009). [Study code 4522IL/0069/ D3560C00069/ NCT00654485]CENTRAL    ",[''],,, COMETS 2005 {published data only}  ,included,CD010254-bbs2-0022,,,,,,,,
CD010254-bib-0050,"Rosenson RS, Otvos JD, Hsia J. ","Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double‐blind, controlled study", Diabetes care ,2009,32,    ,['citation-journal']," Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double‐blind, controlled study.  Diabetes care 2009;32(6):1087‐91. [MEDLINE: 19265025]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2337/dc08-1681', 'https://www.ncbi.nlm.nih.gov/pubmed/19265025', 'https://scholar.google.com/scholar_lookup?title=Effects+of+rosuvastatin+and+atorvastatin+on+LDL+and+HDL+particle+concentrations+in+patients+with+metabolic+syndrome:+a+randomized,+double‐blind,+controlled+study+&author=RS+Rosenson&author=JD+Otvos&author=J+Hsia&publication_year=2009&hl=en']",19265025,https://doi.org/10.2337/dc08-1681, COMETS 2005 {published data only}  ,included,CD010254-bbs2-0022,,19265025,19265025,19265025,65,https://diabetesjournals.org/care/article-pdf/32/6/1087/603281/zdc00609001087.pdf,,19265025
CD010254-bib-0051,"Stalenhoef AF, Ballantyne CM, Sarti C, Murin J, Tonstad S, Rose H, et al. ",A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study, European Heart Journal ,2005,26,    ,['citation-journal']," Stalenhoef AF, Ballantyne CM, Sarti C, Murin J, Tonstad S, Rose H, et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.  European Heart Journal 2005;26(24):2664‐72. [MEDLINE: 16143705]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1093/eurheartj/ehi482', 'https://www.ncbi.nlm.nih.gov/pubmed/16143705', 'https://scholar.google.com/scholar_lookup?title=A+comparative+study+with+rosuvastatin+in+subjects+with+metabolic+syndrome:+results+of+the+COMETS+study+&author=AF+Stalenhoef&author=CM+Ballantyne&author=C+Sarti&author=J+Murin&author=S+Tonstad&author=H+Rose&publication_year=2005&hl=en']",16143705,https://doi.org/10.1093/eurheartj/ehi482, COMETS 2005 {published data only}  ,included,CD010254-bbs2-0022,,,16143705,16143705,117,https://academic.oup.com/eurheartj/article-pdf/26/24/2664/9624379/ehi482.pdf,,16143705
CD010254-bib-0052,Franken A. ,Cholesterol‐lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes, Atherosclerosis Supplements ,2004,5,    ,['citation-journal'], Franken A. Cholesterol‐lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes.  Atherosclerosis Supplements 2004;5(1):118. [MEDLINE: 15185682]CENTRAL    Link to article     Google Scholar     ,"['', 'https://doi.org/10.1016/S1567-5688(04)90511-4', 'https://scholar.google.com/scholar_lookup?title=Cholesterol‐lowering+effects+of+rosuvastatin+compared+with+atorvastatin+in+patients+with+type+2+diabetes+&author=A+Franken&publication_year=2004&hl=en']",,https://doi.org/10.1016/S1567-5688(04)90511-4, CORALL 2005 {published data only}  ,included,CD010254-bbs2-0023,,15910557,,15910557,62,,,15910557
CD010254-bib-0053,"Simsek S, Schalkwijk CG, Wolffenbuttel BH, Simsek S, Schalkwijk CG, Wolffenbuttel BHR. ",Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes‐‐‐the CORALL study, Diabetic Medicine ,2012,29,    ,['citation-journal']," Simsek S, Schalkwijk CG, Wolffenbuttel BH, Simsek S, Schalkwijk CG, Wolffenbuttel BHR. Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes‐‐‐the CORALL study.  Diabetic Medicine 2012;29(5):628‐31. [MEDLINE: 22151023]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1111/j.1464-5491.2011.03553.x', 'https://www.ncbi.nlm.nih.gov/pubmed/22151023', 'https://scholar.google.com/scholar_lookup?title=Effects+of+rosuvastatin+and+atorvastatin+on+glycaemic+control+in+Type+2+diabetes‐‐‐the+CORALL+study+&author=S+Simsek&author=CG+Schalkwijk&author=BH+Wolffenbuttel&author=S+Simsek&author=CG+Schalkwijk&author=BHR+Wolffenbuttel&publication_year=2012&hl=en']",22151023,https://doi.org/10.1111/j.1464-5491.2011.03553.x, CORALL 2005 {published data only}  ,included,CD010254-bbs2-0023,,22151023,22151023,22151023,84,https://pure.rug.nl/ws/files/6777409/Simsek_2012_Diabet_Med.pdf,,22151023
CD010254-bib-0054,"Wolffenbuttel BH, Franken AA, Vincent HH, Dutch Corall Study Group. ",Cholesterol‐lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes ‐‐ CORALL study, Journal of Internal Medicine ,2005,257,    ,['citation-journal']," Wolffenbuttel BH, Franken AA, Vincent HH, Dutch Corall Study Group. Cholesterol‐lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes ‐‐ CORALL study.  Journal of Internal Medicine 2005;257(6):531‐9. [MEDLINE: 15910557]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1111/j.1365-2796.2005.01499.x', 'https://www.ncbi.nlm.nih.gov/pubmed/15910557', 'https://scholar.google.com/scholar_lookup?title=Cholesterol‐lowering+effects+of+rosuvastatin+compared+with+atorvastatin+in+patients+with+type+2+diabetes+‐‐+CORALL+study+&author=BH+Wolffenbuttel&author=AA+Franken&author=HH+Vincent&publication_year=2005&hl=en']",15910557,https://doi.org/10.1111/j.1365-2796.2005.01499.x, CORALL 2005 {published data only}  ,included,CD010254-bbs2-0023,,,,,53,,,15910557
CD010254-bib-0055,AstraZeneca. ,"A 12‐week, randomized, double‐blind, placebo‐controlled, multicenter trial to evaluate the efficacy and safety of ZD4522 5mg and 10 mg and atorvastatin 10 mg in the treatment of subjects with hypercholesterolemia",,,,   ,['citation-other']," AstraZeneca. A 12‐week, randomized, double‐blind, placebo‐controlled, multicenter trial to evaluate the efficacy and safety of ZD4522 5mg and 10 mg and atorvastatin 10 mg in the treatment of subjects with hypercholesterolemia. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/4522il_0024 (access 24 August 2000). [Study code 4522IL/0024]CENTRAL    ",[''],,, Davidson 2002 {published data only}  ,included,CD010254-bbs2-0024,,,,,,,,
CD010254-bib-0056,"Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A. ",Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups, American Journal of Cardiology ,2003,91,    ,['citation-journal']," Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.  American Journal of Cardiology 2003;91(5A):3C‐10C. [MEDLINE: 12646336]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0002-9149(03)00003-1', 'https://www.ncbi.nlm.nih.gov/pubmed/12646336', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+rosuvastatin+compared+with+other+statins+at+selected+starting+doses+in+hypercholesterolemic+patients+and+in+special+population+groups+&author=JW+Blasetto&author=EA+Stein&author=WV+Brown&author=R+Chitra&author=A+Raza&publication_year=2003&hl=en']",12646336,https://doi.org/10.1016/S0002-9149(03)00003-1, Davidson 2002 {published data only}  ,included,CD010254-bbs2-0024,,12646336,12646336,12646336,149,,,12646336
CD010254-bib-0058,Davidson M. ,Rosuvastatin is more effective than atorvastatin at improving the lipid profiles of patients with primary hypercholesterolaemia, Atherosclerosis Supplements ,2001,2,    ,['citation-journal'], Davidson M. Rosuvastatin is more effective than atorvastatin at improving the lipid profiles of patients with primary hypercholesterolaemia.  Atherosclerosis Supplements 2001;2(2):38. [MEDLINE: 11446381]CENTRAL    Link to article     Google Scholar     ,"['', 'https://doi.org/10.1016/S1567-5688(01)80029-5', 'https://scholar.google.com/scholar_lookup?title=Rosuvastatin+is+more+effective+than+atorvastatin+at+improving+the+lipid+profiles+of+patients+with+primary+hypercholesterolaemia+&author=M+Davidson&publication_year=2001&hl=en']",,https://doi.org/10.1016/S1567-5688(01)80029-5, Davidson 2002 {published data only}  ,included,CD010254-bbs2-0024,,,,,6,,,
CD010254-bib-0057,"Davidson M, Ma P, Stein EA, Gotto AM, Raza A, Chitra R, Hutchinson H. ",Comparison of effects on low‐density lipoprotein cholesterol and high‐density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia, American Journal of Cardiology ,2002,89,    ,['citation-journal']," Davidson M, Ma P, Stein EA, Gotto AM, Raza A, Chitra R, Hutchinson H. Comparison of effects on low‐density lipoprotein cholesterol and high‐density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.  American Journal of Cardiology 2002;89(3):268‐75. [MEDLINE: 11809427]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0002-9149(01)02226-3', 'https://www.ncbi.nlm.nih.gov/pubmed/11809427', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+effects+on+low‐density+lipoprotein+cholesterol+and+high‐density+lipoprotein+cholesterol+with+rosuvastatin+versus+atorvastatin+in+patients+with+type+IIa+or+IIb+hypercholesterolemia+&author=M+Davidson&author=P+Ma&author=EA+Stein&author=AM+Gotto&author=A+Raza&author=R+Chitra&author=H+Hutchinson&publication_year=2002&hl=en']",11809427,https://doi.org/10.1016/S0002-9149(01)02226-3, Davidson 2002 {published data only}  ,included,CD010254-bbs2-0024,,11809427,,11809427,234,,,11809427
CD010254-bib-0059,Prescott LM. ,Highlights of the American College of Cardiology's 50th Annual Scientific Session, P and T ,2001,26,    ,['citation-journal'], Prescott LM. Highlights of the American College of Cardiology's 50th Annual Scientific Session.  P and T 2001;26(6):330‐2. [EMBASE: 2001216890]CENTRAL    Google Scholar     ,"['', ""https://scholar.google.com/scholar_lookup?title=Highlights\xa0of\xa0the\xa0American\xa0College\xa0of\xa0Cardiology's\xa050th\xa0Annual\xa0Scientific\xa0Session&author=LM+Prescott&publication_year=2001&hl=en""]",,, Davidson 2002 {published data only}  ,included,CD010254-bbs2-0024,,,,,,,,
CD010254-bib-0060,AstraZeneca. ,"An open‐label, randomized, multi‐centre, phase IIIb/IV, parallel group study to compare the efficacy and safety of rosuvastatin and atorvastatin in subjects with type IIa and IIb hypercholesterolemia (DISCOVERY)",,,,   ,['citation-other']," AstraZeneca. An open‐label, randomized, multi‐centre, phase IIIb/IV, parallel group study to compare the efficacy and safety of rosuvastatin and atorvastatin in subjects with type IIa and IIb hypercholesterolemia (DISCOVERY). Clinical Study Report Synopsis (access 10 February 2007). [Code study D3560L00009/NCT00241488]CENTRAL    ",[''],,, DISCOVERY‐Asia 2007 {published data only}  ,included,CD010254-bbs2-0025,,,,,,,,
CD010254-bib-0061,"Zhu JR, Tomlinson B. ",A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY‐Asia study), Current Medical Research and Opinion ,2007,23,    ,['citation-journal']," Zhu JR, Tomlinson B. A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY‐Asia study).  Current Medical Research and Opinion 2007;23(12):3055‐68. [MEDLINE: 18196620]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1185/030079907X242809', 'https://www.ncbi.nlm.nih.gov/pubmed/18196620', 'https://scholar.google.com/scholar_lookup?title=A+randomised+study+comparing+the+efficacy+and+safety+of+rosuvastatin+with+atorvastatin+for+achieving+lipid+goals+in+clinical+practice+in+Asian+patients+at+high+risk+of+cardiovascular+disease+(DISCOVERY‐Asia+study)+&author=JR+Zhu&author=B+Tomlinson&publication_year=2007&hl=en']",18196620,https://doi.org/10.1185/030079907X242809, DISCOVERY‐Asia 2007 {published data only}  ,included,CD010254-bbs2-0025,,18196620,18196620,18196620,43,,,18196620
CD010254-bib-0062,"Dulay D, LaHaye SA, Lahey KA, Day AG. ",Efficacy of alternate day versus daily dosing of rosuvastatin, Canadian Journal of Cardiology ,2009,25,    ,['citation-journal']," Dulay D, LaHaye SA, Lahey KA, Day AG. Efficacy of alternate day versus daily dosing of rosuvastatin.  Canadian Journal of Cardiology 2009;25(2):e28‐e31. [MEDLINE: 19214297]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0828-282X(09)70480-5', 'https://www.ncbi.nlm.nih.gov/pubmed/19214297', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+alternate+day+versus+daily+dosing+of+rosuvastatin&author=D+Dulay&author=SA+LaHaye&author=KA+Lahey&author=AG+Day&publication_year=2009&hl=en']",19214297,https://doi.org/10.1016/S0828-282X(09)70480-5, Dulay 2009 {published data only}  ,included,CD010254-bbs2-0026,,19214297,,19214297,24,https://europepmc.org/articles/pmc2691915?pdf=render,,19214297
CD010254-bib-0063,AstraZeneca. ,"A 24‐week, randomised, multicentre trial to evaluate the efficacy and safety of ZD4522 and fenofibrate, alone and in various combinations, in the treatment of type IIb and IV hyperlipidaemia associated with type 2 diabetes mellitus",,,,   ,['citation-other']," AstraZeneca. A 24‐week, randomised, multicentre trial to evaluate the efficacy and safety of ZD4522 and fenofibrate, alone and in various combinations, in the treatment of type IIb and IV hyperlipidaemia associated with type 2 diabetes mellitus. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610166 (accessed 06 March 2001). [Study code 4522IL/0036]CENTRAL    ",[''],,, Durrington 2004 {published data only}  ,included,CD010254-bbs2-0027,,,,,,,,
CD010254-bib-0064,"Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K. ",Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia, Diabetes Research and Clinical Practice ,2004,64,    ,['citation-journal']," Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.  Diabetes Research and Clinical Practice 2004;64(2):137‐51. [MEDLINE: 15063607]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.diabres.2003.11.012', 'https://www.ncbi.nlm.nih.gov/pubmed/15063607', 'https://scholar.google.com/scholar_lookup?title=Rosuvastatin+and+fenofibrate+alone+and+in+combination+in+type+2+diabetes+patients+with+combined+hyperlipidaemia+&author=PN+Durrington&author=J+Tuomilehto&author=A+Hamann&author=D+Kallend&author=K+Smith&publication_year=2004&hl=en']",15063607,https://doi.org/10.1016/j.diabres.2003.11.012, Durrington 2004 {published data only}  ,included,CD010254-bbs2-0027,,15063607,15063607,15063607,113,,,15063607
CD010254-bib-0065,"Dzhaiani NA, Ilyina EV, Kochetov AG, Tereshchenko SN. ",Lipid‐lowering and pleiotropic effects of rosuvastatin in patients with acute myocardial infarction, Cardiovascular Therapy and Prevention ,2008,7,    ,['citation-journal']," Dzhaiani NA, Ilyina EV, Kochetov AG, Tereshchenko SN. Lipid‐lowering and pleiotropic effects of rosuvastatin in patients with acute myocardial infarction.  Cardiovascular Therapy and Prevention 2008;7(7):91‐7. [CENTRAL: CN‐00865232 NEW]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Lipid‐lowering+and+pleiotropic+effects+of+rosuvastatin+in+patients+with+acute+myocardial+infarction+&author=NA+Dzhaiani&author=EV+Ilyina&author=AG+Kochetov&author=SN+Tereshchenko&publication_year=2008&hl=en']",,, Dzhaiani 2008 {published data only}  ,included,CD010254-bbs2-0028,,,,,,,,
CD010254-bib-0066,AstraZeneca. ,"A 24‐week, randomised, open‐label, parallel‐group, multicentre study which compares the efficacy and safety of rosuvastatin 10, 20 and 40 mg with atorvastatin 10, 20, 40 and 80 mg when force‐titrated in the treatment of patients with primary hypercholesterolemia and either a history ofcoronary heart disease (CHD) or clinical evidence of atherosclerosis or a CHD risk equivalent (10‐year risk score >20%) ECLIPSE ‐ An Evaluation to Compare Lipid‐lowering effects of rosuvastatin and atorvastatin In force‐titrated patients: a Prospective Study of Efficacy and tolerability",,,,   ,['citation-other']," AstraZeneca. A 24‐week, randomised, open‐label, parallel‐group, multicentre study which compares the efficacy and safety of rosuvastatin 10, 20 and 40 mg with atorvastatin 10, 20, 40 and 80 mg when force‐titrated in the treatment of patients with primary hypercholesterolemia and either a history ofcoronary heart disease (CHD) or clinical evidence of atherosclerosis or a CHD risk equivalent (10‐year risk score >20%) ECLIPSE ‐ An Evaluation to Compare Lipid‐lowering effects of rosuvastatin and atorvastatin In force‐titrated patients: a Prospective Study of Efficacy and tolerability. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/D3569C00002 (accessed 03 February 2006). [Study code D3569C00002]CENTRAL    ",[''],,, ECLIPSE 2008 {published data only}  ,included,CD010254-bbs2-0029,,,,,,,,
CD010254-bib-0067,Faergeman O. ,Efficacy and tolerability of rosuvastatin and atorvastatin when force‐titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study, Cardiology ,2008,111,    ,['citation-journal'], Faergeman O. Efficacy and tolerability of rosuvastatin and atorvastatin when force‐titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study.  Cardiology 2008;111(4):219‐28. [MEDLINE: 18434729]CENTRAL    Link to article     PubMed     Google Scholar     ,"['', 'https://doi.org/10.1159/000127442', 'https://www.ncbi.nlm.nih.gov/pubmed/18434729', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+tolerability+of+rosuvastatin+and+atorvastatin+when+force‐titrated+in+patients+with+primary+hypercholesterolemia:+results+from+the+ECLIPSE+study+&author=O+Faergeman&publication_year=2008&hl=en']",18434729,https://doi.org/10.1159/000127442, ECLIPSE 2008 {published data only}  ,included,CD010254-bbs2-0029,,18434729,18434729,18434729,27,,,18434729
CD010254-bib-0068,AstraZeneca. ,"Open‐labelled, single arm, phase IV clinical study to evaluate the impact of rosuvastatin on lipid levels in patients with metabolic syndrome",,,,   ,['citation-other']," AstraZeneca. Open‐labelled, single arm, phase IV clinical study to evaluate the impact of rosuvastatin on lipid levels in patients with metabolic syndrome. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/D3560L00079 (access 07 March 2011). [Study code D3560L00079]CENTRAL    ",[''],,, EFFORT 2011 {published data only}  ,included,CD010254-bbs2-0030,,,,,,,,
CD010254-bib-0069,ClincialTrials.gov. ,Effect of Crestor (rosuvastatin) on lipid levels in patients with metabolic syndrome (EFFORT),,,,   ,['citation-other'], ClincialTrials.gov. Effect of Crestor (rosuvastatin) on lipid levels in patients with metabolic syndrome (EFFORT). http://clinicaltrials.gov/show/NCT00815659 (access 29 August 2011). [Study code NCT00815659]CENTRAL    ,[''],,, EFFORT 2011 {published data only}  ,included,CD010254-bbs2-0030,,,,,,,,
CD010254-bib-0070,"Erbs S, Beck EB, Linke A, Adams V, Gielen S, Krankel N, et al. ","High‐dose rosuvastatin in chronic heart failure promotes vasculogenesis, corrects endothelial function, and improves cardiac remodeling ‐ Results from a randomized, double‐blind, and placebo‐controlled study", International Journal of Cardiology ,2011,146,    ,['citation-journal']," Erbs S, Beck EB, Linke A, Adams V, Gielen S, Krankel N, et al. High‐dose rosuvastatin in chronic heart failure promotes vasculogenesis, corrects endothelial function, and improves cardiac remodeling ‐ Results from a randomized, double‐blind, and placebo‐controlled study.  International Journal of Cardiology 2011;146(1):56‐63. [MEDLINE: 20236716]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ijcard.2010.02.019', 'https://www.ncbi.nlm.nih.gov/pubmed/20236716', 'https://scholar.google.com/scholar_lookup?title=High‐dose+rosuvastatin+in+chronic+heart+failure+promotes+vasculogenesis,+corrects+endothelial+function,+and+improves+cardiac+remodeling+‐+Results+from+a+randomized,+double‐blind,+and+placebo‐controlled+study+&author=S+Erbs&author=EB+Beck&author=A+Linke&author=V+Adams&author=S+Gielen&author=N+Krankel&publication_year=2011&hl=en']",20236716,https://doi.org/10.1016/j.ijcard.2010.02.019, Erbs 2011 {published data only}  ,included,CD010254-bbs2-0031,,,20236716,20236716,72,,,20236716
CD010254-bib-0071,AstraZeneca. ,"A 6 wk open‐label, randomised, multicentre, phase iiib, parallel group study to compare the safety & efficacy of rosuvastatin 40 mg in comb.with ezetimibe 10mg in subjects with hypercholesterolaemia & CHD or atherosclerosis or a CHD risk equiv. (10 yr risk score >20%)",,,,   ,['citation-other']," AstraZeneca. A 6 wk open‐label, randomised, multicentre, phase iiib, parallel group study to compare the safety & efficacy of rosuvastatin 40 mg in comb.with ezetimibe 10mg in subjects with hypercholesterolaemia & CHD or atherosclerosis or a CHD risk equiv. (10 yr risk score >20%). http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/D3569C00006 (accessed 06 January 2006. [Study code D3569C00006/NCT00653445]CENTRAL    ",[''],,, EXPLORER 2007 {published data only}  ,included,CD010254-bbs2-0032,,41690875,,,,,,41690875
CD010254-bib-0072,"Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, Duffield E. ",Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study), American Journal of Cardiology ,2007,99,    ,['citation-journal']," Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, Duffield E. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).  American Journal of Cardiology 2007;99(5):673‐80. [MEDLINE: 17317370]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.amjcard.2006.10.022', 'https://www.ncbi.nlm.nih.gov/pubmed/17317370', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+rosuvastatin+40+mg+alone+or+in+combination+with+ezetimibe+in+patients+at+high+risk+of+cardiovascular+disease+(results+from+the+EXPLORER+study)+&author=CM+Ballantyne&author=R+Weiss&author=T+Moccetti&author=A+Vogt&author=B+Eber&author=F+Sosef&author=E+Duffield&publication_year=2007&hl=en']",17317370,https://doi.org/10.1016/j.amjcard.2006.10.022, EXPLORER 2007 {published data only}  ,included,CD010254-bbs2-0032,,17317370,,17317370,195,http://www.ajconline.org/article/S0002914906022715/pdf,,17317370
CD010254-bib-0073,Lepor NE. ,"Key findings from the 2006 World Congress of Cardiology: A summary from the Joint Meeting of the European Society of Cardiology and the World Heart Federation, September 2‐5, 2006, Barcelona, Spain", Reviews in Cardiovascular Medicine ,2007,8,    ,['citation-journal']," Lepor NE. Key findings from the 2006 World Congress of Cardiology: A summary from the Joint Meeting of the European Society of Cardiology and the World Heart Federation, September 2‐5, 2006, Barcelona, Spain.  Reviews in Cardiovascular Medicine 2007;8(2):90‐100. [EMBASE: 2007331650]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Key+findings+from+the+2006+World+Congress+of+Cardiology:+A+summary+from+the+Joint+Meeting+of+the+European+Society+of+Cardiology+and+the+World+Heart+Federation,+September+2‐5,+2006,+Barcelona,+Spain+&author=NE+Lepor&publication_year=2007&hl=en']",,, EXPLORER 2007 {published data only}  ,included,CD010254-bbs2-0032,,,,,,,,
CD010254-bib-0074,"Florentin M, Liberopoulos EN, Rizos CV, Kei AA, Liamis G, Kostapanos MS, et al. ",Colesevelam plus rosuvastatin 5mg/day versus rosuvastatin 10mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose, Metabolic Syndrome & Related Disorders ,2013,11,    ,['citation-journal']," Florentin M, Liberopoulos EN, Rizos CV, Kei AA, Liamis G, Kostapanos MS, et al. Colesevelam plus rosuvastatin 5mg/day versus rosuvastatin 10mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose.  Metabolic Syndrome & Related Disorders 2013;11(3):152‐6. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1089/met.2012.0103', 'https://scholar.google.com/scholar_lookup?title=Colesevelam+plus+rosuvastatin+5mg/day+versus+rosuvastatin+10mg/day+alone+on+markers+of+insulin+resistance+in+patients+with+hypercholesterolemia+and+impaired+fasting+glucose+&author=M+Florentin&author=EN+Liberopoulos&author=CV+Rizos&author=AA+Kei&author=G+Liamis&author=MS+Kostapanos&publication_year=2013&hl=en']",,https://doi.org/10.1089/met.2012.0103, Florentin 2013 {published data only}  ,included,CD010254-bbs2-0033,,,,23170931,15,,,23170931
CD010254-bib-0075,Gao RL. ,"The efficacy and safety of rosuvastatin on treating patients with hypercholesterolemia in Chinese: a randomized, double‐blind, multi‐center clinical trial", Zhonghua xin xue guan bing za zhi [Chinese Journal of Cardiovascular Diseases] ,2007,35,    ,['citation-journal']," Gao RL. The efficacy and safety of rosuvastatin on treating patients with hypercholesterolemia in Chinese: a randomized, double‐blind, multi‐center clinical trial.  Zhonghua xin xue guan bing za zhi [Chinese Journal of Cardiovascular Diseases] 2007;35(3):207‐11. [EMBASE: 17582281]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=The+efficacy+and+safety+of+rosuvastatin+on+treating+patients+with+hypercholesterolemia+in+Chinese:+a+randomized,+double‐blind,+multi‐center+clinical+trial+&author=RL+Gao&publication_year=2007&hl=en']",,, Gao 2007 {published data only}  ,included,CD010254-bbs2-0034,,17582281,17582281,,,,,17582281
CD010254-bib-0076,"Gomez‐Garcia A, Martinez Torres G, Ortega‐Pierres LE, Rodriguez‐Ayala E, Alvarez‐Aguilar C. ",Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia, Revista Espanola de Cardiologia ,2007,60,    ,['citation-journal']," Gomez‐Garcia A, Martinez Torres G, Ortega‐Pierres LE, Rodriguez‐Ayala E, Alvarez‐Aguilar C. Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia.  Revista Espanola de Cardiologia 2007;60(12):1242‐9. [MEDLINE: 18082089]CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/18082089', 'https://scholar.google.com/scholar_lookup?title=Rosuvastatin+and+metformin+decrease+inflammation+and+oxidative+stress+in+patients+with+hypertension+and+dyslipidemia+&author=A+Gomez‐Garcia&author=G+MartinezTorres&author=LE+Ortega‐Pierres&author=E+Rodriguez‐Ayala&author=C+Alvarez‐Aguilar&publication_year=2007&hl=en']",18082089,, Gomez‐Garcia 2007 {published data only}  ,included,CD010254-bbs2-0035,,18082089,18082089,,,,,18082089
CD010254-bib-0077,ClinicalTrials.gov. ,"12‐week open‐label, phase IIIb comparing efficacy and safety of rosuvastatin (CRESTOR) in combination with ezetimibe (GRAVITY)",,,,   ,['citation-other']," ClinicalTrials.gov. 12‐week open‐label, phase IIIb comparing efficacy and safety of rosuvastatin (CRESTOR) in combination with ezetimibe (GRAVITY). http://clinicaltrials.gov/ct2/show/results/NCT00525824 (accessed 03 September 2009). [Study code NCT0052584/D356FC00003]CENTRAL    ",[''],,, GRAVITY 2009 {published data only}  ,included,CD010254-bbs2-0036,,,,,,,,
CD010254-bib-0078,Guo Chunhong. ,Efficacy and safety of rosuvastatin in treatment of patients with ischemic stroke for secondary prevention of stroke, Chinese Journal of Hospital Pharmacy [Zhongguo yiyuan yaoxue zazhi] ,2012,32,    ,['citation-journal'], Guo Chunhong. Efficacy and safety of rosuvastatin in treatment of patients with ischemic stroke for secondary prevention of stroke.  Chinese Journal of Hospital Pharmacy [Zhongguo yiyuan yaoxue zazhi] 2012;32(3):211‐3. [CENTRAL: CN‐00858141 NEW]CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+rosuvastatin+in+treatment+of+patients+with+ischemic+stroke+for+secondary+prevention+of+stroke+&author=Chunhong+Guo&publication_year=2012&hl=en']",,, Guo 2012 {published data only}  ,included,CD010254-bbs2-0037,,,,,,,,
CD010254-bib-0079,"Han Hui, Xue Jing, Zhang Jing, Xu Fang, Wang Yu. ",Efficacy and safety of rosuvastatin and atorvastatin in aged patients with hypercholesterolemia, Zhongguo Xinyao yu Linchuang Zazhi ,2008,27,    ,['citation-journal']," Han Hui, Xue Jing, Zhang Jing, Xu Fang, Wang Yu. Efficacy and safety of rosuvastatin and atorvastatin in aged patients with hypercholesterolemia.  Zhongguo Xinyao yu Linchuang Zazhi 2008;27(2):120‐3. [CENTRAL: CN‐00865233 NEW]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+rosuvastatin+and+atorvastatin+in+aged+patients+with+hypercholesterolemia&author=Hui+Han&author=Jing+Xue&author=Jing+Zhang&author=Fang+Xu&author=Yu+Wang&publication_year=2008&hl=en']",,, Han 2008 {published data only}  ,included,CD010254-bbs2-0038,,,,,,,,
CD010254-bib-0080,AstraZeneca. ,"A 24‐week, randomised, double‐blind, multicentre, multinational trial to evaluate the efficacy and safety of ZD4522 and atorvastatin in the treatment of subjects with heterozygous familial hypercholesterolaemia",,,,   ,['citation-other']," AstraZeneca. A 24‐week, randomised, double‐blind, multicentre, multinational trial to evaluate the efficacy and safety of ZD4522 and atorvastatin in the treatment of subjects with heterozygous familial hypercholesterolaemia. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610156 (accessed 09 February 2001. [Study code 4522IL/0030]CENTRAL    ",[''],,, HeFH 2003 {published data only}  ,included,CD010254-bbs2-0039,,,,,,,,
CD010254-bib-0081,"Stein EA, Strutt K, Southworth H, Diggle PJ, Miller E. ",Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia, American Journal of Cardiology ,2003,92,    ,['citation-journal']," Stein EA, Strutt K, Southworth H, Diggle PJ, Miller E. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia.  American Journal of Cardiology 2003;92(11):1287‐93. [MEDLINE: 14636905]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.amjcard.2003.08.009', 'https://www.ncbi.nlm.nih.gov/pubmed/14636905', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+rosuvastatin+versus+atorvastatin+in+patients+with+heterozygous+familial+hypercholesterolemia+&author=EA+Stein&author=K+Strutt&author=H+Southworth&author=PJ+Diggle&author=E+Miller&publication_year=2003&hl=en']",14636905,https://doi.org/10.1016/j.amjcard.2003.08.009, HeFH 2003 {published data only}  ,included,CD010254-bbs2-0039,,14636905,14636905,14636905,117,,,14636905
CD010254-bib-0082,"Her AY, Kim JY, Kang SM, Choi D, Jang Y, Chung N, et al. ","Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism", Journal of Cardiovascular Pharmacology and Therapeutics ,2010,15,    ,['citation-journal']," Her AY, Kim JY, Kang SM, Choi D, Jang Y, Chung N, et al. Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism.  Journal of Cardiovascular Pharmacology and Therapeutics 2010;15(2):167‐74. [MEDLINE: 20147603]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1177/1074248409357922', 'https://www.ncbi.nlm.nih.gov/pubmed/20147603', 'https://scholar.google.com/scholar_lookup?title=Effects+of+atorvastatin+20+mg,+rosuvastatin+10+mg,+and+atorvastatin/+ezetimibe+5+mg/5+mg+on+lipoproteins+and+glucose+metabolism+&author=AY+Her&author=JY+Kim&author=SM+Kang&author=D+Choi&author=Y+Jang&author=N+Chung&publication_year=2010&hl=en']",20147603,https://doi.org/10.1177/1074248409357922, Her 2010 {published data only}  ,included,CD010254-bbs2-0040,,,,20147603,40,,,20147603
CD010254-bib-0083,AstraZeneca. ,"A 12‐week, multicenter, randomized, double‐blind, placebo‐controlled trial to evaluate the efficacy and safety of ZD4522 5 to 80 mg in the treatment of subjects with hypertriglyceridemia",,,,   ,['citation-other']," AstraZeneca. A 12‐week, multicenter, randomized, double‐blind, placebo‐controlled trial to evaluate the efficacy and safety of ZD4522 5 to 80 mg in the treatment of subjects with hypertriglyceridemia. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/9256747 (accessed 15 January 2001). [Study code 4522IL/0035]CENTRAL    ",[''],,, Hunninghake 2004 {published data only}  ,included,CD010254-bbs2-0041,,,,,,,,
CD010254-bib-0084,"Hunninghake D, Chitra R, Simonson S, Schneck D. ",Rosuvastatin markedly improved the atherogenic lipid profile in hypertriglyceridaemic patients, European Heart Journal ,2001,22 Abstract Supplement,    ,['citation-journal']," Hunninghake D, Chitra R, Simonson S, Schneck D. Rosuvastatin markedly improved the atherogenic lipid profile in hypertriglyceridaemic patients.  European Heart Journal 2001;22 Abstract Supplement:270. [BIOSIS:PREV200200091177]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Rosuvastatin+markedly+improved+the+atherogenic+lipid+profile+in+hypertriglyceridaemic+patients+&author=D+Hunninghake&author=R+Chitra&author=S+Simonson&author=D+Schneck&publication_year=2001&hl=en']",,, Hunninghake 2004 {published data only}  ,included,CD010254-bbs2-0041,,,,,,,,
CD010254-bib-0086,Hunninghake DB. ,Effects of rosuvastatin on serum lipids and lipid subfractions in patients with hypertriglyceridemia, International Journal of Clinical Practice ,2002,Suppl 124,    ,['citation-journal'], Hunninghake DB. Effects of rosuvastatin on serum lipids and lipid subfractions in patients with hypertriglyceridemia.  International Journal of Clinical Practice 2002;Suppl 124:10. [CENTRAL: CN‐00866593 NEW]CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Effects+of+rosuvastatin+on+serum+lipids+and+lipid+subfractions+in+patients+with+hypertriglyceridemia&author=DB+Hunninghake&publication_year=2002&hl=en']",,, Hunninghake 2004 {published data only}  ,included,CD010254-bbs2-0041,,,,,,,,
CD010254-bib-0087,Hunninghake DB. ,Treatment of hypertriglyceridemic patients with rosuvastatin, Diabetes ,2001,50 Suppl 2,    ,['citation-journal'], Hunninghake DB. Treatment of hypertriglyceridemic patients with rosuvastatin.  Diabetes 2001;50 Suppl 2:A143. [CENTRAL: CN‐00866594 NEW]CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Treatment+of+hypertriglyceridemic+patients+with+rosuvastatin&author=DB+Hunninghake&publication_year=2001&hl=en']",,, Hunninghake 2004 {published data only}  ,included,CD010254-bbs2-0041,,15024300,,,,,,15024300
CD010254-bib-0085,"Hunninghake DB, Stein EA, Bays HE, Rader DJ, Chitra RR, Simonson SG, et al. ",Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia, Coronary Artery Disease ,2004,15,    ,['citation-journal']," Hunninghake DB, Stein EA, Bays HE, Rader DJ, Chitra RR, Simonson SG, et al. Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia.  Coronary Artery Disease 2004;15(2):115‐23. [MEDLINE: 15024300]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/00019501-200403000-00008', 'https://www.ncbi.nlm.nih.gov/pubmed/15024300', 'https://scholar.google.com/scholar_lookup?title=Rosuvastatin+improves+the+atherogenic+and+atheroprotective+lipid+profiles+in+patients+with+hypertriglyceridemia+&author=DB+Hunninghake&author=EA+Stein&author=HE+Bays&author=DJ+Rader&author=RR+Chitra&author=SG+Simonson&publication_year=2004&hl=en']",15024300,https://doi.org/10.1097/00019501-200403000-00008, Hunninghake 2004 {published data only}  ,included,CD010254-bbs2-0041,,,15024300,15024300,69,,,15024300
CD010254-bib-0088,"Igase M, Kohara K, Katagi R, Yamashita S, Fujisawa M, Miki T. ",Predictive value of the low‐density lipoprotein cholesterol to high‐density lipoprotein cholesterol ratio for the prevention of stroke recurrence in Japanese patients treated with rosuvastatin, Clinical Drug Investigation ,2012,32,    ,['citation-journal']," Igase M, Kohara K, Katagi R, Yamashita S, Fujisawa M, Miki T. Predictive value of the low‐density lipoprotein cholesterol to high‐density lipoprotein cholesterol ratio for the prevention of stroke recurrence in Japanese patients treated with rosuvastatin [I].  Clinical Drug Investigation 2012;32(8):513‐21. [MEDLINE: 9504817]CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/22741749', 'https://scholar.google.com/scholar_lookup?title=Predictive+value+of+the+low‐density+lipoprotein+cholesterol+to+high‐density+lipoprotein+cholesterol+ratio+for+the+prevention+of+stroke+recurrence+in+Japanese+patients+treated+with+rosuvastatin+&author=M+Igase&author=K+Kohara&author=R+Katagi&author=S+Yamashita&author=M+Fujisawa&author=T+Miki&publication_year=2012&hl=en']",22741749,, Igase 2012a {published data only}  ,included,CD010254-bbs2-0042,,22741749,22741749,,,,,22741749
CD010254-bib-0089,"Igase M, Kohara K, Tabara Y, Nagai T, Ochi N, Kido T, et al. ",Low‐dose rosuvastatin improves the functional and morphological markers of atherosclerosis in asymptomatic postmenopausal women with dyslipidemia, Menopause ,2012,19,    ,['citation-journal']," Igase M, Kohara K, Tabara Y, Nagai T, Ochi N, Kido T, et al. Low‐dose rosuvastatin improves the functional and morphological markers of atherosclerosis in asymptomatic postmenopausal women with dyslipidemia.  Menopause 2012;19(12):1294‐9. [MEDLINE: 22850442]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/gme.0b013e318259c04e', 'https://www.ncbi.nlm.nih.gov/pubmed/22850442', 'https://scholar.google.com/scholar_lookup?title=Low‐dose+rosuvastatin+improves+the+functional+and+morphological+markers+of+atherosclerosis+in+asymptomatic+postmenopausal+women+with+dyslipidemia+&author=M+Igase&author=K+Kohara&author=Y+Tabara&author=T+Nagai&author=N+Ochi&author=T+Kido&publication_year=2012&hl=en']",22850442,https://doi.org/10.1097/gme.0b013e318259c04e, Igase 2012b {published data only}  ,included,CD010254-bbs2-0043,,,22850442,22850442,23,,,22850442
CD010254-bib-0090,ClinicalTrials.gov. ,"A 6‐week, randomized,open‐label, comparative study to evaluate the efficacy and safety of rosuvastatin and atorvastatin in the treatment of hypercholesterolaemia in South Asian subjects",,,,   ,['citation-other']," ClinicalTrials.gov. A 6‐week, randomized,open‐label, comparative study to evaluate the efficacy and safety of rosuvastatin and atorvastatin in the treatment of hypercholesterolaemia in South Asian subjects. http://clinicaltrials.gov/show/NCT00654225 (accessed 13 March 2009). [study code NCT00654225]CENTRAL    ",[''],,, IRIS 2007 {published data only}  ,included,CD010254-bbs2-0044,,,,,,,,
CD010254-bib-0091,"Deedwania PC, Gupta M, Stein M, Ycas J, Gold A. ",Comparison of rosuvastatin versus atorvastatin in South‐Asian patients at risk of coronary heart disease (from the IRIS Trial), American Journal of Cardiology ,2007,99,    ,['citation-journal']," Deedwania PC, Gupta M, Stein M, Ycas J, Gold A. Comparison of rosuvastatin versus atorvastatin in South‐Asian patients at risk of coronary heart disease (from the IRIS Trial).  American Journal of Cardiology 2007;99(11):1538‐43. [MEDLINE: 17531577]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.amjcard.2007.01.028', 'https://www.ncbi.nlm.nih.gov/pubmed/17531577', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+rosuvastatin+versus+atorvastatin+in+South‐Asian+patients+at+risk+of+coronary+heart+disease+(from+the+IRIS+Trial)+&author=PC+Deedwania&author=M+Gupta&author=M+Stein&author=J+Ycas&author=A+Gold&publication_year=2007&hl=en']",17531577,https://doi.org/10.1016/j.amjcard.2007.01.028, IRIS 2007 {published data only}  ,included,CD010254-bbs2-0044,,17531577,17531577,17531577,67,,,17531577
CD010254-bib-0092,"Nohara R, Daida H, Hata M, Kaku K, Kawamori R, Kishimoto J, et al. ",Effect of intensive lipid‐lowering therapy with rosuvastatin on progression of carotid intima‐media thickness in Japanese patients, Circulation Journal ,2012,76,    ,['citation-journal']," Nohara R, Daida H, Hata M, Kaku K, Kawamori R, Kishimoto J, et al. Effect of intensive lipid‐lowering therapy with rosuvastatin on progression of carotid intima‐media thickness in Japanese patients.  Circulation Journal 2012;76(1):221‐9. [MEDLINE: 22094911]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1253/circj.CJ-11-0887', 'https://www.ncbi.nlm.nih.gov/pubmed/22094911', 'https://scholar.google.com/scholar_lookup?title=Effect+of+intensive+lipid‐lowering+therapy+with+rosuvastatin+on+progression+of+carotid+intima‐media+thickness+in+Japanese+patients+&author=R+Nohara&author=H+Daida&author=M+Hata&author=K+Kaku&author=R+Kawamori&author=J+Kishimoto&publication_year=2012&hl=en']",22094911,https://doi.org/10.1253/circj.CJ-11-0887, JART 2012 {published data only}  ,included,CD010254-bbs2-0045,,,,22094911,52,https://www.jstage.jst.go.jp/article/circj/76/1/76_CJ-11-0887/_pdf,,22094911
CD010254-bib-0093,"Yamazaki T, Nohara R, Daida H, Hata M, Kaku K, Kawamori R, et al. ",Intensive lipid‐lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study, International Heart Journal ,2013,54,    ,['citation-journal']," Yamazaki T, Nohara R, Daida H, Hata M, Kaku K, Kawamori R, et al. Intensive lipid‐lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study.  International Heart Journal 2013;54(1):33‐9. [MEDLINE: 23428922]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1536/ihj.54.33', 'https://www.ncbi.nlm.nih.gov/pubmed/23428922', 'https://scholar.google.com/scholar_lookup?title=Intensive+lipid‐lowering+therapy+for+slowing+progression+as+well+as+inducing+regression+of+atherosclerosis+in+Japanese+patients:+subanalysis+of+the+JART+study+&author=T+Yamazaki&author=R+Nohara&author=H+Daida&author=M+Hata&author=K+Kaku&author=R+Kawamori&publication_year=2013&hl=en']",23428922,https://doi.org/10.1536/ihj.54.33, JART 2012 {published data only}  ,included,CD010254-bbs2-0045,,,23428922,23428922,25,https://www.jstage.jst.go.jp/article/ihj/54/1/54_33/_pdf,,23428922
CD010254-bib-0094,"Jing S, Sun N ‐L, Li X ‐Y, Hua Q, Wang L, Li Z ‐Q, et al. ",Efficacy and safety of rosuvastatin in the treatment of hypercholesterolemia, Chinese Journal of New Drugs ,2013,22,    ,['citation-journal']," Jing S, Sun N ‐L, Li X ‐Y, Hua Q, Wang L, Li Z ‐Q, et al. Efficacy and safety of rosuvastatin in the treatment of hypercholesterolemia.  Chinese Journal of New Drugs 2013;22(8):937‐40. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+rosuvastatin+in+the+treatment+of+hypercholesterolemia&author=S+Jing&author=N‐L+Sun&author=X‐Y+Li&author=Q+Hua&author=L+Wang&author=Z‐Q+Li&publication_year=2013&hl=en']",,, Jing 2013 {published data only}  ,included,CD010254-bbs2-0046,,,,,,,,
CD010254-bib-0095,"Bays HE, Jones PH, Mohiuddin SM, Kelly MT, Sun H, Setze CM, et al. ",Long‐term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia, Journal of Clinical Lipidology ,2008,2,    ,['citation-journal']," Bays HE, Jones PH, Mohiuddin SM, Kelly MT, Sun H, Setze CM, et al. Long‐term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia.  Journal of Clinical Lipidology 2008;2(6):426‐35. [EMBASE: 2008584794]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.jacl.2008.10.001', 'https://www.ncbi.nlm.nih.gov/pubmed/21291776', 'https://scholar.google.com/scholar_lookup?title=Long‐term\xa0safety\xa0and\xa0efficacy\xa0of\xa0fenofibric\xa0acid\xa0in\xa0combination\xa0with\xa0statin\xa0therapy\xa0for\xa0the\xa0treatment+of\xa0patients\xa0with\xa0mixed\xa0dyslipidemia+&author=HE+Bays&author=PH+Jones&author=SM+Mohiuddin&author=MT+Kelly&author=H+Sun&author=CM+Setze&publication_year=2008&hl=en']",21291776,https://doi.org/10.1016/j.jacl.2008.10.001, Jones 2009 {published data only}  ,included,CD010254-bbs2-0047,,,,21291776,49,,,21291776
CD010254-bib-0096,"Bays HE, Roth EM, McKenney JM, Kelly MT, Thakker KM, Setze CM, et al. ",The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia, Diabetes care ,2010,33,    ,['citation-journal']," Bays HE, Roth EM, McKenney JM, Kelly MT, Thakker KM, Setze CM, et al. The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.  Diabetes care 2010;33(9):2113‐6. [MEDLINE: 20573750]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2337/dc10-0357', 'https://www.ncbi.nlm.nih.gov/pubmed/20573750', 'https://scholar.google.com/scholar_lookup?title=The+effects+of+fenofibric+acid+alone+and+with+statins+on+the+prevalence+of+metabolic+syndrome+and+its+diagnostic+components+in+patients+with+mixed+dyslipidemia+&author=HE+Bays&author=EM+Roth&author=JM+McKenney&author=MT+Kelly&author=KM+Thakker&author=CM+Setze&publication_year=2010&hl=en']",20573750,https://doi.org/10.2337/dc10-0357, Jones 2009 {published data only}  ,included,CD010254-bbs2-0047,,,20573750,20573750,17,https://diabetesjournals.org/care/article-pdf/33/9/2113/606792/zdc00910002113.pdf,,20573750
CD010254-bib-0097,ClinicalTrials.gov. ,Evaluate safety and efficacy of ABT‐335 in combination with rosuvastatin calcium in subjects with multiple abnormal lipid levels in the blood,,,,   ,['citation-other'], ClinicalTrials.gov. Evaluate safety and efficacy of ABT‐335 in combination with rosuvastatin calcium in subjects with multiple abnormal lipid levels in the blood. http://clinicaltrials.gov/show/NCT00300482 (accessed 03 June 2009). [Study code NCT00300482]CENTRAL    ,[''],,, Jones 2009 {published data only}  ,included,CD010254-bbs2-0047,,,,,,,,
CD010254-bib-0098,"Jones PH, Bays HE, Davidson MH, Kelly MT, Buttler SM, Setze CM, et al. ","Evaluation of a new formulation of fenofibric acid, ABT‐335, co‐administered with statins : study design and rationale of a phase III clinical programme", Clinical Drug Investigation ,2008,28,    ,['citation-journal']," Jones PH, Bays HE, Davidson MH, Kelly MT, Buttler SM, Setze CM, et al. Evaluation of a new formulation of fenofibric acid, ABT‐335, co‐administered with statins : study design and rationale of a phase III clinical programme.  Clinical Drug Investigation 2008;28(10):625‐34. [MEDLINE: 18783301]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2165/00044011-200828100-00003', 'https://www.ncbi.nlm.nih.gov/pubmed/18783301', 'https://scholar.google.com/scholar_lookup?title=Evaluation+of+a+new+formulation+of+fenofibric+acid,+ABT‐335,+co‐administered+with+statins+:+study+design+and+rationale+of+a+phase+III+clinical+programme+&author=PH+Jones&author=HE+Bays&author=MH+Davidson&author=MT+Kelly&author=SM+Buttler&author=CM+Setze&publication_year=2008&hl=en']",18783301,https://doi.org/10.2165/00044011-200828100-00003, Jones 2009 {published data only}  ,included,CD010254-bbs2-0047,,,18783301,18783301,40,,,18783301
CD010254-bib-0099,"Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, et al. ","Efficacy and safety of fenofibric acid co‐administered with low‐ or moderate‐dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double‐blind trials"," American Journal of Cardiovascular Drugs : drugs, devices, and other interventions ",2010,10,    ,['citation-journal']," Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, et al. Efficacy and safety of fenofibric acid co‐administered with low‐ or moderate‐dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double‐blind trials.  American Journal of Cardiovascular Drugs : drugs, devices, and other interventions 2010;10(2):73‐84. [MEDLINE: 20136164]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2165/10061630-000000000-00000', 'https://www.ncbi.nlm.nih.gov/pubmed/20136164', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+fenofibric+acid+co‐administered+with+low‐+or+moderate‐dose+statin+in+patients+with+mixed+dyslipidemia+and+type+2+diabetes+mellitus:+results+of+a+pooled+subgroup+analysis+from+three+randomized,+controlled,+double‐blind+trials+&author=PH+Jones&author=K+Cusi&author=MH+Davidson&author=MT+Kelly&author=CM+Setze&author=K+Thakker&publication_year=2010&hl=en']",20136164,https://doi.org/10.2165/10061630-000000000-00000, Jones 2009 {published data only}  ,included,CD010254-bbs2-0047,,,20136164,20136164,20,,,20136164
CD010254-bib-0100,"Jones PH, Davidson MH, Kashyap ML, Kelly MT, Buttler SM, Setze CM, et al. ",Efficacy and safety of ABT‐335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study, Atherosclerosis ,2009,204,    ,['citation-journal']," Jones PH, Davidson MH, Kashyap ML, Kelly MT, Buttler SM, Setze CM, et al. Efficacy and safety of ABT‐335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study.  Atherosclerosis 2009;204(1):208‐15. [MEDLINE: 18996523]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.atherosclerosis.2008.09.027', 'https://www.ncbi.nlm.nih.gov/pubmed/18996523', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+ABT‐335+(fenofibric+acid)+in+combination+with+rosuvastatin+in+patients+with+mixed+dyslipidemia:+A+phase+3+study+&author=PH+Jones&author=MH+Davidson&author=ML+Kashyap&author=MT+Kelly&author=SM+Buttler&author=CM+Setze&publication_year=2009&hl=en']",18996523,https://doi.org/10.1016/j.atherosclerosis.2008.09.027, Jones 2009 {published data only}  ,included,CD010254-bbs2-0047,,,18996523,18996523,89,,,18996523
CD010254-bib-0101,"Kanazawa I, Yamaguchi T, Yamauchi M, Sugimoto T. ",Rosuvastatin increased serum osteocalcin levels independent of its serum cholesterol‐lowering effect in patients with type 2 diabetes and hypercholesterolemia, Internal Medicine ,2009,48,    ,['citation-journal']," Kanazawa I, Yamaguchi T, Yamauchi M, Sugimoto T. Rosuvastatin increased serum osteocalcin levels independent of its serum cholesterol‐lowering effect in patients with type 2 diabetes and hypercholesterolemia.  Internal Medicine 2009;48(21):1869‐73. [MEDLINE: 19881236]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2169/internalmedicine.48.2645', 'https://www.ncbi.nlm.nih.gov/pubmed/19881236', 'https://scholar.google.com/scholar_lookup?title=Rosuvastatin+increased+serum+osteocalcin+levels+independent+of+its+serum+cholesterol‐lowering+effect+in+patients+with+type+2+diabetes+and+hypercholesterolemia+&author=I+Kanazawa&author=T+Yamaguchi&author=M+Yamauchi&author=T+Sugimoto&publication_year=2009&hl=en']",19881236,https://doi.org/10.2169/internalmedicine.48.2645, Kanazawa 2009 {published data only}  ,included,CD010254-bbs2-0048,,19881236,19881236,19881236,23,,,19881236
CD010254-bib-0102,"Kim W, Hong MJ, Woo JS, Kang WY, Hwang SH, Kim W. ","Rosuvastatin does not affect fasting glucose, insulin resistance, or adiponectin in patients with mild to moderate hypertension", Chonnam Medical Journal ,2013,49,    ,['citation-journal']," Kim W, Hong MJ, Woo JS, Kang WY, Hwang SH, Kim W. Rosuvastatin does not affect fasting glucose, insulin resistance, or adiponectin in patients with mild to moderate hypertension.  Chonnam Medical Journal 2013;49(1):31‐7. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4068/cmj.2013.49.1.31', 'https://www.ncbi.nlm.nih.gov/pubmed/23678475', 'https://scholar.google.com/scholar_lookup?title=Rosuvastatin+does+not+affect+fasting+glucose,+insulin+resistance,+or+adiponectin+in+patients+with+mild+to+moderate+hypertension+&author=W+Kim&author=MJ+Hong&author=JS+Woo&author=WY+Kang&author=SH+Hwang&author=W+Kim&publication_year=2013&hl=en']",23678475,https://doi.org/10.4068/cmj.2013.49.1.31, Kim 2013 {published data only}  ,included,CD010254-bbs2-0049,,,,23678475,9,https://europepmc.org/articles/pmc3651984?pdf=render,,23678475
CD010254-bib-0103,"Koh KK, Quon MJ, Sakuma I, Han SH, Choi H, Lee K, et al. ",Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients, International Journal of Cardiology ,2013,166,    ,['citation-journal']," Koh KK, Quon MJ, Sakuma I, Han SH, Choi H, Lee K, et al. Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients.  International Journal of Cardiology 2013;166(2):509‐15. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ijcard.2011.11.028', 'https://www.ncbi.nlm.nih.gov/pubmed/22204857', 'https://scholar.google.com/scholar_lookup?title=Differential+metabolic+effects+of+rosuvastatin+and+pravastatin+in+hypercholesterolemic+patients+&author=KK+Koh&author=MJ+Quon&author=I+Sakuma&author=SH+Han&author=H+Choi&author=K+Lee&publication_year=2013&hl=en']",22204857,https://doi.org/10.1016/j.ijcard.2011.11.028, Koh 2013 {published data only}  ,included,CD010254-bbs2-0050,,,22204857,,,,,22204857
CD010254-bib-0104,"Kostapanos MS, Milionis HJ, Gazi I, Kostara C Bairaktari ET, Elisaf M. ",Rosuvastatin increases alpha‐1 microglobulin urinary excretion in patients with primary dyslipidemia, Journal of Clinical Pharmacology ,2006,46,    ,['citation-journal']," Kostapanos MS, Milionis HJ, Gazi I, Kostara C Bairaktari ET, Elisaf M. Rosuvastatin increases alpha‐1 microglobulin urinary excretion in patients with primary dyslipidemia.  Journal of Clinical Pharmacology 2006;46(11):1337‐43. [MEDLINE: 17050799]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1177/0091270006292629', 'https://www.ncbi.nlm.nih.gov/pubmed/17050799', 'https://scholar.google.com/scholar_lookup?title=Rosuvastatin+increases+alpha‐1+microglobulin+urinary+excretion+in+patients+with+primary+dyslipidemia+&author=MS+Kostapanos&author=HJ+Milionis&author=I+Gazi&author=CBairaktariET+Kostara&author=M+Elisaf&publication_year=2006&hl=en']",17050799,https://doi.org/10.1177/0091270006292629, Kostapanos 2006 {published data only}  ,included,CD010254-bbs2-0051,,17050799,17050799,,26,,,17050799
CD010254-bib-0105,"Kostapanos MS, Milionis HJ, Filippatos TD, Nakou ES, Bairaktari ET, Tselepis AD, et al. ","A 12‐week, prospective, open‐label analysis of the effect of rosuvastatin on triglyceride‐rich lipoprotein metabolism in patients with primary dyslipidemia", Clinical Therapeutics ,2007,29,    ,['citation-journal']," Kostapanos MS, Milionis HJ, Filippatos TD, Nakou ES, Bairaktari ET, Tselepis AD, et al. A 12‐week, prospective, open‐label analysis of the effect of rosuvastatin on triglyceride‐rich lipoprotein metabolism in patients with primary dyslipidemia.  Clinical Therapeutics 2007;29(7):1403‐14. [MEDLINE: 17825691]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.clinthera.2007.07.019', 'https://www.ncbi.nlm.nih.gov/pubmed/17825691', 'https://scholar.google.com/scholar_lookup?title=A+12‐week,+prospective,+open‐label+analysis+of+the+effect+of+rosuvastatin+on+triglyceride‐rich+lipoprotein+metabolism+in+patients+with+primary+dyslipidemia+&author=MS+Kostapanos&author=HJ+Milionis&author=TD+Filippatos&author=ES+Nakou&author=ET+Bairaktari&author=AD+Tselepis&publication_year=2007&hl=en']",17825691,https://doi.org/10.1016/j.clinthera.2007.07.019, Kostapanos 2007a {published data only}  ,included,CD010254-bbs2-0052,,,17825691,17825691,52,,,17825691
CD010254-bib-0106,"Kostapanos MS, Milionis HJ, Saougos VG, Lagos KG, Kostara C, Bairaktari ET, et al. ",Dose‐dependent effect of rosuvastatin treatment on urinary protein excretion, Journal of Cardiovascular Pharmacology and Therapeutics ,2007,12,    ,['citation-journal']," Kostapanos MS, Milionis HJ, Saougos VG, Lagos KG, Kostara C, Bairaktari ET, et al. Dose‐dependent effect of rosuvastatin treatment on urinary protein excretion.  Journal of Cardiovascular Pharmacology and Therapeutics 2007;12(4):292‐7. [MEDLINE: 18172223]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1177/1074248407306676', 'https://www.ncbi.nlm.nih.gov/pubmed/18172223', 'https://scholar.google.com/scholar_lookup?title=Dose‐dependent+effect+of+rosuvastatin+treatment+on+urinary+protein+excretion&author=MS+Kostapanos&author=HJ+Milionis&author=VG+Saougos&author=KG+Lagos&author=C+Kostara&author=ET+Bairaktari&publication_year=2007&hl=en']",18172223,https://doi.org/10.1177/1074248407306676, Kostapanos 2007b {published data only}  ,included,CD010254-bbs2-0053,,,18172223,18172223,24,,,18172223
CD010254-bib-0107,"Kostapanos MS, Derdemezis CS, Filippatos TD, Milionis HJ, Kiortsis DN, Tselepis AD, et al. ",Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia, European Journal of Pharmacology ,2008,578,    ,['citation-journal']," Kostapanos MS, Derdemezis CS, Filippatos TD, Milionis HJ, Kiortsis DN, Tselepis AD, et al. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia.  European Journal of Pharmacology 2008;578(2‐3):249‐52. [MEDLINE: 17931620]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ejphar.2007.09.019', 'https://www.ncbi.nlm.nih.gov/pubmed/17931620', 'https://scholar.google.com/scholar_lookup?title=Effect+of+rosuvastatin+treatment+on+plasma+visfatin+levels+in+patients+with+primary+hyperlipidemia+&author=MS+Kostapanos&author=CS+Derdemezis&author=TD+Filippatos&author=HJ+Milionis&author=DN+Kiortsis&author=AD+Tselepis&publication_year=2008&hl=en']",17931620,https://doi.org/10.1016/j.ejphar.2007.09.019, Kostapanos 2008a {published data only}  ,included,CD010254-bbs2-0054,,,17931620,17931620,32,,,17931620
CD010254-bib-0108,"Kostapanos MS, Milionis HJ, Lagos KG, Rizos CB, Tselepis AD, Elisaf MS. ",Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia, European Journal of Pharmacology ,2008,590,    ,['citation-journal']," Kostapanos MS, Milionis HJ, Lagos KG, Rizos CB, Tselepis AD, Elisaf MS. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.  European Journal of Pharmacology 2008;590(1‐3):327‐32. [MEDLINE: 18585701]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ejphar.2008.06.007', 'https://www.ncbi.nlm.nih.gov/pubmed/18585701', 'https://scholar.google.com/scholar_lookup?title=Baseline+triglyceride+levels+and+insulin+sensitivity+are+major+determinants+of+the+increase+of+LDL+particle+size+and+buoyancy+induced+by+rosuvastatin+treatment+in+patients+with+primary+hyperlipidemia+&author=MS+Kostapanos&author=HJ+Milionis&author=KG+Lagos&author=CB+Rizos&author=AD+Tselepis&author=MS+Elisaf&publication_year=2008&hl=en']",18585701,https://doi.org/10.1016/j.ejphar.2008.06.007, Kostapanos 2008b {published data only}  ,included,CD010254-bbs2-0055,,18585701,18585701,18585701,26,,,18585701
CD010254-bib-0109,"Kostapanos MS, Milionis HJ, Filippatos TD, Christogiannis LG, Bairaktari ET Tselepis AD, et al. ",Dose‐dependent effect of rosuvastatin treatment on HDL‐subfraction phenotype in patients with primary hyperlipidemia, Journal of Cardiovascular Pharmacology and Therapeutics ,2009,14,    ,['citation-journal']," Kostapanos MS, Milionis HJ, Filippatos TD, Christogiannis LG, Bairaktari ET Tselepis AD, et al. Dose‐dependent effect of rosuvastatin treatment on HDL‐subfraction phenotype in patients with primary hyperlipidemia.  Journal of Cardiovascular Pharmacology and Therapeutics 2009;14(1):5‐13. [MEDLINE: 19246334]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1177/1074248408331031', 'https://www.ncbi.nlm.nih.gov/pubmed/19246334', 'https://scholar.google.com/scholar_lookup?title=Dose‐dependent+effect+of+rosuvastatin+treatment+on+HDL‐subfraction+phenotype+in+patients+with+primary+hyperlipidemia+&author=MS+Kostapanos&author=HJ+Milionis&author=TD+Filippatos&author=LG+Christogiannis&author=AD+BairaktariETTselepis&publication_year=2009&hl=en']",19246334,https://doi.org/10.1177/1074248408331031, Kostapanos 2009 {published data only}  ,included,CD010254-bbs2-0056,,,19246334,19246334,28,https://journals.sagepub.com/doi/pdf/10.1177/1074248408331031,,19246334
CD010254-bib-0110,"Lamendola C, Abbasi F, Chu JW, Hutchinson H, Cain V, Leary E, et al. ","Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin‐resistant, nondiabetic patients with combined dyslipidemia", American Journal of Cardiology ,2005,95,    ,['citation-journal']," Lamendola C, Abbasi F, Chu JW, Hutchinson H, Cain V, Leary E, et al. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin‐resistant, nondiabetic patients with combined dyslipidemia.  American Journal of Cardiology 2005;95(2):189‐93. [MEDLINE: 15642550]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.amjcard.2004.09.005', 'https://www.ncbi.nlm.nih.gov/pubmed/15642550', 'https://scholar.google.com/scholar_lookup?title=Comparative+effects+of+rosuvastatin+and+gemfibrozil+on+glucose,+insulin,+and+lipid+metabolism+in+insulin‐resistant,+nondiabetic+patients+with+combined+dyslipidemia+&author=C+Lamendola&author=F+Abbasi&author=JW+Chu&author=H+Hutchinson&author=V+Cain&author=E+Leary&publication_year=2005&hl=en']",15642550,https://doi.org/10.1016/j.amjcard.2004.09.005, Lamendola 2005 {published data only}  ,included,CD010254-bbs2-0057,,,15642550,15642550,46,,,15642550
CD010254-bib-0111,"Liberopoulos EN, Moutzouri E, Rizos CV, Barkas F, Liamis G, Elisaf MS, et al. ","Effects of manidipine plus rosuvastatin versus olmesartan plus rosuvastatin on markers of insulin resistance in patients with impaired fasting glucose, hypertension, and mixed dyslipidemia", Journal of Cardiovascular Pharmacology & Therapeutics ,2013,18,    ,['citation-journal']," Liberopoulos EN, Moutzouri E, Rizos CV, Barkas F, Liamis G, Elisaf MS, et al. Effects of manidipine plus rosuvastatin versus olmesartan plus rosuvastatin on markers of insulin resistance in patients with impaired fasting glucose, hypertension, and mixed dyslipidemia.  Journal of Cardiovascular Pharmacology & Therapeutics 2013;18(2):113‐8. [MEDLINE: 23113965]CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1177/1074248412463611', 'https://scholar.google.com/scholar_lookup?title=Effects+of+manidipine+plus+rosuvastatin+versus+olmesartan+plus+rosuvastatin+on+markers+of+insulin+resistance+in+patients+with+impaired+fasting+glucose,+hypertension,+and+mixed+dyslipidemia+&author=EN+Liberopoulos&author=E+Moutzouri&author=CV+Rizos&author=F+Barkas&author=G+Liamis&author=MS+Elisaf&publication_year=2013&hl=en']",,https://doi.org/10.1177/1074248412463611, Liberopoulos 2013 {published data only}  ,included,CD010254-bbs2-0058,,,23113965,23113965,7,https://journals.sagepub.com/doi/pdf/10.1177/1074248412463611,,23113965
CD010254-bib-0112,"Lu T‐M, Ding Y‐A, Leu H‐B, Yin W‐H, Sheu WH‐H, Chu K‐M. ",Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia, American Journal of Cardiology ,2004,94,    ,['citation-journal']," Lu T‐M, Ding Y‐A, Leu H‐B, Yin W‐H, Sheu WH‐H, Chu K‐M. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia.  American Journal of Cardiology 2004;94(2):157‐61. [MEDLINE: 15246890]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.amjcard.2004.03.052', 'https://www.ncbi.nlm.nih.gov/pubmed/15246890', 'https://scholar.google.com/scholar_lookup?title=Effect+of+rosuvastatin+on+plasma+levels+of+asymmetric+dimethylarginine+in+patients+with+hypercholesterolemia+&author=T‐M+Lu&author=Y‐A+Ding&author=H‐B+Leu&author=W‐H+Yin&author=WH‐H+Sheu&author=K‐M+Chu&publication_year=2004&hl=en']",15246890,https://doi.org/10.1016/j.amjcard.2004.03.052, Lu 2004 {published data only}  ,included,CD010254-bbs2-0059,,15246890,,15246890,166,,,15246890
CD010254-bib-0113,Lui SH. ,,Pharmacogenetic and environmental determinants of response to HMG‐CoA reductase inhibitors,2007,,   ,['citation-book']," Lui SH. Pharmacogenetic and environmental determinants of response to HMG‐CoA reductase inhibitors. Hong Kong: ProQuest, UMI Dissertations, 2007. CENTRAL    ",[''],,, Lui 2007 {published data only}  ,included,CD010254-bbs2-0060,,34898030,,,,,,34898030
CD010254-bib-0114,AstraZeneca. ,"A 12‐week randomized, open‐label 3‐arm, parallel group, multicenter Phase IIIb study comparing efficacy and safety of rosuvastatin 20mg and 40mg with that of atorvastatin 80 mg in subjects with acute coronary syndromes (LUNAR)",,,,   ,['citation-other']," AstraZeneca. A 12‐week randomized, open‐label 3‐arm, parallel group, multicenter Phase IIIb study comparing efficacy and safety of rosuvastatin 20mg and 40mg with that of atorvastatin 80 mg in subjects with acute coronary syndromes (LUNAR). http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/D3560L00021 (accessed 22 April 2008). [Study code D3560L00021/4522US/0001]CENTRAL    ",[''],,, LUNAR 2012 {published data only}  ,included,CD010254-bbs2-0061,,,,,,,,
CD010254-bib-0115,"Ballantyne CM, Pitt B, Loscalzo J, Cain VA, Raichlen JS. ",Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial), American Journal of Cardiology ,2013,111,    ,['citation-journal']," Ballantyne CM, Pitt B, Loscalzo J, Cain VA, Raichlen JS. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).  American Journal of Cardiology 2013;111(4):506‐9. [MEDLINE: 23237107]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.amjcard.2012.10.037', 'https://www.ncbi.nlm.nih.gov/pubmed/23237107', 'https://scholar.google.com/scholar_lookup?title=Alteration+of+relation+of+atherogenic+lipoprotein+cholesterol+to+apolipoprotein+B+by+intensive+statin+therapy+in+patients+with+acute+coronary+syndrome+(from+the+Limiting+UNdertreatment+of+lipids+in+ACS+With+Rosuvastatin+[LUNAR]+Trial)+&author=CM+Ballantyne&author=B+Pitt&author=J+Loscalzo&author=VA+Cain&author=JS+Raichlen&publication_year=2013&hl=en']",23237107,https://doi.org/10.1016/j.amjcard.2012.10.037, LUNAR 2012 {published data only}  ,included,CD010254-bbs2-0061,,23237107,23237107,23237107,39,,,23237107
CD010254-bib-0116,"Pitt B, Loscalzo J, Monyak J, Miller E, Raichlen J. ",Comparison of lipid‐modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study), American Journal of Cardiology ,2012,109,    ,['citation-journal']," Pitt B, Loscalzo J, Monyak J, Miller E, Raichlen J. Comparison of lipid‐modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study).  American Journal of Cardiology 2012;109(9):1239‐46. [MEDLINE: 22360820]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.amjcard.2011.12.015', 'https://www.ncbi.nlm.nih.gov/pubmed/22360820', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+lipid‐modifying+efficacy+of+rosuvastatin+versus+atorvastatin+in+patients+with+acute+coronary+syndrome+(from+the+LUNAR+study)+&author=B+Pitt&author=J+Loscalzo&author=J+Monyak&author=E+Miller&author=J+Raichlen&publication_year=2012&hl=en']",22360820,https://doi.org/10.1016/j.amjcard.2011.12.015, LUNAR 2012 {published data only}  ,included,CD010254-bbs2-0061,,22360820,22360820,22360820,63,,,22360820
CD010254-bib-0117,"Pitt B, Loscalzo J, Ycas J, Raichlen JS. ",Lipid levels after acute coronary syndromes, Journal of the American College of Cardiology ,2008,51,    ,['citation-journal']," Pitt B, Loscalzo J, Ycas J, Raichlen JS. Lipid levels after acute coronary syndromes.  Journal of the American College of Cardiology 2008;51(15):1440‐5. [EMBASE: 2008161797]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.jacc.2007.11.075', 'https://www.ncbi.nlm.nih.gov/pubmed/18402897', 'https://scholar.google.com/scholar_lookup?title=Lipid+levels+after+acute+coronary+syndromes&author=B+Pitt&author=J+Loscalzo&author=J+Ycas&author=JS+Raichlen&publication_year=2008&hl=en']",18402897,https://doi.org/10.1016/j.jacc.2007.11.075, LUNAR 2012 {published data only}  ,included,CD010254-bbs2-0061,,18402897,,18402897,164,https://doi.org/10.1016/j.jacc.2007.11.075,,18402897
CD010254-bib-0118,"Mabuchi H, Nohara A, Higashikata T, Ueda K, Bujo H, Matsushima T, et al. ",Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia, Journal of Atherosclerosis and Thrombosis ,2004,11,    ,['citation-journal']," Mabuchi H, Nohara A, Higashikata T, Ueda K, Bujo H, Matsushima T, et al. Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia.  Journal of Atherosclerosis and Thrombosis 2004;11(3):152‐8. [MEDLINE: 15256766]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.5551/jat.11.152', 'https://www.ncbi.nlm.nih.gov/pubmed/15256766', 'https://scholar.google.com/scholar_lookup?title=Clinical+efficacy+and+safety+of+rosuvastatin+in+Japanese+patients+with+heterozygous+familial+hypercholesterolemia+&author=H+Mabuchi&author=A+Nohara&author=T+Higashikata&author=K+Ueda&author=H+Bujo&author=T+Matsushima&publication_year=2004&hl=en']",15256766,https://doi.org/10.5551/jat.11.152, Mabuchi 2004 {published data only}  ,included,CD010254-bbs2-0062,,,,15256766,22,https://www.jstage.jst.go.jp/article/jat/11/3/11_3_152/_pdf,,15256766
CD010254-bib-0119,"Makariou SE, Liberopoulos EN, Agouridis AP, Challa A, Elisaf M, Makariou SE, et al. ",Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega‐3 fatty acids on serum vitamin D levels, Journal of Cardiovascular Pharmacology & Therapeutics ,2012,17,    ,['citation-journal']," Makariou SE, Liberopoulos EN, Agouridis AP, Challa A, Elisaf M, Makariou SE, et al. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega‐3 fatty acids on serum vitamin D levels.  Journal of Cardiovascular Pharmacology & Therapeutics 2012;17(4):382‐6. [MEDLINE: 22431864]CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1177/1074248412439470', 'https://scholar.google.com/scholar_lookup?title=Effect+of+rosuvastatin+monotherapy+and+in+combination+with+fenofibrate+or+omega‐3+fatty+acids+on+serum+vitamin+D+levels+&author=SE+Makariou&author=EN+Liberopoulos&author=AP+Agouridis&author=A+Challa&author=M+Elisaf&author=SE+Makariou&publication_year=2012&hl=en']",,https://doi.org/10.1177/1074248412439470, Makariou 2012 {published data only}  ,included,CD010254-bbs2-0063,,,,22431864,22,https://journals.sagepub.com/doi/pdf/10.1177/1074248412439470,,22431864
CD010254-bib-0120,AstraZeneca. ,"A 30‐week, forced‐titration and randomised, crossover, multicentre, multinational trial to evaluate the efficacy and safety of ZD4522 and atorvastatin in subjects with homozygous familial hypercholesterolaemia (4522IL/0054): Report of the first 18 weeks of treatment (Open label ZD4522 20/40/80 mg, forced‐titration period)",,,,   ,['citation-other']," AstraZeneca. A 30‐week, forced‐titration and randomised, crossover, multicentre, multinational trial to evaluate the efficacy and safety of ZD4522 and atorvastatin in subjects with homozygous familial hypercholesterolaemia (4522IL/0054): Report of the first 18 weeks of treatment (Open label ZD4522 20/40/80 mg, forced‐titration period). http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610186 (accessed 30 March 2001). [Study code 4522IL/0054]CENTRAL    ",[''],,, Marais 2008 {published data only}  ,included,CD010254-bbs2-0064,,,,,,,,
CD010254-bib-0121,"Marais AD, Raal FJ, Stein EA, Rader DJ, Blasetto J, Palmer M, et al. ",A dose‐titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia, Atherosclerosis ,2008,197,    ,['citation-journal']," Marais AD, Raal FJ, Stein EA, Rader DJ, Blasetto J, Palmer M, et al. A dose‐titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia.  Atherosclerosis 2008;197(1):400‐6. [MEDLINE: 17727860]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.atherosclerosis.2007.06.028', 'https://www.ncbi.nlm.nih.gov/pubmed/17727860', 'https://scholar.google.com/scholar_lookup?title=A+dose‐titration+and+comparative+study+of+rosuvastatin+and+atorvastatin+in+patients+with+homozygous+familial+hypercholesterolaemia+&author=AD+Marais&author=FJ+Raal&author=EA+Stein&author=DJ+Rader&author=J+Blasetto&author=M+Palmer&publication_year=2008&hl=en']",17727860,https://doi.org/10.1016/j.atherosclerosis.2007.06.028, Marais 2008 {published data only}  ,included,CD010254-bbs2-0064,,,17727860,17727860,95,,,17727860
CD010254-bib-0122,"Marino F, Maresca AM, Cosentino M, Castiglioni L, Rasini E, Mongiardi C, et al. ",Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3‐month rosuvastatin treatment, Cardiovascular Diabetology ,2012,11,    ,['citation-journal']," Marino F, Maresca AM, Cosentino M, Castiglioni L, Rasini E, Mongiardi C, et al. Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3‐month rosuvastatin treatment.  Cardiovascular Diabetology 2012;11:153. [MEDLINE: 23259529]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1186/1475-2840-11-153', 'https://www.ncbi.nlm.nih.gov/pubmed/23259529', 'https://scholar.google.com/scholar_lookup?title=Angiotensin+II+type+1+and+type+2+receptor+expression+in+circulating+monocytes+of+diabetic+and+hypercholesterolemic+patients+over+3‐month+rosuvastatin+treatment+&author=F+Marino&author=AM+Maresca&author=M+Cosentino&author=L+Castiglioni&author=E+Rasini&author=C+Mongiardi&publication_year=2012&hl=en']",23259529,https://doi.org/10.1186/1475-2840-11-153, Marino 2012 {published data only}  ,included,CD010254-bbs2-0065,,,23259529,23259529,11,https://cardiab.biomedcentral.com/counter/pdf/10.1186/1475-2840-11-153,,23259529
CD010254-bib-0123,AstraZeneca. ,"An open‐label randomised, multicentre, Phase‐IIIb, parallel‐group switching study to compare the efficacy and safety of lipid‐lowering agents atorvastatin, pravastatin, simvastatin and rosuvastatin in subjects with Type IIa and IIb hypercholesterolaemia (MERCURY I)",,,,   ,['citation-other']," AstraZeneca. An open‐label randomised, multicentre, Phase‐IIIb, parallel‐group switching study to compare the efficacy and safety of lipid‐lowering agents atorvastatin, pravastatin, simvastatin and rosuvastatin in subjects with Type IIa and IIb hypercholesterolaemia (MERCURY I). http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610186 (accessed 30 March 2001). [Study code D3560C00081/4522IL/0081]CENTRAL    ",[''],,, MERCURY I 2004 {published data only}  ,included,CD010254-bbs2-0066,,,,,,,,
CD010254-bib-0124,"Cheung RC, Morrell JM, Kallend D, Watkins C, Schuster H. ",Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study, International Journal of Cardiology ,2005,100,    ,['citation-journal']," Cheung RC, Morrell JM, Kallend D, Watkins C, Schuster H. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.  International Journal of Cardiology 2005;100(2):309‐16. [MEDLINE: 15823640]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ijcard.2004.12.011', 'https://www.ncbi.nlm.nih.gov/pubmed/15823640', 'https://scholar.google.com/scholar_lookup?title=Effects+of+switching+statins+on+lipid+and+apolipoprotein+ratios+in+the+MERCURY+I+study&author=RC+Cheung&author=JM+Morrell&author=D+Kallend&author=C+Watkins&author=H+Schuster&publication_year=2005&hl=en']",15823640,https://doi.org/10.1016/j.ijcard.2004.12.011, MERCURY I 2004 {published data only}  ,included,CD010254-bbs2-0066,,15823640,,15823640,27,,,15823640
CD010254-bib-0125,"Schuster H, Palmer MK, Ditmarsch M. ",The MERCURY I open‐label extension study ‐ Subgroup analysis in patients with diabetes, British Journal of Diabetes and Vascular Disease ,2008,8,    ,['citation-journal']," Schuster H, Palmer MK, Ditmarsch M. The MERCURY I open‐label extension study ‐ Subgroup analysis in patients with diabetes.  British Journal of Diabetes and Vascular Disease 2008;8(3):142‐7. [EMBASE: 2008340601]CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1177/14746514080080030601', 'https://scholar.google.com/scholar_lookup?title=The\xa0MERCURY\xa0I\xa0open‐label\xa0extension\xa0study\xa0‐\xa0Subgroup\xa0analysis\xa0in\xa0patients\xa0with\xa0diabetes&author=H+Schuster&author=MK+Palmer&author=M+Ditmarsch&publication_year=2008&hl=en']",,https://doi.org/10.1177/14746514080080030601, MERCURY I 2004 {published data only}  ,included,CD010254-bbs2-0066,,,,,3,,,
CD010254-bib-0126,"Stender S, Schuster H, Barter P, Watkins C, Kallend D, MERCURY I Study Group. ","Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial"," Diabetes, Obesity & Metabolism ",2005,7,    ,['citation-journal']," Stender S, Schuster H, Barter P, Watkins C, Kallend D, MERCURY I Study Group. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.  Diabetes, Obesity & Metabolism 2005;7(4):430‐8. [MEDLINE: 15955130]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1111/j.1463-1326.2004.00450.x', 'https://www.ncbi.nlm.nih.gov/pubmed/15955130', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+rosuvastatin+with+atorvastatin,+simvastatin+and+pravastatin+in+achieving+cholesterol+goals+and+improving+plasma+lipids+in+hypercholesterolaemic+patients+with+or+without+the+metabolic+syndrome+in+the+MERCURY+I+trial+&author=S+Stender&author=H+Schuster&author=P+Barter&author=C+Watkins&author=D+Kallend&publication_year=2005&hl=en']",15955130,https://doi.org/10.1111/j.1463-1326.2004.00450.x, MERCURY I 2004 {published data only}  ,included,CD010254-bbs2-0066,,,,15955130,82,,,15955130
CD010254-bib-0127,AstraZeneca. ,"An open label, randomized, multi‐center, Phase IIIB, parallel group switching study to compare the efficacy and safety of lipid lowering agents atorvastatin and simvastatin with rosuvastatin in high risk subjects with Type IIa and IIb hypercholesterolemia",,,,   ,['citation-other']," AstraZeneca. An open label, randomized, multi‐center, Phase IIIB, parallel group switching study to compare the efficacy and safety of lipid lowering agents atorvastatin and simvastatin with rosuvastatin in high risk subjects with Type IIa and IIb hypercholesterolemia. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/9256928 (accessed 17 November 2004). [Study code D3560C00068/4522IL/0068]CENTRAL    ",[''],,, MERCURY II 2006 {published data only}  ,included,CD010254-bbs2-0067,,,,,,,,
CD010254-bib-0128,"Ballantyne CM, Bertolami M, Garcia HRH, Nul D, Stein EA, Theroux P, et al. ","Achieving LDL cholesterol, non‐HDL cholesterol, and apolipoprotein B target levels in high‐risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II", American Heart Journal ,2006,151,    ,['citation-journal']," Ballantyne CM, Bertolami M, Garcia HRH, Nul D, Stein EA, Theroux P, et al. Achieving LDL cholesterol, non‐HDL cholesterol, and apolipoprotein B target levels in high‐risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.  American Heart Journal 2006;151(5):975.e1‐975.e9. [MEDLINE: 16644314]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ahj.2005.12.013', 'https://www.ncbi.nlm.nih.gov/pubmed/16644314', 'https://scholar.google.com/scholar_lookup?title=Achieving+LDL+cholesterol,+non‐HDL+cholesterol,+and+apolipoprotein+B+target+levels+in+high‐risk+patients:+Measuring+Effective+Reductions+in+Cholesterol+Using+Rosuvastatin+therapY+(MERCURY)+II+&author=CM+Ballantyne&author=M+Bertolami&author=HRH+Garcia&author=D+Nul&author=EA+Stein&author=P+Theroux&publication_year=2006&hl=en']",16644314,https://doi.org/10.1016/j.ahj.2005.12.013, MERCURY II 2006 {published data only}  ,included,CD010254-bbs2-0067,,,,16644314,114,,,16644314
CD010254-bib-0129,"Ballantyne CM, Raichlen JS, Cain VA. ",Statin therapy alters the relationship between apolipoprotein B and low‐density lipoprotein cholesterol and non‐high‐density lipoprotein cholesterol targets in high‐risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial, Journal of the American College of Cardiology ,2008,52,    ,['citation-journal']," Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low‐density lipoprotein cholesterol and non‐high‐density lipoprotein cholesterol targets in high‐risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.  Journal of the American College of Cardiology 2008;52(8):626‐32. [MEDLINE: 18702965]CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/18702965', 'https://scholar.google.com/scholar_lookup?title=Statin+therapy+alters+the+relationship+between+apolipoprotein+B+and+low‐density+lipoprotein+cholesterol+and+non‐high‐density+lipoprotein+cholesterol+targets+in+high‐risk+patients:+the+MERCURY+II+(Measuring+Effective+Reductions+in+Cholesterol+Using+Rosuvastatin)+trial+&author=CM+Ballantyne&author=JS+Raichlen&author=VA+Cain&publication_year=2008&hl=en']",18702965,, MERCURY II 2006 {published data only}  ,included,CD010254-bbs2-0067,,,,,,,,18702965
CD010254-bib-0130,Izzat I. ,The MERCURY II trial: Benefits of rosuvastatin, British Journal of Diabetes and Vascular Disease ,2006,6,    ,['citation-journal'], Izzat I. The MERCURY II trial: Benefits of rosuvastatin.  British Journal of Diabetes and Vascular Disease 2006;6(4):171‐6. [EMBASE: 2006426646]CENTRAL    Link to article     Google Scholar     ,"['', 'https://doi.org/10.1177/14746514060060040501', 'https://scholar.google.com/scholar_lookup?title=The+MERCURY+II+trial:+Benefits+of+rosuvastatin&author=I+Izzat&publication_year=2006&hl=en']",,https://doi.org/10.1177/14746514060060040501, MERCURY II 2006 {published data only}  ,included,CD010254-bbs2-0067,,,,,3,,,
CD010254-bib-0131,"Milionis HJ, Gazi IF, Filippatos TD, Tzovaras V, Chasiotis G, Goudevenos J, et al. ",Starting with rosuvastatin in primary hyperlipidemia ‐ Is there more than lipid lowering?, Angiology ,2005,56,    ,['citation-journal']," Milionis HJ, Gazi IF, Filippatos TD, Tzovaras V, Chasiotis G, Goudevenos J, et al. Starting with rosuvastatin in primary hyperlipidemia ‐ Is there more than lipid lowering?.  Angiology 2005;56(5):585‐92. [MEDLINE: 16193198]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1177/000331970505600510', 'https://www.ncbi.nlm.nih.gov/pubmed/16193198', 'https://scholar.google.com/scholar_lookup?title=Starting+with+rosuvastatin+in+primary+hyperlipidemia+‐+Is+there+more+than+lipid+lowering?&author=HJ+Milionis&author=IF+Gazi&author=TD+Filippatos&author=V+Tzovaras&author=G+Chasiotis&author=J+Goudevenos&publication_year=2005&hl=en']",16193198,https://doi.org/10.1177/000331970505600510, Milionis 2005 {published data only}  ,included,CD010254-bbs2-0068,,,,16193198,20,,,16193198
CD010254-bib-0132,"Mori H, Okada Y, Tanaka Y. ","Effects of pravastatin, atorvastatin, and rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia", Diabetology International ,2013,4,    ,['citation-journal']," Mori H, Okada Y, Tanaka Y. Effects of pravastatin, atorvastatin, and rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia.  Diabetology International 2013;4(2):117‐25. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1007/s13340-012-0103-x', 'https://scholar.google.com/scholar_lookup?title=Effects+of+pravastatin,+atorvastatin,+and+rosuvastatin+in+patients+with+type+2+diabetes+mellitus+and+hypercholesterolemia+&author=H+Mori&author=Y+Okada&author=Y+Tanaka&publication_year=2013&hl=en']",,https://doi.org/10.1007/s13340-012-0103-x, Mori 2013 {published data only}  ,included,CD010254-bbs2-0069,,,,,6,,,
CD010254-bib-0133,"Moutzouri E, Liberopoulos E, Mikhailidis DP, Kostapanos MS, Kei AA, Milionis H, et al. ",Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance, International Journal of Clinical Practice ,2011,65,    ,['citation-journal']," Moutzouri E, Liberopoulos E, Mikhailidis DP, Kostapanos MS, Kei AA, Milionis H, et al. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance.  International Journal of Clinical Practice 2011;65(11):1141‐8. [MEDLINE: 21995692]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1111/j.1742-1241.2011.02779.x', 'https://www.ncbi.nlm.nih.gov/pubmed/21995692', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+the+effects+of+simvastatin+vs.+rosuvastatin+vs.+simvastatin/ezetimibe+on+parameters+of+insulin+resistance+&author=E+Moutzouri&author=E+Liberopoulos&author=DP+Mikhailidis&author=MS+Kostapanos&author=AA+Kei&author=H+Milionis&publication_year=2011&hl=en']",21995692,https://doi.org/10.1111/j.1742-1241.2011.02779.x, Moutzouri 2011 {published data only}  ,included,CD010254-bbs2-0070,,,21995692,21995692,73,https://doi.org/10.1111/j.1742-1241.2011.02779.x,,21995692
CD010254-bib-0134,AstraZeneca. ,"A Randomised, Double‐blind, Parallel‐group, Dose‐response Study with the HMG‐CoA Reductase Inhibitor ZD4522 in Subjects with Primary Hypercholesterolaemia",,,,   ,['citation-other']," AstraZeneca. A Randomised, Double‐blind, Parallel‐group, Dose‐response Study with the HMG‐CoA Reductase Inhibitor ZD4522 in Subjects with Primary Hypercholesterolaemia. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/4522il_0023 (accessed 28 March 2000). [Code study 4522IL/0023]CENTRAL    ",[''],,, Olsson 2001 {published data only}  ,included,CD010254-bbs2-0071,,,,,,,,
CD010254-bib-0135,AstraZeneca. ,"A Randomised, Parallel‐Group Dose‐Response Study with the HMG‐CoA Reductase Inhibitor ZD4522 and Atorvastatin in Subjects with Primary Hypercholesterolaemia",,,,   ,['citation-other']," AstraZeneca. A Randomised, Parallel‐Group Dose‐Response Study with the HMG‐CoA Reductase Inhibitor ZD4522 and Atorvastatin in Subjects with Primary Hypercholesterolaemia. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/4522IL_0008 (accessed 14 January 2000). [Code study 4522IL/0008]CENTRAL    ",[''],,, Olsson 2001 {published data only}  ,included,CD010254-bbs2-0071,,,,,,,,
CD010254-bib-0136,Olsson A G. ,A new statin: a new standard,,2001,,    ,['citation-other']," Olsson A G. A new statin: a new standard. The American journal of managed care. United States, 2001; Vol. 7, issue 5 Suppl:S152‐4. [MEDLINE: 11383378]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=A+new+statin:+a+new+standard&author=AG+Olsson&publication_year=2001&hl=en']",,, Olsson 2001 {published data only}  ,included,CD010254-bbs2-0071,,28504565,,,,,,28504565
CD010254-bib-0137,"Olsson AG, Pears J, McKellar J, Mizan J, Raza A. ",Effect of rosuvastatin on low‐density lipoprotein cholesterol in patients with hypercholesterolemia, American Journal of Cardiology ,2001,88,    ,['citation-journal']," Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low‐density lipoprotein cholesterol in patients with hypercholesterolemia.  American Journal of Cardiology 2001;88(5):504‐8. [MEDLINE: 11524058]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0002-9149(01)01727-1', 'https://www.ncbi.nlm.nih.gov/pubmed/11524058', 'https://scholar.google.com/scholar_lookup?title=Effect+of+rosuvastatin+on+low‐density+lipoprotein+cholesterol+in+patients+with+hypercholesterolemia&author=AG+Olsson&author=J+Pears&author=J+McKellar&author=J+Mizan&author=A+Raza&publication_year=2001&hl=en']",11524058,https://doi.org/10.1016/S0002-9149(01)01727-1, Olsson 2001 {published data only}  ,included,CD010254-bbs2-0071,,11524058,,11524058,204,,,11524058
CD010254-bib-0138,AstraZeneca. ,"A randomised, double‐blind, multinational, multicentre trial to compare the short‐term and long‐term efficacy and safety of ZD4522 and atorvastatin in the treatment of subjects with hypercholesterolaemia",,,,   ,['citation-other']," AstraZeneca. A randomised, double‐blind, multinational, multicentre trial to compare the short‐term and long‐term efficacy and safety of ZD4522 and atorvastatin in the treatment of subjects with hypercholesterolaemia. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/4522il_0026 (accessed 14 March 2001). [Code study 4522IL/0026]CENTRAL    ",[''],,, Olsson 2002 {published data only}  ,included,CD010254-bbs2-0072,,,,,,,,
CD010254-bib-0139,"Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, et al. ",Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia, American Heart Journal ,2002,144,    ,['citation-journal']," Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.  American Heart Journal 2002;144(6):1044‐51. [MEDLINE: 12486429]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1067/mhj.2002.128049', 'https://www.ncbi.nlm.nih.gov/pubmed/12486429', 'https://scholar.google.com/scholar_lookup?title=Effects+of+rosuvastatin+and+atorvastatin+compared+over+52+weeks+of+treatment+in+patients+with+hypercholesterolemia+&author=AG+Olsson&author=H+Istad&author=O+Luurila&author=L+Ose&author=S+Stender&author=J+Tuomilehto&publication_year=2002&hl=en']",12486429,https://doi.org/10.1067/mhj.2002.128049, Olsson 2002 {published data only}  ,included,CD010254-bbs2-0072,,,,12486429,192,,,12486429
CD010254-bib-0140,"Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A. ",Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups, American Jjournal of Cardiology ,2003,91,    ,['citation-journal']," Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.  American Jjournal of Cardiology 2003;91(5A):3C‐10C. [MEDLINE: 12646336]CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/S0002-9149(03)00003-1', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+rosuvastatin+compared+with+other+statins+at+selected+starting+doses+in+hypercholesterolemic+patients+and+in+special+population+groups+&author=JW+Blasetto&author=EA+Stein&author=WV+Brown&author=R+Chitra&author=A+Raza&publication_year=2003&hl=en']",,https://doi.org/10.1016/S0002-9149(03)00003-1, Paoletti 2009 {published data only}  ,included,CD010254-bbs2-0073,,12646336,12646336,12646336,149,,,12646336
CD010254-bib-0141,"Chapman MJ, Caslake M. ",Non‐high‐density lipoprotein cholesterol as a risk factor: Addressing risk associated with apolipoprotein B‐containing lipoproteins," European Heart Journal, Supplement ",2004,6,    ,['citation-journal']," Chapman MJ, Caslake M. Non‐high‐density lipoprotein cholesterol as a risk factor: Addressing risk associated with apolipoprotein B‐containing lipoproteins.  European Heart Journal, Supplement 2004;6(A):A43‐A48. [EMBASE: 2004139456]CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.ehjsup.2004.01.010', 'https://scholar.google.com/scholar_lookup?title=Non‐high‐density\xa0lipoprotein\xa0cholesterol\xa0as\xa0a\xa0risk\xa0factor:+Addressing\xa0risk\xa0associated+with+apolipoprotein+B‐containing+lipoproteins+&author=MJ+Chapman&author=M+Caslake&publication_year=2004&hl=en']",,https://doi.org/10.1016/j.ehjsup.2004.01.010, Paoletti 2009 {published data only}  ,included,CD010254-bbs2-0073,,,,,26,https://academic.oup.com/eurheartjsupp/article-pdf/6/suppl_A/A43/9792827/A43.pdf,,
CD010254-bib-0142,"Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. ","Rosuvastatin demonstrates greater reduction of low‐density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: A randomized, double‐blind study", Journal of Cardiovascular Risk ,2001,8,    ,['citation-journal']," Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low‐density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: A randomized, double‐blind study.  Journal of Cardiovascular Risk 2001;8(6):383‐90. [MEDLINE: 11873095]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1177/174182670100800608', 'https://www.ncbi.nlm.nih.gov/pubmed/11873095', 'https://scholar.google.com/scholar_lookup?title=Rosuvastatin+demonstrates+greater+reduction+of+low‐density+lipoprotein+cholesterol+compared+with+pravastatin+and+simvastatin+in+hypercholesterolaemic+patients:+A+randomized,+double‐blind+study+&author=R+Paoletti&author=M+Fahmy&author=G+Mahla&author=J+Mizan&author=H+Southworth&publication_year=2001&hl=en']",11873095,https://doi.org/10.1177/174182670100800608, Paoletti 2009 {published data only}  ,included,CD010254-bbs2-0073,,11873095,11873095,11873095,145,https://academic.oup.com/eurjpc/article-pdf/8/6/383/34312456/eurjpc0383.pdf,,11873095
CD010254-bib-0143,ClinicalTrials.gov. ,"A 6‐week, randomised, open‐label, parallel group, multi‐centre study to compare the efficacy of rosuvastatin 10mg with atorvastatin 10mg in the treatment of non‐diabetic metabolic syndrome subjects with raised LDL‐C",,,,   ,['citation-other']," ClinicalTrials.gov. A 6‐week, randomised, open‐label, parallel group, multi‐centre study to compare the efficacy of rosuvastatin 10mg with atorvastatin 10mg in the treatment of non‐diabetic metabolic syndrome subjects with raised LDL‐C. http://clinicaltrials.gov/show/NCT00335699 (accessed 25 November 2012). [Study code NCT00335699/D3560L00053 or KREST]CENTRAL    ",[''],,, Park 2010 {published data only}  ,included,CD010254-bbs2-0074,,,,,,,,
CD010254-bib-0144,"Park JS, Kim YJ, Choi JY, Kim YN, Hong TJ, Kim DS, et al. ",Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia, Korean Journal of Internal Medicine ,2010,25,    ,['citation-journal']," Park JS, Kim YJ, Choi JY, Kim YN, Hong TJ, Kim DS, et al. Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia.  Korean Journal of Internal Medicine 2010;25(1):27‐35. [MEDLINE: 20195400]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.3904/kjim.2010.25.1.27', 'https://www.ncbi.nlm.nih.gov/pubmed/20195400', 'https://scholar.google.com/scholar_lookup?title=Comparative+study+of+low+doses+of+rosuvastatin+and+atorvastatin+on+lipid+and+glycemic+control+in+patients+with+metabolic+syndrome+and+hypercholesterolemia+&author=JS+Park&author=YJ+Kim&author=JY+Choi&author=YN+Kim&author=TJ+Hong&author=DS+Kim&publication_year=2010&hl=en']",20195400,https://doi.org/10.3904/kjim.2010.25.1.27, Park 2010 {published data only}  ,included,CD010254-bbs2-0074,,,20195400,,,,,20195400
CD010254-bib-0145,"Patel K, Jhaveri R, George J, Qiang G, Kenedi C, Brown K, et al. ","Open‐label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C", Journal of Viral Hepatitis ,2011,18,    ,['citation-journal']," Patel K, Jhaveri R, George J, Qiang G, Kenedi C, Brown K, et al. Open‐label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C.  Journal of Viral Hepatitis 2011;18(5):331‐7. [EMBASE: 2011197820]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1111/j.1365-2893.2010.01310.x', 'https://www.ncbi.nlm.nih.gov/pubmed/20367801', 'https://scholar.google.com/scholar_lookup?title=Open‐label,+ascending+dose,+prospective+cohort+study+evaluating+the+antiviral+efficacy+of+Rosuvastatin+therapy+in+serum+and+lipid+fractions+in+patients+with+chronic+hepatitis+C+&author=K+Patel&author=R+Jhaveri&author=J+George&author=G+Qiang&author=C+Kenedi&author=K+Brown&publication_year=2011&hl=en']",20367801,https://doi.org/10.1111/j.1365-2893.2010.01310.x, Patel 2011 {published data only}  ,included,CD010254-bbs2-0075,,,20367801,20367801,22,https://europepmc.org/articles/pmc3826439?pdf=render,,20367801
CD010254-bib-0146,"Pirro M, Schillaci G, Mannarino MR, Savarese G, Vaudo G, Siepi D, et al. ",Effects of rosuvastatin on 3‐nitrotyrosine and aortic stiffness in hypercholesterolemia," Nutrition, Metabolism and Cardiovascular Diseases ",2007,17,    ,['citation-journal']," Pirro M, Schillaci G, Mannarino MR, Savarese G, Vaudo G, Siepi D, et al. Effects of rosuvastatin on 3‐nitrotyrosine and aortic stiffness in hypercholesterolemia.  Nutrition, Metabolism and Cardiovascular Diseases 2007;17(6):436‐41. [MEDLINE: 17134956]CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.numecd.2006.02.009', 'https://scholar.google.com/scholar_lookup?title=Effects+of+rosuvastatin+on+3‐nitrotyrosine+and+aortic+stiffness+in+hypercholesterolemia&author=M+Pirro&author=G+Schillaci&author=MR+Mannarino&author=G+Savarese&author=G+Vaudo&author=D+Siepi&publication_year=2007&hl=en']",,https://doi.org/10.1016/j.numecd.2006.02.009, Pirro 2007 {published data only}  ,included,CD010254-bbs2-0076,,,17134956,17134956,68,,,17134956
CD010254-bib-0147,"Pirro M, Schillaci G, Romagno PF, Mannarino MR, Bagaglia F, Razzi R, et al. ",Influence of short‐term rosuvastatin therapy on endothelial progenitor cells and endothelial function, Journal of Cardiovascular Pharmacology and Therapeutics ,2009,14,    ,['citation-journal']," Pirro M, Schillaci G, Romagno PF, Mannarino MR, Bagaglia F, Razzi R, et al. Influence of short‐term rosuvastatin therapy on endothelial progenitor cells and endothelial function.  Journal of Cardiovascular Pharmacology and Therapeutics 2009;14(1):14‐21. [MEDLINE: 19158317]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1177/1074248408331021', 'https://www.ncbi.nlm.nih.gov/pubmed/19158317', 'https://scholar.google.com/scholar_lookup?title=Influence+of+short‐term+rosuvastatin+therapy+on+endothelial+progenitor+cells+and+endothelial+function+&author=M+Pirro&author=G+Schillaci&author=PF+Romagno&author=MR+Mannarino&author=F+Bagaglia&author=R+Razzi&publication_year=2009&hl=en']",19158317,https://doi.org/10.1177/1074248408331021, Pirro 2009 {published data only}  ,included,CD010254-bbs2-0077,,,,19158317,61,,,19158317
CD010254-bib-0148,AstraZeneca. ,"A phase IIIb, efficacy, and safety study of rosuvastatin in children and adolescents 10 to 17 years of age with heterozygous familial hypercholesterolemia (HeFH): a 12‐week, double‐blind, randomized, multicenter, placebo‐controlled study with a 40‐week, open‐label, follow‐up period",,,,   ,['citation-other']," AstraZeneca. A phase IIIb, efficacy, and safety study of rosuvastatin in children and adolescents 10 to 17 years of age with heterozygous familial hypercholesterolemia (HeFH): a 12‐week, double‐blind, randomized, multicenter, placebo‐controlled study with a 40‐week, open‐label, follow‐up period. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610528 (accessed 11 March 2008). [Study code D3561C00087/4522IL/0087]CENTRAL    ",[''],,, PLUTO 2010 {published data only}  ,included,CD010254-bbs2-0078,,,,,,,,
CD010254-bib-0149,"Avis HJ, Hargreaves IP, Ruiter JPN, Land JM, Wanders RJ, Wijburg FA. ","Rosuvastatin lowers coenzyme Q10 levels, but not mitochondrial adenosine triphosphate synthesis, in children with familial hypercholesterolemia",,2011,,    ,['citation-other']," Avis HJ, Hargreaves IP, Ruiter JPN, Land JM, Wanders RJ, Wijburg FA. Rosuvastatin lowers coenzyme Q10 levels, but not mitochondrial adenosine triphosphate synthesis, in children with familial hypercholesterolemia. Journal of Pediatrics. United States: Department of Pediatrics, Academic Medical Center, Amsterdam, The Netherlands., 2011; Vol. 158, issue 3:458‐62. [MEDLINE: 20884007]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Rosuvastatin+lowers+coenzyme+Q10+levels,+but+not+mitochondrial+adenosine+triphosphate+synthesis,+in+children+with+familial+hypercholesterolemia+&author=HJ+Avis&author=IP+Hargreaves&author=JPN+Ruiter&author=JM+Land&author=RJ+Wanders&author=FA+Wijburg&publication_year=2011&hl=en']",,, PLUTO 2010 {published data only}  ,included,CD010254-bbs2-0078,,,,,,,,
CD010254-bib-0150,"Avis HJ, Hutten BA, Gagne C, Langslet G, McCrindle BW, Wiegman A, et al. ",Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia, Journal of the American College of Cardiology ,2010,55,    ,['citation-journal']," Avis HJ, Hutten BA, Gagne C, Langslet G, McCrindle BW, Wiegman A, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia.  Journal of the American College of Cardiology 2010;55(11):1121‐6. [MEDLINE: 20223367]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.jacc.2009.10.042', 'https://www.ncbi.nlm.nih.gov/pubmed/20223367', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+rosuvastatin+therapy+for+children+with+familial+hypercholesterolemia&author=HJ+Avis&author=BA+Hutten&author=C+Gagne&author=G+Langslet&author=BW+McCrindle&author=A+Wiegman&publication_year=2010&hl=en']",20223367,https://doi.org/10.1016/j.jacc.2009.10.042, PLUTO 2010 {published data only}  ,included,CD010254-bbs2-0078,,,,20223367,160,https://doi.org/10.1016/j.jacc.2009.10.042,,20223367
CD010254-bib-0151,"Polenova NV, Vaulin NA, Masenko VP, Iavelov IS, Gratsianskii NA. ",Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation, Kardiologiia ,2009,49,    ,['citation-journal']," Polenova NV, Vaulin NA, Masenko VP, Iavelov IS, Gratsianskii NA. Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation.  Kardiologiia 2009;49(2):9‐14. [MEDLINE: 19254210]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Rosuvastatin+and+fenofibrate+in+patients+with+diabetes+and+low+high+density+lipoprotein+cholesterol:+comparison+of+changes+of+lipid+levels+and+some+markers+of+inflammation+&author=NV+Polenova&author=NA+Vaulin&author=VP+Masenko&author=IS+Iavelov&author=NA+Gratsianskii&publication_year=2009&hl=en']",,, Polenova 2009 {published data only}  ,included,CD010254-bbs2-0079,,,,,,,,
CD010254-bib-0152,"Semenova AE, Sergienko IV, Masenko VP, Gabrusenko SA, Kukharchuk VV, Belenkov IuN, et al. ",Effect of rosuvastatin therapy and myocardial revascularization on angiogenesis in coronary artery disease patients, Kardiologiia ,2007,47,    ,['citation-journal']," Semenova AE, Sergienko IV, Masenko VP, Gabrusenko SA, Kukharchuk VV, Belenkov IuN, et al. Effect of rosuvastatin therapy and myocardial revascularization on angiogenesis in coronary artery disease patients.  Kardiologiia 2007;47(11):4‐8. [MEDLINE: 18260956]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effect+of+rosuvastatin+therapy+and+myocardial+revascularization+on+angiogenesis+in+coronary+artery+disease+patients+&author=AE+Semenova&author=IV+Sergienko&author=VP+Masenko&author=SA+Gabrusenko&author=VV+Kukharchuk&author=IuN+Belenkov&publication_year=2007&hl=en']",,, Polenova 2009 {published data only}  ,included,CD010254-bbs2-0079,,,,,,,,
CD010254-bib-0153,"Sergienko IV, Samoilenko EI, Masenko VP, Ezhov MV, Sumarokov AB, Tkachev GA, et al. ","Effect of therapy with rosuvastatin on lipid spectrum, factors of inflammation and endothelial function in patients with ischemic heart disease", Kardiologiia ,2006,46,    ,['citation-journal']," Sergienko IV, Samoilenko EI, Masenko VP, Ezhov MV, Sumarokov AB, Tkachev GA, et al. Effect of therapy with rosuvastatin on lipid spectrum, factors of inflammation and endothelial function in patients with ischemic heart disease.  Kardiologiia 2006;46(5):4‐8. [MEDLINE: 16858347]CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/16858347', 'https://scholar.google.com/scholar_lookup?title=Effect+of+therapy+with+rosuvastatin+on+lipid+spectrum,+factors+of+inflammation+and+endothelial+function+in+patients+with+ischemic+heart+disease+&author=IV+Sergienko&author=EI+Samoilenko&author=VP+Masenko&author=MV+Ezhov&author=AB+Sumarokov&author=GA+Tkachev&publication_year=2006&hl=en']",16858347,, Polenova 2009 {published data only}  ,included,CD010254-bbs2-0079,,,,,,,,16858347
CD010254-bib-0154,"Postadzhiyan AS, Tzontcheva AV, Kehajov I, Kyurkchiev S, Apostolova MD, Finkov B. ",Effect of conventional and more aggressive rosuvastatin treatment on markers of endothelial activation, Journal of Medical Biochemistry ,2008,27,    ,['citation-journal']," Postadzhiyan AS, Tzontcheva AV, Kehajov I, Kyurkchiev S, Apostolova MD, Finkov B. Effect of conventional and more aggressive rosuvastatin treatment on markers of endothelial activation.  Journal of Medical Biochemistry 2008;27(4):432‐8. [EMBASE: 2008553110]CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.2478/v10011-008-0028-x', 'https://scholar.google.com/scholar_lookup?title=Effect+of+conventional+and+more+aggressive+rosuvastatin+treatment+on+markers+of+endothelial+activation+&author=AS+Postadzhiyan&author=AV+Tzontcheva&author=I+Kehajov&author=S+Kyurkchiev&author=MD+Apostolova&author=B+Finkov&publication_year=2008&hl=en']",,https://doi.org/10.2478/v10011-008-0028-x, Postadzhiyan 2008 {published data only}  ,included,CD010254-bbs2-0080,,,,,1,https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2008/1452-82580804432P.pdf,,
CD010254-bib-0155,AstraZeneca. ,"A 6‐week open‐label, randomised, multicentre, Phase IIIb, parallel‐group study to compare the efficacy and safety of rosuvastatin (10 mg) with atorvastatin (20 mg) in subjects with hypercholesterolaemia and either a history of CHD or clinical evidence of CHD",,2005,,    ,['citation-other']," AstraZeneca. A 6‐week open‐label, randomised, multicentre, Phase IIIb, parallel‐group study to compare the efficacy and safety of rosuvastatin (10 mg) with atorvastatin (20 mg) in subjects with hypercholesterolaemia and either a history of CHD or clinical evidence of CHD. Protocol D3569C00001 or 4522IL/01022005. [Study code D3569C0001/4522IL/0102]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=A+6‐week+open‐label,+randomised,+multicentre,+Phase+IIIb,+parallel‐group+study+to+compare+the+efficacy+and+safety+of+rosuvastatin+(10+mg)+with+atorvastatin+(20+mg)+in+subjects+with+hypercholesterolaemia+and+either+a+history+of+CHD+or+clinical+evidence+of+CHD+&author=+AstraZeneca&publication_year=2005&hl=en']",,, PULSAR 2006 {published data only}  ,included,CD010254-bbs2-0081,,41674894,,,,,,41674894
CD010254-bib-0156,"Clearfield MB, Amerena J, Bassand JP Hernandez Garcia HR, Miller SS, et al. ",Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high‐risk patients with hypercholesterolemia ‐ Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR), Trials ,2006,7,    ,['citation-journal']," Clearfield MB, Amerena J, Bassand JP Hernandez Garcia HR, Miller SS, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high‐risk patients with hypercholesterolemia ‐ Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR).  Trials 2006;7:Article 35. [EMBASE: 2007065270]CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1186/1745-6215-7-35', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+the+efficacy+and+safety+of+rosuvastatin+10+mg+and+atorvastatin+20+mg+in+high‐risk+patients+with+hypercholesterolemia+‐+Prospective+study+to+evaluate+the+Use+of+Low+doses+of+the+Statins+Atorvastatin+and+Rosuvastatin+(PULSAR)+&author=MB+Clearfield&author=J+Amerena&author=HR+BassandJPHernandezGarcia&author=SS+Miller&publication_year=2006&hl=en']",,https://doi.org/10.1186/1745-6215-7-35, PULSAR 2006 {published data only}  ,included,CD010254-bbs2-0081,,,17184550,17184550,87,https://trialsjournal.biomedcentral.com/counter/pdf/10.1186/1745-6215-7-35,,17184550
CD010254-bib-0157,"Bergheanu SC, Reijmers T, Zwinderman AH, Bobeldijk I, Ramaker R, Liem AH, et al. ",Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins,,2008,,    ,['citation-other']," Bergheanu SC, Reijmers T, Zwinderman AH, Bobeldijk I, Ramaker R, Liem AH, et al. Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Current Medical Research and Opinion. England: Leiden University Medical Center, Leiden, The Netherlands., 2008; Vol. 24, issue 9:2477‐87. [MEDLINE: 18655752]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Lipidomic+approach+to+evaluate+rosuvastatin+and+atorvastatin+at+various+dosages:+investigating+differential+effects+among+statins+&author=SC+Bergheanu&author=T+Reijmers&author=AH+Zwinderman&author=I+Bobeldijk&author=R+Ramaker&author=AH+Liem&publication_year=2008&hl=en']",,, RADAR 2005 {published data only}  ,included,CD010254-bbs2-0082,,,18655752,,,,,18655752
CD010254-bib-0158,"Bergheanu SC, Van Tol A, Dallinga‐Thie GM, Liem A, Dunselman PHJ, Van der Bom JG, et al. ",Effect of rosuvastatin versus atorvastatin treatment on paraoxonase‐1 activity in men with established cardiovascular disease and a low HDL‐cholesterol,,2007,,    ,['citation-other']," Bergheanu SC, Van Tol A, Dallinga‐Thie GM, Liem A, Dunselman PHJ, Van der Bom JG, et al. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase‐1 activity in men with established cardiovascular disease and a low HDL‐cholesterol. Current Medical Research and Opinion. England: Leiden University Medical Center, Leiden, The Netherlands., 2007; Vol. 23, issue 9:2235‐40. [MEDLINE: 17692153]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effect+of+rosuvastatin+versus+atorvastatin+treatment+on+paraoxonase‐1+activity+in+men+with+established+cardiovascular+disease+and+a+low+HDL‐cholesterol+&author=SC+Bergheanu&author=A+Tol&author=GM+Dallinga‐Thie&author=A+Liem&author=PHJ+Dunselman&author=JG+Bom&publication_year=2007&hl=en']",,, RADAR 2005 {published data only}  ,included,CD010254-bbs2-0082,,,,,,,,
CD010254-bib-0159,"Jukema JW, Liem A‐H, Dunselman PHJM, Van Der Sloot JAP, Lok DJA, Zwinderman AH. ",LDL‐C/HDL‐C ratio in subjects with cardiovascular disease and a low HDL‐C: Results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages and Reverse cholesterol transport) study, Current Medical Research and Opinion ,2005,21,    ,['citation-journal']," Jukema JW, Liem A‐H, Dunselman PHJM, Van Der Sloot JAP, Lok DJA, Zwinderman AH. LDL‐C/HDL‐C ratio in subjects with cardiovascular disease and a low HDL‐C: Results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages and Reverse cholesterol transport) study.  Current Medical Research and Opinion 2005;21(11):1865‐74. [MEDLINE: 16307708]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1185/030079905X74952', 'https://www.ncbi.nlm.nih.gov/pubmed/16307708', 'https://scholar.google.com/scholar_lookup?title=LDL‐C/HDL‐C+ratio+in+subjects+with+cardiovascular+disease+and+a+low+HDL‐C:+Results+of+the+RADAR+(Rosuvastatin+and+Atorvastatin+in+different+Dosages+and+Reverse+cholesterol+transport)+study+&author=JW+Jukema&author=A‐H+Liem&author=PHJM+Dunselman&author=JAP+Sloot&author=DJA+Lok&author=AH+Zwinderman&publication_year=2005&hl=en']",16307708,https://doi.org/10.1185/030079905X74952, RADAR 2005 {published data only}  ,included,CD010254-bbs2-0082,,,,16307708,64,,,16307708
CD010254-bib-0160,"Karalis IK, Bergheanu SC, Wolterbeek R, Dallinga‐Thie G M, Hattori H, van Tol A, et al. ","Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters",,2010,,    ,['citation-other']," Karalis IK, Bergheanu SC, Wolterbeek R, Dallinga‐Thie G M, Hattori H, van Tol A, et al. Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters. Current Medical Research and Opinion. England: Leiden University Medical Center, Leiden, The Netherlands., 2010; Vol. 26, issue 10:2301‐13. [MEDLINE: 20731529]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effect+of+increasing+doses+of+Rosuvastatin+and+Atorvastatin+on+apolipoproteins,+enzymes+and+lipid+transfer+proteins+involved+in+lipoprotein+metabolism+and+inflammatory+parameters+&author=IK+Karalis&author=SC+Bergheanu&author=R+Wolterbeek&author=GM+Dallinga‐Thie&author=H+Hattori&author=A+Tol&publication_year=2010&hl=en']",,, RADAR 2005 {published data only}  ,included,CD010254-bbs2-0082,,,20731529,,,,,20731529
CD010254-bib-0161,"Raza A, inventor. ",Use of Cholesterol‐lowering agent,,,,   ,['citation-other']," Raza A, inventor. Use of Cholesterol‐lowering agent. World patent 20000458/9 2000 Aug 10. [Patent Number WO20000458/9]CENTRAL    ",[''],,, Raza 2000 {published data only}  ,included,CD010254-bbs2-0083,,,,,,,,
CD010254-bib-0162,AstraZeneca. ,"A 6‐week, randomised, open‐label, parallel group, multi‐centre study to compare the efficacy of rosuvastatin 10mg with atorvastatin 10mg in the treatment of metabolic syndrome subjects with raised LDL‐C; ROsuvastatin in MEtabolic syndrOm (ROMEO)",,,,   ,['citation-other']," AstraZeneca. A 6‐week, randomised, open‐label, parallel group, multi‐centre study to compare the efficacy of rosuvastatin 10mg with atorvastatin 10mg in the treatment of metabolic syndrome subjects with raised LDL‐C; ROsuvastatin in MEtabolic syndrOm (ROMEO). http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/D3560L00061 (accessed 10 March 2009). [Study code D3560L00061]CENTRAL    ",[''],,, ROMEO 2009 {published data only}  ,included,CD010254-bbs2-0084,,,,,,,,
CD010254-bib-0163,ClinicalTrials.gov. ,"A 6‐week, randomised, open‐label, parallel group, multi‐centre study to compare the efficacy of rosuvastatin 10mg with atorvastatin 10mg in the treatment of metabolic syndrome subjects with raised LDL‐C",,,,   ,['citation-other']," ClinicalTrials.gov. A 6‐week, randomised, open‐label, parallel group, multi‐centre study to compare the efficacy of rosuvastatin 10mg with atorvastatin 10mg in the treatment of metabolic syndrome subjects with raised LDL‐C. http://clinicaltrials.gov/ct2/show/results/NCT00395486 (accessed 30 June 2011). [Study code NCT00395486]CENTRAL    ",[''],,, ROMEO 2009 {published data only}  ,included,CD010254-bbs2-0084,,,,,,,,
CD010254-bib-0164,ClinicalTrials.gov. ,A multicenter study comparing the safety and efficacy of ABT‐335 and rosuvastatin calcium combination therapy to monotherapy in subjects with dyslipidemia,,,,   ,['citation-other'], ClinicalTrials.gov. A multicenter study comparing the safety and efficacy of ABT‐335 and rosuvastatin calcium combination therapy to monotherapy in subjects with dyslipidemia. http://clinicaltrials.gov/ct2/show/NCT00463606 (accessed 27 September 2012). [Study code NCT00463606]CENTRAL    ,[''],,, Rosenson 2011 {published data only}  ,included,CD010254-bbs2-0085,,,,,,,,
CD010254-bib-0165,ClinicalTrials.gov. ,Evaluate safety and efficacy of ABT‐335 in combination with rosuvastatin calcium in subjects with multiple abnormal lipid levels in the blood,,,,   ,['citation-other'], ClinicalTrials.gov. Evaluate safety and efficacy of ABT‐335 in combination with rosuvastatin calcium in subjects with multiple abnormal lipid levels in the blood. http://clinicaltrials.gov/show/NCT00300482 (assessed 03 June 2009). [Study code NCT00300482]CENTRAL    ,[''],,, Rosenson 2011 {published data only}  ,included,CD010254-bbs2-0085,,,,,,,,
CD010254-bib-0166,"Rosenson RS, Carlson DM, Kelly MT, Carolyn MS, Hirshberg B, Stolzenbach JV, et al. ",Achievement of lipid targets with the combination of rosuvastatin and fenofibric acid in patients with type 2 diabetes mellitus, Cardiovascular Drugs and Therapy ,2011,25,    ,['citation-journal']," Rosenson RS, Carlson DM, Kelly MT, Carolyn MS, Hirshberg B, Stolzenbach JV, et al. Achievement of lipid targets with the combination of rosuvastatin and fenofibric acid in patients with type 2 diabetes mellitus.  Cardiovascular Drugs and Therapy 2011;25(1):47‐57. [MEDLINE: 21174145]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1007/s10557-010-6273-5', 'https://www.ncbi.nlm.nih.gov/pubmed/21174145', 'https://scholar.google.com/scholar_lookup?title=Achievement+of+lipid+targets+with+the+combination+of+rosuvastatin+and+fenofibric+acid+in+patients+with+type+2+diabetes+mellitus+&author=RS+Rosenson&author=DM+Carlson&author=MT+Kelly&author=MS+Carolyn&author=B+Hirshberg&author=JV+Stolzenbach&publication_year=2011&hl=en']",21174145,https://doi.org/10.1007/s10557-010-6273-5, Rosenson 2011 {published data only}  ,included,CD010254-bbs2-0085,,,21174145,21174145,16,https://link.springer.com/content/pdf/10.1007/s10557-010-6273-5.pdf,,21174145
CD010254-bib-0167,AstraZeneca. ,"A randomised, double‐blind, dose‐response study with the HMG‐CoA reductase inhibitor ZD4522 in subjects with hyperlipidaemis (a Phase II clinical study)",,,,   ,['citation-other']," AstraZeneca. A randomised, double‐blind, dose‐response study with the HMG‐CoA reductase inhibitor ZD4522 in subjects with hyperlipidaemis (a Phase II clinical study). http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/9256762 (accessed 10 December 2001). [Study code 4522IL/0055]CENTRAL    ",[''],,, Saito 2003 {published data only}  ,included,CD010254-bbs2-0086,,,,,,,,
CD010254-bib-0168,Saito Y. ,Randomized dose‐response study of rosuvastatin in Japanese patients with hypercholesterolemia, Journal of Atherosclerosis and Thrombosis ,2003,10,    ,['citation-journal'], Saito Y. Randomized dose‐response study of rosuvastatin in Japanese patients with hypercholesterolemia.  Journal of Atherosclerosis and Thrombosis 2003;10(6):329. [MEDLINE: 15037821]CENTRAL    Link to article     PubMed     Google Scholar     ,"['', 'https://doi.org/10.5551/jat.10.329', 'https://www.ncbi.nlm.nih.gov/pubmed/15037821', 'https://scholar.google.com/scholar_lookup?title=Randomized+dose‐response+study+of+rosuvastatin+in+Japanese+patients+with+hypercholesterolemia&author=Y+Saito&publication_year=2003&hl=en']",15037821,https://doi.org/10.5551/jat.10.329, Saito 2003 {published data only}  ,included,CD010254-bbs2-0086,,25186922,,15037821,54,https://www.jstage.jst.go.jp/article/jat/10/6/10_6_329/_pdf,,15037821
CD010254-bib-0169,"Saito Y, Yamada N, Shirai K, Sasaki J, Ebihara Y, Yanase T, et al. ",Effect of rosuvastatin 5‐20 mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia, Atherosclerosis ,2007,194,    ,['citation-journal']," Saito Y, Yamada N, Shirai K, Sasaki J, Ebihara Y, Yanase T, et al. Effect of rosuvastatin 5‐20 mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia.  Atherosclerosis 2007;194(2):505‐11. [EMBASE: 2007483718]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.atherosclerosis.2006.11.028', 'https://www.ncbi.nlm.nih.gov/pubmed/17223112', 'https://scholar.google.com/scholar_lookup?title=Effect+of+rosuvastatin+5‐20+mg+on+triglycerides+and+other+lipid+parameters+in+Japanese+patients+with+hypertriglyceridemia+&author=Y+Saito&author=N+Yamada&author=K+Shirai&author=J+Sasaki&author=Y+Ebihara&author=T+Yanase&publication_year=2007&hl=en']",17223112,https://doi.org/10.1016/j.atherosclerosis.2006.11.028, Saito 2007 {published data only}  ,included,CD010254-bbs2-0087,,,,17223112,30,,,17223112
CD010254-bib-0170,AstraZeneca Pharmaceuticals. ,"A 6‐week, randomized, double‐blind, multicenter trial to evaluate the safety and efficacy of ZD4522 (5, 10, 20, 40, and 80 mg) and atorvastatin (10, 20, 40, and 80 mg) across their respective dose ranges in the treatment of subjects with hypercholesterolemia",,,,   ,['citation-other']," AstraZeneca Pharmaceuticals. A 6‐week, randomized, double‐blind, multicenter trial to evaluate the safety and efficacy of ZD4522 (5, 10, 20, 40, and 80 mg) and atorvastatin (10, 20, 40, and 80 mg) across their respective dose ranges in the treatment of subjects with hypercholesterolemia. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/9256742 (accessed 06 December 2000). [Study code 4522IL/0033]CENTRAL    ",[''],,, Schneck 2003 {published data only}  ,included,CD010254-bbs2-0088,,,,,,,,
CD010254-bib-0171,Packard CJ. ,Apolipoproteins: The new prognostic indicator?," European Heart Journal, Supplement ",2003,5,    ,['citation-journal']," Packard CJ. Apolipoproteins: The new prognostic indicator?.  European Heart Journal, Supplement 2003;5(D):D9‐D16. [EMBASE: 2003238419]CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/S1520-765X(03)90032-0', 'https://scholar.google.com/scholar_lookup?title=Apolipoproteins:+The+new+prognostic+indicator?&author=CJ+Packard&publication_year=2003&hl=en']",,https://doi.org/10.1016/S1520-765X(03)90032-0, Schneck 2003 {published data only}  ,included,CD010254-bbs2-0088,,,,,18,https://academic.oup.com/eurheartjsupp/article-pdf/5/suppl_D/D9/9796056/D9.pdf,,
CD010254-bib-0172,"Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. ",Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease, American Journal of Cardiology ,2003,91,    ,['citation-journal']," Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease.  American Journal of Cardiology 2003;91(1):33‐41. [MEDLINE: 12505568]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0002-9149(02)02994-6', 'https://www.ncbi.nlm.nih.gov/pubmed/12505568', 'https://scholar.google.com/scholar_lookup?title=Comparative+effects+of+rosuvastatin+and+atorvastatin+across+their+dose+ranges+in+patients+with+hypercholesterolemia+and+without+active+arterial+disease+&author=DW+Schneck&author=RH+Knopp&author=CM+Ballantyne&author=R+McPherson&author=RR+Chitra&author=SG+Simonson&publication_year=2003&hl=en']",12505568,https://doi.org/10.1016/S0002-9149(02)02994-6, Schneck 2003 {published data only}  ,included,CD010254-bbs2-0088,,12505568,12505568,12505568,147,,,12505568
CD010254-bib-0173,AstraZeneca. ,"A 24‐week, randomized, double‐blind, multicenter trial to evaluate the efficacy and safety of starting and maximum doses of ZD4522 and atorvastatin in the treatment of high risk hypercholesterolemic subjects",,,,   ,['citation-other']," AstraZeneca. A 24‐week, randomized, double‐blind, multicenter trial to evaluate the efficacy and safety of starting and maximum doses of ZD4522 and atorvastatin in the treatment of high risk hypercholesterolemic subjects. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/4522il_0025 (accessed 23 March 2001). [Study code 4522IL/0025]CENTRAL    ",[''],,, Schwartz 2004 {published data only}  ,included,CD010254-bbs2-0089,,,,,,,,
CD010254-bib-0174,"Schwartz GG, Bolognese MA, Tremblay BP Caplan R, Hutchinson H, Raza A, et al. ","Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial", American Heart Journal ,2004,148,    ,['citation-journal']," Schwartz GG, Bolognese MA, Tremblay BP Caplan R, Hutchinson H, Raza A, et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.  American Heart Journal 2004;148(1):e4. [MEDLINE: 15215813]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ahj.2004.01.020', 'https://www.ncbi.nlm.nih.gov/pubmed/15215813', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+rosuvastatin+and+atorvastatin+in+patients+with+hypercholesterolemia+and+a+high+risk+of+coronary+heart+disease:+a+randomized,+controlled+trial+&author=GG+Schwartz&author=MA+Bolognese&author=R+TremblayBPCaplan&author=H+Hutchinson&author=A+Raza&publication_year=2004&hl=en']",15215813,https://doi.org/10.1016/j.ahj.2004.01.020, Schwartz 2004 {published data only}  ,included,CD010254-bbs2-0089,,,,15215813,54,,,15215813
CD010254-bib-0175,"Semenova AE, Sergienko IV, Masenko VP, Ezhov MV, Gabrusenko SA, Kuharchuk VV, et al. ",The influence of rosuvastatin therapy and percutaneous coronary intervention on angiogenic growth factors in coronary artery disease patients, Acta Cardiologica ,2009,64,    ,['citation-journal']," Semenova AE, Sergienko IV, Masenko VP, Ezhov MV, Gabrusenko SA, Kuharchuk VV, et al. The influence of rosuvastatin therapy and percutaneous coronary intervention on angiogenic growth factors in coronary artery disease patients.  Acta Cardiologica 2009;64(3):405‐9. [MEDLINE: 19593954]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2143/AC.64.3.2038029', 'https://www.ncbi.nlm.nih.gov/pubmed/19593954', 'https://scholar.google.com/scholar_lookup?title=The+influence+of+rosuvastatin+therapy+and+percutaneous+coronary+intervention+on+angiogenic+growth+factors+in+coronary+artery+disease+patients+&author=AE+Semenova&author=IV+Sergienko&author=VP+Masenko&author=MV+Ezhov&author=SA+Gabrusenko&author=VV+Kuharchuk&publication_year=2009&hl=en']",19593954,https://doi.org/10.2143/AC.64.3.2038029, Semenova 2009 {published data only}  ,included,CD010254-bbs2-0090,,,19593954,19593954,14,,,19593954
CD010254-bib-0176,"Semenova AE, Sergienko IV, Masenko VP, Gabrusenko SA, Kukharchuk VV, Belenkov IuN. ",Effect of rosuvastatin therapy and myocardial revascularization on angiogenesis in coronary artery disease patients,,2007,,    ,['citation-other']," Semenova AE, Sergienko IV, Masenko VP, Gabrusenko SA, Kukharchuk VV, Belenkov IuN. Effect of rosuvastatin therapy and myocardial revascularization on angiogenesis in coronary artery disease patients. Kardiologiia. Russia (Federation): Cardiology Research Complex, ul Tretiya Cherepkovskaya 15a, Moscow, Russia., 2007; Vol. 47, issue 11:4‐8. [MEDLINE: 18260956]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effect+of+rosuvastatin+therapy+and+myocardial+revascularization+on+angiogenesis+in+coronary+artery+disease+patients+&author=AE+Semenova&author=IV+Sergienko&author=VP+Masenko&author=SA+Gabrusenko&author=VV+Kukharchuk&author=IuN+Belenkov&publication_year=2007&hl=en']",,, Semenova 2009 {published data only}  ,included,CD010254-bbs2-0090,,18260956,,,,,,18260956
CD010254-bib-0177,AstraZeneca. ,"An 18‐week, randomised, double‐blind, multicentre, placebo‐controlled trial to evaluate the efficacy and safety of rosuvastatin (5 and 10 mg) in the treatment of hypercholesterolaemic postmenopausal women receiving hormone replacement therapy",,,,   ,['citation-other']," AstraZeneca. An 18‐week, randomised, double‐blind, multicentre, placebo‐controlled trial to evaluate the efficacy and safety of rosuvastatin (5 and 10 mg) in the treatment of hypercholesterolaemic postmenopausal women receiving hormone replacement therapy. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610161 (accessed 24 August 2001). [Study code 4522IL/0032]CENTRAL    ",[''],,, Shepherd 2004 {published data only}  ,included,CD010254-bbs2-0091,,,,,,,,
CD010254-bib-0178,Shepherd J. ,Lipid‐modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy, Current Medical Research and Opinion ,2004,20,    ,['citation-journal'], Shepherd J. Lipid‐modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy.  Current Medical Research and Opinion 2004;20(10):1571. [MEDLINE: 15462690]CENTRAL    Link to article     PubMed     Google Scholar     ,"['', 'https://doi.org/10.1185/030079904X4167', 'https://www.ncbi.nlm.nih.gov/pubmed/15462690', 'https://scholar.google.com/scholar_lookup?title=Lipid‐modifying+effects+of+rosuvastatin+in+postmenopausal+women+with+hypercholesterolemia+who+are+receiving+hormone+replacement+therapy+&author=J+Shepherd&publication_year=2004&hl=en']",15462690,https://doi.org/10.1185/030079904X4167, Shepherd 2004 {published data only}  ,included,CD010254-bbs2-0091,,15462690,15462690,15462690,12,,,15462690
CD010254-bib-0179,ClinicalTrials.com. ,Study of Asian patients with hypercholesterolaemia in the UK ‐ rosuvastatin 5mg versus atorvastatin 10mg,,,,   ,['citation-other'], ClinicalTrials.com. Study of Asian patients with hypercholesterolaemia in the UK ‐ rosuvastatin 5mg versus atorvastatin 10mg. http://clinicaltrials.gov/show/NCT00427960 (accessed 30 November 2010). [Study code NCT00427960]CENTRAL    ,[''],,, SHUKRA 2009 {published data only}  ,included,CD010254-bbs2-0092,,,,,,,,
CD010254-bib-0180,"Siddiqi SS, Misbahuddin, Ahmad F, Rahman SZ, Khan AU. ",Dyslipidemic drugs in metabolic syndrome, Indian Journal of Endocrinology and Metabolism ,2013,17,    ,['citation-journal']," Siddiqi SS, Misbahuddin, Ahmad F, Rahman SZ, Khan AU. Dyslipidemic drugs in metabolic syndrome.  Indian Journal of Endocrinology and Metabolism 2013;17(3):472‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4103/2230-8210.111644', 'https://www.ncbi.nlm.nih.gov/pubmed/23869305', 'https://scholar.google.com/scholar_lookup?title=Dyslipidemic+drugs+in+metabolic+syndrome&author=SS+Siddiqi&author=+Misbahuddin&author=F+Ahmad&author=SZ+Rahman&author=AU+Khan&publication_year=2013&hl=en']",23869305,https://doi.org/10.4103/2230-8210.111644, Siddiqi 2013 {published data only}  ,included,CD010254-bbs2-0093,,,,23869305,12,https://doi.org/10.4103/2230-8210.111644,,23869305
CD010254-bib-0181,AstraZeneca. ,"A 12‐week, randomized, open‐label, 3 arm parallel group, multicenter, Phase IIIb study comparing the efficacy and safety of rosuvastatin with atorvastatin and simvastatin achieving NCEP ATP III LDL‐C goals in high risk subjects with hypercholesterolaemia in the managed care setting",,,,   ,['citation-other']," AstraZeneca. A 12‐week, randomized, open‐label, 3 arm parallel group, multicenter, Phase IIIb study comparing the efficacy and safety of rosuvastatin with atorvastatin and simvastatin achieving NCEP ATP III LDL‐C goals in high risk subjects with hypercholesterolaemia in the managed care setting. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/9256968 (accessed 21 July 2005). [Study code D3560L00023]CENTRAL    ",[''],,, SOLAR 2007 {published data only}  ,included,CD010254-bbs2-0094,,,,,,,,
CD010254-bib-0183,Insull. ,"Erratum: Achieving low‐density lipoprotein cholesterol goals in high‐risk patients in managed care: Comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial (Mayo Clinic Proceedings (2007) 82, (543‐550))", Mayo Clinic Proceedings ,2007,82,    ,['citation-journal']," Insull. Erratum: Achieving low‐density lipoprotein cholesterol goals in high‐risk patients in managed care: Comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial (Mayo Clinic Proceedings (2007) 82, (543‐550)).  Mayo Clinic Proceedings 2007;82(7):890. [EMBASE: 2007319758]CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/17605975', 'https://scholar.google.com/scholar_lookup?title=Erratum:+Achieving+low‐density+lipoprotein+cholesterol+goals+in+high‐risk+patients+in+managed+care:+Comparison+of+rosuvastatin,+atorvastatin,+and+simvastatin+in+the+SOLAR+trial+(Mayo+Clinic+Proceedings+(2007)+82,+(543‐550))+&author=+Insull&publication_year=2007&hl=en']",17605975,, SOLAR 2007 {published data only}  ,included,CD010254-bbs2-0094,,,,,,,,17605975
CD010254-bib-0182,"Insull W, Ghali JK, Hassman DR, Y As JW, Gandhi SK, Miller E, et al. SOLAR Study Group. ","Achieving low‐density lipoprotein cholesterol goals in high‐risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial.[Erratum appears in Mayo Clin Proc. 2007 Jul;82(7):890]", Mayo Clinic Proceedings ,2007,82,    ,['citation-journal']," Insull W, Ghali JK, Hassman DR, Y As JW, Gandhi SK, Miller E, et al. SOLAR Study Group. Achieving low‐density lipoprotein cholesterol goals in high‐risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial.[Erratum appears in Mayo Clin Proc. 2007 Jul;82(7):890].  Mayo Clinic Proceedings 2007;82(5):543‐50. [MEDLINE: 17493418]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4065/82.5.543', 'https://www.ncbi.nlm.nih.gov/pubmed/17493418', 'https://scholar.google.com/scholar_lookup?title=Achieving+low‐density+lipoprotein+cholesterol+goals+in+high‐risk+patients+in+managed+care:+comparison+of+rosuvastatin,+atorvastatin,+and+simvastatin+in+the+SOLAR+trial.[Erratum+appears+in+Mayo+Clin+Proc.+2007+Jul;82(7):890]+&author=W+Insull&author=JK+Ghali&author=DR+Hassman&author=+YAsJW&author=SK+Gandhi&author=E+Miller&publication_year=2007&hl=en']",17493418,https://doi.org/10.4065/82.5.543, SOLAR 2007 {published data only}  ,included,CD010254-bbs2-0094,,,,17493418,45,,,17493418
CD010254-bib-0184,AstraZeneca. ,"A 6‐week, randomized, open‐label, comparative study to evaluate the efficacy and safety of rosuvastatin and atorvastatin in the treatment of hypercholesterolaemia in Hispanic subjects",,,,   ,['citation-other']," AstraZeneca. A 6‐week, randomized, open‐label, comparative study to evaluate the efficacy and safety of rosuvastatin and atorvastatin in the treatment of hypercholesterolaemia in Hispanic subjects. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/9256985 (accessed 22 December 2005). [Study code D3560L00027_OLE]CENTRAL    ",[''],,, STARSHIP 2006 {published data only}  ,included,CD010254-bbs2-0095,,,,,,,,
CD010254-bib-0185,"Lloret R, Ycas J, Stein M, Haffner S, STARSHIP Study Group. ",Comparison of rosuvastatin versus atorvastatin in Hispanic‐Americans with hypercholesterolemia (from the STARSHIP trial), American Journal of Cardiology ,2006,98,    ,['citation-journal']," Lloret R, Ycas J, Stein M, Haffner S, STARSHIP Study Group. Comparison of rosuvastatin versus atorvastatin in Hispanic‐Americans with hypercholesterolemia (from the STARSHIP trial).  American Journal of Cardiology 2006;98(6):768‐73. [MEDLINE: 6950182]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.amjcard.2006.04.014', 'https://www.ncbi.nlm.nih.gov/pubmed/16950182', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+rosuvastatin+versus+atorvastatin+in+Hispanic‐Americans+with+hypercholesterolemia+(from+the+STARSHIP+trial)+&author=R+Lloret&author=J+Ycas&author=M+Stein&author=S+Haffner&publication_year=2006&hl=en']",16950182,https://doi.org/10.1016/j.amjcard.2006.04.014, STARSHIP 2006 {published data only}  ,included,CD010254-bbs2-0095,,,16950182,16950182,43,,,16950182
CD010254-bib-0186,"Stein EA, Marais AD, Ducobu J, Farnier M, Gavish D, Hauner H, et al. ","Comparison of short‐term renal effects and efficacy of rosuvastatin 40 mg and simvastatin 80 mg, followed by assessment of long‐term renal effects of rosuvastatin 40 mg, in patients with dyslipidemia", Journal of Clinical Lipidology ,2007,1,    ,['citation-journal']," Stein EA, Marais AD, Ducobu J, Farnier M, Gavish D, Hauner H, et al. Comparison of short‐term renal effects and efficacy of rosuvastatin 40 mg and simvastatin 80 mg, followed by assessment of long‐term renal effects of rosuvastatin 40 mg, in patients with dyslipidemia.  Journal of Clinical Lipidology 2007;1(4):287‐99. [EMBASE: 2007438964]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.jacl.2007.07.004', 'https://www.ncbi.nlm.nih.gov/pubmed/21291693', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+short‐term+renal+effects+and+efficacy+of+rosuvastatin+40+mg+and+simvastatin+80+mg,+followed+by+assessment+of+long‐term+renal+effects+of+rosuvastatin+40+mg,+in+patients+with+dyslipidemia+&author=EA+Stein&author=AD+Marais&author=J+Ducobu&author=M+Farnier&author=D+Gavish&author=H+Hauner&publication_year=2007&hl=en']",21291693,https://doi.org/10.1016/j.jacl.2007.07.004, Stein 2007a {published data only}  ,included,CD010254-bbs2-0096,,,21291693,21291693,5,,,21291693
CD010254-bib-0187,AstraZeneca. ,"A 48‐week open‐label, non‐comparative, multicentre, Phase IIIb study to evaluate the efficacy and safety of the lipid‐regulating agent rosuvastatinin the treatment of patients with Fredrickson Type IIa and Type IIb dyslipidaemia, including heterozygous familial hypercholesterolaemia",,,,   ,['citation-other']," AstraZeneca. A 48‐week open‐label, non‐comparative, multicentre, Phase IIIb study to evaluate the efficacy and safety of the lipid‐regulating agent rosuvastatinin the treatment of patients with Fredrickson Type IIa and Type IIb dyslipidaemia, including heterozygous familial hypercholesterolaemia. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/D3560C00091 (accessed 14 March 2005). [Study code D3560C00091]CENTRAL    ",[''],,, Stein 2007b {published data only}  ,included,CD010254-bbs2-0097,,,,,,,,
CD010254-bib-0188,"Stein EA, Amerena J, Ballantyne CM, Brice E, Farnier M, Guthrie RM, et al. ",Long‐term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia, American Journal of Cardiology ,2007,100,    ,['citation-journal']," Stein EA, Amerena J, Ballantyne CM, Brice E, Farnier M, Guthrie RM, et al. Long‐term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia.  American Journal of Cardiology 2007;100(9):1387‐96. [MEDLINE: 17950795]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.amjcard.2007.06.029', 'https://www.ncbi.nlm.nih.gov/pubmed/17950795', 'https://scholar.google.com/scholar_lookup?title=Long‐term+efficacy+and+safety+of+rosuvastatin+40+mg+in+patients+with+severe+hypercholesterolemia&author=EA+Stein&author=J+Amerena&author=CM+Ballantyne&author=E+Brice&author=M+Farnier&author=RM+Guthrie&publication_year=2007&hl=en']",17950795,https://doi.org/10.1016/j.amjcard.2007.06.029, Stein 2007b {published data only}  ,included,CD010254-bbs2-0097,,,17950795,17950795,33,,,17950795
CD010254-bib-0189,"Ai M, Otokozawa S, Asztalos BF, Nakajima K, Stein E, Jones PH, et al. ",Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low‐density lipoprotein cholesterol levels,,2008,,    ,['citation-other']," Ai M, Otokozawa S, Asztalos BF, Nakajima K, Stein E, Jones PH, et al. Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low‐density lipoprotein cholesterol levels. American Journal of Cardiology2008; Vol. 101, issue 3:315‐8. [MEDLINE: 18237592]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effects+of+maximal+doses+of+atorvastatin+versus+rosuvastatin+on+small+dense+low‐density+lipoprotein+cholesterol+levels+&author=M+Ai&author=S+Otokozawa&author=BF+Asztalos&author=K+Nakajima&author=E+Stein&author=PH+Jones&publication_year=2008&hl=en']",,, STELLAR 2003 {published data only}  ,included,CD010254-bbs2-0098,,,18237592,,,,,18237592
CD010254-bib-0190,"Asztalos BF, Le Maulf F, Dallal GE, Stein E, Jones PH, Horvath KV, et al. ",Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high‐density lipoproteins,,2007,,    ,['citation-other']," Asztalos BF, Le Maulf F, Dallal GE, Stein E, Jones PH, Horvath KV, et al. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high‐density lipoproteins. American Journal of Cardiology. United States: Cardiovascular Research Laboratory, Tufts University, Boston, Massachusetts, USA. [email protected], 2007; Vol. 99, issue 5:681‐5. [MEDLINE: 17317371]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+the+effects+of+high+doses+of+rosuvastatin+versus+atorvastatin+on+the+subpopulations+of+high‐density+lipoproteins+&author=BF+Asztalos&author=F+Maulf&author=GE+Dallal&author=E+Stein&author=PH+Jones&author=KV+Horvath&publication_year=2007&hl=en']",,, STELLAR 2003 {published data only}  ,included,CD010254-bbs2-0098,,,,,,,,
CD010254-bib-0191,"Barrios V, Lobos JM, Serrano A, Brosa M, Capel M, Alvarez Sanz C, et al. ",Cost‐effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain, Journal of Medical Economics ,2012,15 Suppl 1,    ,['citation-journal']," Barrios V, Lobos JM, Serrano A, Brosa M, Capel M, Alvarez Sanz C, et al. Cost‐effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.  Journal of Medical Economics 2012;15 Suppl 1:45‐54. [MEDLINE: 22954062]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.3111/13696998.2012.726674', 'https://www.ncbi.nlm.nih.gov/pubmed/22954062', 'https://scholar.google.com/scholar_lookup?title=Cost‐effectiveness+analysis+of+rosuvastatin+vs+generic+atorvastatin+in+Spain&author=V+Barrios&author=JM+Lobos&author=A+Serrano&author=M+Brosa&author=M+Capel&author=C+AlvarezSanz&publication_year=2012&hl=en']",22954062,https://doi.org/10.3111/13696998.2012.726674, STELLAR 2003 {published data only}  ,included,CD010254-bbs2-0098,,,22954062,22954062,14,,,22954062
CD010254-bib-0192,"Chong PH, Varner D. ",Cost‐efficacy analysis of 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase inhibitors based on results of the STELLAR trial: clinical implications for therapeutic selection,,2005,,    ,['citation-other']," Chong PH, Varner D. Cost‐efficacy analysis of 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase inhibitors based on results of the STELLAR trial: clinical implications for therapeutic selection. Pharmacotherapy. United States: Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA., 2005; Vol. 25, issue 2:270‐8. [MEDLINE: 15767241]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Cost‐efficacy+analysis+of+3‐hydroxy‐3‐methylglutaryl+coenzyme+a+reductase+inhibitors+based+on+results+of+the+STELLAR+trial:+clinical+implications+for+therapeutic+selection+&author=PH+Chong&author=D+Varner&publication_year=2005&hl=en']",,, STELLAR 2003 {published data only}  ,included,CD010254-bbs2-0098,,15767241,15767241,,,,,15767241
CD010254-bib-0193,ClinicalTrials.gov. ,"A 6 week open label, dose comparison study to evaluate the safety and efficacy of rosuvastatin versus atorvastatin, pravastatin, and simvastatin in subjects with hypercholesterolemia",,,,   ,['citation-other']," ClinicalTrials.gov. A 6 week open label, dose comparison study to evaluate the safety and efficacy of rosuvastatin versus atorvastatin, pravastatin, and simvastatin in subjects with hypercholesterolemia. http://clinicaltrials.gov/show/NCT00654537 (accessed 13 March 2009). [Study code NCT00654537]CENTRAL    ",[''],,, STELLAR 2003 {published data only}  ,included,CD010254-bbs2-0098,,,,,,,,
CD010254-bib-0194,"Costa‐Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S. ","Cost‐effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective",,2008,,    ,['citation-other']," Costa‐Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S. Cost‐effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective. Clinical Therapeutics. United States: AstraZeneca, Sodertalje, Sweden. Madlaina.Costa‐[email protected], 2008; Vol. 30, issue 7:1345‐57. [MEDLINE: 18691996]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Cost‐effectiveness+analysis+of+rosuvastatin+versus+atorvastatin,+simvastatin,+and+pravastatin+from+a+Canadian+health+system+perspective+&author=M+Costa‐Scharplatz&author=K+Ramanathan&author=T+Frial&author=B+Beamer&author=S+Gandhi&publication_year=2008&hl=en']",,, STELLAR 2003 {published data only}  ,included,CD010254-bbs2-0098,,18691996,18691996,,,,,18691996
CD010254-bib-0195,"Deedwania PC, Hunninghake DB, Bays HE, Jones PH, Cain VA, Blasetto JW, et al. STELLAR Study Group. ","Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome",,2005,,    ,['citation-other']," Deedwania PC, Hunninghake DB, Bays HE, Jones PH, Cain VA, Blasetto JW, et al. STELLAR Study Group. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. American Journal of Cardiology. United States: VA Central California Health Care System and University of California‐San Francisco, Fresno, California, USA., 2005; Vol. 95, issue 3:360‐6. [MEDLINE: 15670545]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effects+of+rosuvastatin,+atorvastatin,+simvastatin,+and+pravastatin+on+atherogenic+dyslipidemia+in+patients+with+characteristics+of+the+metabolic+syndrome+&author=PC+Deedwania&author=DB+Hunninghake&author=HE+Bays&author=PH+Jones&author=VA+Cain&author=JW+Blasetto&publication_year=2005&hl=en']",,, STELLAR 2003 {published data only}  ,included,CD010254-bbs2-0098,,,15670545,,,,,15670545
CD010254-bib-0196,"Hirsch M, O'Donnell JC, Jones P. ","Rosuvastatin is cost‐effective in treating patients to low‐density lipoprotein‐cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial",,2005,,    ,['citation-other']," Hirsch M, O'Donnell JC, Jones P. Rosuvastatin is cost‐effective in treating patients to low‐density lipoprotein‐cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. European Journal of Cardiovascular Prevention and Rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. England: AstraZeneca, Macclesfield, Cheshire SK10 4TG, UK. [email protected], 2005; Vol. 12, issue 1:18‐28. [MEDLINE: 15703502]CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Rosuvastatin+is+cost‐effective+in+treating+patients+to+low‐density+lipoprotein‐cholesterol+goals+compared+with+atorvastatin,+pravastatin+and+simvastatin:+analysis+of+the+STELLAR+trial+&author=M+Hirsch&author=JC+O'Donnell&author=P+Jones&publication_year=2005&hl=en""]",,, STELLAR 2003 {published data only}  ,included,CD010254-bbs2-0098,,15703502,,,,,,15703502
CD010254-bib-0197,"Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. ","Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)", American Journal of Cardiology ,2003,92,    ,['citation-journal']," Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).  American Journal of Cardiology 2003;92(2):152‐60. [MEDLINE: 12860216]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0002-9149(03)00530-7', 'https://www.ncbi.nlm.nih.gov/pubmed/12860216', 'https://scholar.google.com/scholar_lookup?title=Comparison\xa0of\xa0the\xa0efficacy\xa0and\xa0safety\xa0of\xa0rosuvastatin\xa0versus\xa0atorvastatin,+simvastatin,+and+pravastatin+across+doses+(STELLAR*+Trial)+&author=PH+Jones&author=MH+Davidson&author=EA+Stein&author=HE+Bays&author=JM+McKenney&author=E+Miller&publication_year=2003&hl=en']",12860216,https://doi.org/10.1016/S0002-9149(03)00530-7, STELLAR 2003 {published data only}  ,included,CD010254-bbs2-0098,,,,,282,,,12860216
CD010254-bib-0198,"Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, et al. ","Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non‐high‐density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial",,2004,,    ,['citation-other']," Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non‐high‐density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clinical therapeutics. United States: Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, Texas 77030, USA. [email protected], 2004; Vol. 26, issue 9:1388‐99. [MEDLINE: 15531001]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effects+of+rosuvastatin+versus+atorvastatin,+simvastatin,+and+pravastatin+on+non‐high‐density+lipoprotein+cholesterol,+apolipoproteins,+and+lipid+ratios+in+patients+with+hypercholesterolemia:+additional+results+from+the+STELLAR+trial+&author=PH+Jones&author=DB+Hunninghake&author=KC+Ferdinand&author=EA+Stein&author=A+Gold&author=RJ+Caplan&publication_year=2004&hl=en']",,, STELLAR 2003 {published data only}  ,included,CD010254-bbs2-0098,,,15531001,,,,,15531001
CD010254-bib-0199,Malacco E. ,"Erratum: Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non‐high‐density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: Additional results from the STELLAR trial (Clinical Therapeutics (September 2004))", Clinical Therapeutics ,2005,27,    ,['citation-journal']," Malacco E. Erratum: Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non‐high‐density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: Additional results from the STELLAR trial (Clinical Therapeutics (September 2004)).  Clinical Therapeutics 2005;27(1):142. [EMBASE: 2005115209]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Erratum:+Effects+of+rosuvastatin+versus+atorvastatin,+simvastatin,+and+pravastatin+on+non‐high‐density+lipoprotein+cholesterol,+apolipoproteins,+and+lipid+ratios+in+patients+with+hypercholesterolemia:+Additional+results+from+the+STELLAR+trial+(Clinical+Therapeutics+(September+2004))+&author=E+Malacco&publication_year=2005&hl=en']",,, STELLAR 2003 {published data only}  ,included,CD010254-bbs2-0098,,,,,,,,
CD010254-bib-0200,Mayor S. ,Rosuvastatin increases the number of patients getting to LDL‐cholesterol targets,,2003,,    ,['citation-other']," Mayor S. Rosuvastatin increases the number of patients getting to LDL‐cholesterol targets. British Journal of Diabetes and Vascular Disease2003; Vol. 3, issue 3:236. [EMBASE: 2003286835]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Rosuvastatin+increases+the+number+of+patients+getting+to+LDL‐cholesterol+targets&author=S+Mayor&publication_year=2003&hl=en']",,, STELLAR 2003 {published data only}  ,included,CD010254-bbs2-0098,,,,,,,,
CD010254-bib-0201,"McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW, et al. ","Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial",,2003,,    ,['citation-other']," McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Current Medical Research and Opinion. England: National Clinical Research, Richmond, Virginia, USA. [email protected], 2003; Vol. 19, issue 8:689‐98. [MEDLINE: 14687438]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+the+efficacy+of+rosuvastatin+versus+atorvastatin,+simvastatin,+and+pravastatin+in+achieving+lipid+goals:+results+from+the+STELLAR+trial+&author=JM+McKenney&author=PH+Jones&author=MA+Adamczyk&author=VA+Cain&author=BS+Bryzinski&author=JW+Blasetto&publication_year=2003&hl=en']",,, STELLAR 2003 {published data only}  ,included,CD010254-bbs2-0098,,,14687438,,,,,14687438
CD010254-bib-0202,"Miller PSJ, Smith DG, Jones P. ","Cost effectiveness of rosuvastatin in treating patients to low‐density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial)",,2005,,    ,['citation-other']," Miller PSJ, Smith DG, Jones P. Cost effectiveness of rosuvastatin in treating patients to low‐density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial). American Journal of Cardiology. United States: AstraZeneca UK Limited, Macclesfield, United Kingdom. [email protected], 2005; Vol. 95, issue 11:1314‐9. [MEDLINE: 15904635]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Cost+effectiveness+of+rosuvastatin+in+treating+patients+to+low‐density+lipoprotein+cholesterol+goals+compared+with+atorvastatin,+pravastatin,+and+simvastatin+(a+US+Analysis+of+the+STELLAR+Trial)+&author=PSJ+Miller&author=DG+Smith&author=P+Jones&publication_year=2005&hl=en']",,, STELLAR 2003 {published data only}  ,included,CD010254-bbs2-0098,,15904635,15904635,,,,,15904635
CD010254-bib-0203,"Otokozawa S, Ai M, Van Himbergen T, Asztalos BF, Tanaka A, Stein EA, et al. ",Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B‐48 and remnant lipoprotein cholesterol levels,,2009,,    ,['citation-other']," Otokozawa S, Ai M, Van Himbergen T, Asztalos BF, Tanaka A, Stein EA, et al. Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B‐48 and remnant lipoprotein cholesterol levels. Atherosclerosis. Ireland: Cardiovascular Research Laboratory, Friedman School of Nutrition Science and Policy at Tufts University and Tufts University School of Medicine, Boston, MA 02111, USA., 2009; Vol. 205, issue 1:197‐201. [MEDLINE: 19200542]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effects+of+intensive+atorvastatin+and+rosuvastatin+treatment+on+apolipoprotein+B‐48+and+remnant+lipoprotein+cholesterol+levels+&author=S+Otokozawa&author=M+Ai&author=T+Himbergen&author=BF+Asztalos&author=A+Tanaka&author=EA+Stein&publication_year=2009&hl=en']",,, STELLAR 2003 {published data only}  ,included,CD010254-bbs2-0098,,,19200542,,,,,19200542
CD010254-bib-0204,Prescott LM. ,Highlights of the 52nd Scientific Session of the American College of Cardiology, P and T ,2003,28,    ,['citation-journal'], Prescott LM. Highlights of the 52nd Scientific Session of the American College of Cardiology.  P and T 2003;28(5):346‐9. [EMBASE: 2003500316]CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Highlights\xa0of\xa0the\xa052nd\xa0Scientific\xa0Session\xa0of\xa0the\xa0American\xa0College\xa0of\xa0Cardiology&author=LM+Prescott&publication_year=2003&hl=en']",,, STELLAR 2003 {published data only}  ,included,CD010254-bbs2-0098,,,,,,,,
CD010254-bib-0205,"Thongtang N, Ai Mi, Otokozawa S, Himbergen TV, Asztalos BF, Nakajima K, et al. ",Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation,,2011,,    ,['citation-other']," Thongtang N, Ai Mi, Otokozawa S, Himbergen TV, Asztalos BF, Nakajima K, et al. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. American Journal of Cardiology. United States: Jean Mayer United States Department of Agriculture, Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts, USA., 2011; Vol. 107, issue 3:387‐92. [MEDLINE: 21257003]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effects+of+maximal+atorvastatin+and+rosuvastatin+treatment+on+markers+of+glucose+homeostasis+and+inflammation+&author=N+Thongtang&author=Mi+Ai&author=S+Otokozawa&author=TV+Himbergen&author=BF+Asztalos&author=K+Nakajima&publication_year=2011&hl=en']",,, STELLAR 2003 {published data only}  ,included,CD010254-bbs2-0098,,,21257003,,,,,21257003
CD010254-bib-0206,"van Himbergen TM, Matthan NR, Resteghini NA, Otokozawa S, Ai M, Stein EA, et al. ",Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers,,2009,,    ,['citation-other']," van Himbergen TM, Matthan NR, Resteghini NA, Otokozawa S, Ai M, Stein EA, et al. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. Journal of Lipid Research. United States: Lipid Metabolism Laboratory, Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA. [email protected], 2009; Vol. 50, issue 4:730‐9. [MEDLINE: 19043140]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+the+effects+of+maximal+dose+atorvastatin+and+rosuvastatin+therapy+on+cholesterol+synthesis+and+absorption+markers+&author=TM+Himbergen&author=NR+Matthan&author=NA+Resteghini&author=S+Otokozawa&author=M+Ai&author=EA+Stein&publication_year=2009&hl=en']",,, STELLAR 2003 {published data only}  ,included,CD010254-bbs2-0098,,,,,,,,
CD010254-bib-0207,"Szapary L, Feher G. ",Effectiveness of generic rosuvastatin in patients with ischaemic cerebrovascular disease,,2012,,    ,['citation-other']," Szapary L, Feher G. Effectiveness of generic rosuvastatin in patients with ischaemic cerebrovascular disease. Orvosi Hetilap. Medicina Kiado RT (Zoltan u. 8., Budapest 1054, Hungary), 2012; Vol. 153, issue 22:857‐60. [MEDLINE: 22641260]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effectiveness+of+generic+rosuvastatin+in+patients+with+ischaemic+cerebrovascular+disease&author=L+Szapary&author=G+Feher&publication_year=2012&hl=en']",,, Szapary 2012 {published data only}  ,included,CD010254-bbs2-0099,,22641260,,,,,,22641260
CD010254-bib-0208,"Takebayashi K, Suetsugu M, Matsumoto S, Aso Y, Inukai T. ",Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein‐1 in type 2 diabetic patients with hyperlipidemia, Southern Medical Journal ,2009,102,    ,['citation-journal']," Takebayashi K, Suetsugu M, Matsumoto S, Aso Y, Inukai T. Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein‐1 in type 2 diabetic patients with hyperlipidemia.  Southern Medical Journal 2009;102(4):361‐8. [MEDLINE: 19279518]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/SMJ.0b013e31819bd023', 'https://www.ncbi.nlm.nih.gov/pubmed/19279518', 'https://scholar.google.com/scholar_lookup?title=Effects+of+rosuvastatin+and+colestimide+on+metabolic+parameters+and+urinary+monocyte+chemoattractant+protein‐1+in+type+2+diabetic+patients+with+hyperlipidemia+&author=K+Takebayashi&author=M+Suetsugu&author=S+Matsumoto&author=Y+Aso&author=T+Inukai&publication_year=2009&hl=en']",19279518,https://doi.org/10.1097/SMJ.0b013e31819bd023, Takebayashi 2009 {published data only}  ,included,CD010254-bbs2-0100,,19279518,19279518,19279518,27,,,19279518
CD010254-bib-0209,Tateishi J. ,Efficacy of three potent statins in patients with hypercholesterolemia who were newly prescribed statins, Therapeutic Research ,2011,32,    ,['citation-journal'], Tateishi J. Efficacy of three potent statins in patients with hypercholesterolemia who were newly prescribed statins.  Therapeutic Research 2011;32(12):1653‐61. [EMBASE: 2012051834]CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+three+potent+statins+in+patients+with+hypercholesterolemia+who+were+newly+prescribed+statins+&author=J+Tateishi&publication_year=2011&hl=en']",,, Tateishi 2011 {published data only}  ,included,CD010254-bbs2-0101,,,,,,,,
CD010254-bib-0210,Tsunoda S. ,Efficacy and safety of rosuvastatin 2.5 mg and atorvastatin 10 mg in patients with hypercholesterolemia, Therapeutic Research ,2011,32,    ,['citation-journal'], Tsunoda S. Efficacy and safety of rosuvastatin 2.5 mg and atorvastatin 10 mg in patients with hypercholesterolemia.  Therapeutic Research 2011;32(11):1507‐12. [EMBASE: 2011711049]CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+rosuvastatin+2.5+mg+and+atorvastatin+10+mg+in+patients+with+hypercholesterolemia+&author=S+Tsunoda&publication_year=2011&hl=en']",,, Tsunoda 2011 {published data only}  ,included,CD010254-bbs2-0102,,,,,,,,
CD010254-bib-0211,"Wang Guo Hua, Zhang Xu, Cao Juan, Li Hai Tao, Yin Di, Zhou Chang Ju. ",Lipid‐lowering efficacy and safety of rosuvastatin calcium in treatment of patients with chronic kidney disease, Guangdong Yixue ,2012,33,    ,['citation-journal']," Wang Guo Hua, Zhang Xu, Cao Juan, Li Hai Tao, Yin Di, Zhou Chang Ju. Lipid‐lowering efficacy and safety of rosuvastatin calcium in treatment of patients with chronic kidney disease.  Guangdong Yixue 2012;33(1):125‐7. [CAPLUS AN 2012:1577414]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Lipid‐lowering+efficacy+and+safety+of+rosuvastatin+calcium+in+treatment+of+patients+with+chronic+kidney+disease+&author=Hua+WangGuo&author=Xu+Zhang&author=Juan+Cao&author=Tao+LiHai&author=Di+Yin&author=Ju+ZhouChang&publication_year=2012&hl=en']",,, Wang 2012 {published data only}  ,included,CD010254-bbs2-0103,,,,,,,,
CD010254-bib-0212,"Weinstein DL, Williams LA, Carlson DM, Kelly MT, Burns KM, Setze CM, et al. ","A randomized, double‐blind study of fenofibric Acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease", Clinical Therapeutics ,2013,35,    ,['citation-journal']," Weinstein DL, Williams LA, Carlson DM, Kelly MT, Burns KM, Setze CM, et al. A randomized, double‐blind study of fenofibric Acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.  Clinical Therapeutics 2013;35(8):1186‐98. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.clinthera.2013.06.013', 'https://www.ncbi.nlm.nih.gov/pubmed/23891363', 'https://scholar.google.com/scholar_lookup?title=A+randomized,+double‐blind+study+of+fenofibric+Acid+plus+rosuvastatin+compared+with+rosuvastatin+alone+in+stage+3+chronic+kidney+disease+&author=DL+Weinstein&author=LA+Williams&author=DM+Carlson&author=MT+Kelly&author=KM+Burns&author=CM+Setze&publication_year=2013&hl=en']",23891363,https://doi.org/10.1016/j.clinthera.2013.06.013, Weinstein 2013 {published data only}  ,included,CD010254-bbs2-0104,,,23891363,23891363,11,,,23891363
CD010254-bib-0213,"Wongwiwatthananukit S, Sansanayudh N, Dhummauppakorn R, Kitiyadisai C. ",Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia, Annals of Pharmacotherapy ,2006,40,    ,['citation-journal']," Wongwiwatthananukit S, Sansanayudh N, Dhummauppakorn R, Kitiyadisai C. Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia.  Annals of Pharmacotherapy 2006;40(11):1917‐23. [MEDLINE: 17003082]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1345/aph.1H124', 'https://www.ncbi.nlm.nih.gov/pubmed/17003082', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+rosuvastatin+every+other+day+compared+with+once+daily+in+patients+with+hypercholesterolemia+&author=S+Wongwiwatthananukit&author=N+Sansanayudh&author=R+Dhummauppakorn&author=C+Kitiyadisai&publication_year=2006&hl=en']",17003082,https://doi.org/10.1345/aph.1H124, Wongwiwatthananukit 2006 {published data only}  ,included,CD010254-bbs2-0105,,17003082,17003082,17003082,30,,,17003082
CD010254-bib-0214,"Yamamoto A, Arakawa K, Sasaki J, Matsuzawa Y, Takemura K, Tsushima M, et al. ","Clinical effects of rosuvastatin, a new HMG‐CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study", Journal of Atherosclerosis and Thrombosis ,2002,9,    ,['citation-journal']," Yamamoto A, Arakawa K, Sasaki J, Matsuzawa Y, Takemura K, Tsushima M, et al. Clinical effects of rosuvastatin, a new HMG‐CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study.  Journal of Atherosclerosis and Thrombosis 2002;9(1):48‐56. [MEDLINE: 12238638]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.5551/jat.9.48', 'https://www.ncbi.nlm.nih.gov/pubmed/12238638', 'https://scholar.google.com/scholar_lookup?title=Clinical+effects+of+rosuvastatin,+a+new+HMG‐CoA+reductase+inhibitor,+in+Japanese+patients+with+primary+hypercholesterolemia:+an+early+phase+II+study+&author=A+Yamamoto&author=K+Arakawa&author=J+Sasaki&author=Y+Matsuzawa&author=K+Takemura&author=M+Tsushima&publication_year=2002&hl=en']",12238638,https://doi.org/10.5551/jat.9.48, Yamamoto 2002 {published data only}  ,included,CD010254-bbs2-0106,,,,12238638,18,,,12238638
CD010254-bib-0215,"Yanagi K, Monden T, Ikeda S, Matsumura M, Kasai K. ",A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes, Advances in Therapy ,2011,28,    ,['citation-journal']," Yanagi K, Monden T, Ikeda S, Matsumura M, Kasai K. A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes.  Advances in Therapy 2011;28(2):160‐71. [MEDLINE: 21222064]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1007/s12325-010-0098-2', 'https://www.ncbi.nlm.nih.gov/pubmed/21222064', 'https://scholar.google.com/scholar_lookup?title=A+crossover+study+of+rosuvastatin+and+pitavastatin+in+patients+with+type+2+diabetes&author=K+Yanagi&author=T+Monden&author=S+Ikeda&author=M+Matsumura&author=K+Kasai&publication_year=2011&hl=en']",21222064,https://doi.org/10.1007/s12325-010-0098-2, Yanagi 2011 {published data only}  ,included,CD010254-bbs2-0107,,21222064,,21222064,17,,,21222064
CD010254-bib-0216,"Yoshino G, Nakano S, Matsumoto T, Murakami E, Morita T, Kuboki K. ",Rosuvastatin reduces plasma small dense LDL‐cholesterol predominantly in non‐diabetic hypercholesterolemic patients, Pharmacology & Pharmacy ,2012,3,    ,['citation-journal']," Yoshino G, Nakano S, Matsumoto T, Murakami E, Morita T, Kuboki K. Rosuvastatin reduces plasma small dense LDL‐cholesterol predominantly in non‐diabetic hypercholesterolemic patients.  Pharmacology & Pharmacy 2012;3(1):72‐8. [CAPLUS AN 2012:748036]CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.4236/pp.2012.31011', 'https://scholar.google.com/scholar_lookup?title=Rosuvastatin+reduces+plasma+small+dense+LDL‐cholesterol+predominantly+in+non‐diabetic+hypercholesterolemic+patients+&author=G+Yoshino&author=S+Nakano&author=T+Matsumoto&author=E+Murakami&author=T+Morita&author=K+Kuboki&publication_year=2012&hl=en']",,https://doi.org/10.4236/pp.2012.31011, Yoshino 2012 {published data only}  ,included,CD010254-bbs2-0108,,,,,8,http://www.scirp.org/journal/PaperDownload.aspx?paperID=16949,,
CD010254-bib-0217,AstraZeneca. ,"A multicenter, randomized, double‐blind, parallel‐group, dose titration ( 10 mg and 20 mg) study to compare the efficacy and safety of Rosuvastatin versus Atorvastatin in patients with primary hypercholesterolemia",,,,   ,['citation-other']," AstraZeneca. A multicenter, randomized, double‐blind, parallel‐group, dose titration ( 10 mg and 20 mg) study to compare the efficacy and safety of Rosuvastatin versus Atorvastatin in patients with primary hypercholesterolemia. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/9256791 (accessed 18 January 2007). [Study code 4522SP/0001]CENTRAL    ",[''],,, AstraZeneca 2007 {published data only}  ,excluded,CD010254-bbs2-0109, Exact number of participants receiving rosuvastatin not reported ,,,,,,,
CD010254-bib-0218,"Bays HE, Davidson MH, Massaad R, Flaim D, Lowe RS, Tershakovec AM, et al. ",Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up‐titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study), American Journal of Cardiology ,2011,108,    ,['citation-journal']," Bays HE, Davidson MH, Massaad R, Flaim D, Lowe RS, Tershakovec AM, et al. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up‐titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).  American Journal of Cardiology 2011;108(4):523‐30. [MEDLINE: 21596364]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.amjcard.2011.03.079', 'https://www.ncbi.nlm.nih.gov/pubmed/21596364', 'https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+ezetimibe+added+on+to+rosuvastatin+5+or+10+mg+versus+up‐titration+of+rosuvastatin+in+patients+with+hypercholesterolemia+(the+ACTE+Study)+&author=HE+Bays&author=MH+Davidson&author=R+Massaad&author=D+Flaim&author=RS+Lowe&author=AM+Tershakovec&publication_year=2011&hl=en']",21596364,https://doi.org/10.1016/j.amjcard.2011.03.079, Bays 2011 {published data only}  ,excluded,CD010254-bbs2-0110, Participants received confounding drug ezetimibe added to the rosuvastatin ,,21596364,21596364,69,,,21596364
CD010254-bib-0219,"Bertolotti M, Del Puppo M, Corna F, Anzivino C, Gabbi C, Baldelli E, et al. ",Increased appearance rate of 27‐hydroxycholesterol in vivo in hypercholesterolemia: a possible compensatory mechanism, Nutrition Metabolism & Cardiovascular Diseases ,2012,22,    ,['citation-journal']," Bertolotti M, Del Puppo M, Corna F, Anzivino C, Gabbi C, Baldelli E, et al. Increased appearance rate of 27‐hydroxycholesterol in vivo in hypercholesterolemia: a possible compensatory mechanism.  Nutrition Metabolism & Cardiovascular Diseases 2012;22(10):823‐30. [MEDLINE: 21546230]CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.numecd.2011.02.009', 'https://scholar.google.com/scholar_lookup?title=Increased+appearance+rate+of+27‐hydroxycholesterol+in+vivo+in+hypercholesterolemia:+a+possible+compensatory+mechanism+&author=M+Bertolotti&author=M+Puppo&author=F+Corna&author=C+Anzivino&author=C+Gabbi&author=E+Baldelli&publication_year=2012&hl=en']",,https://doi.org/10.1016/j.numecd.2011.02.009, Bertolotti 2012 {published data only}  ,excluded,CD010254-bbs2-0111," Specific dose not reported, range of doses given ",,21546230,21546230,18,,,21546230
CD010254-bib-0220,"Bottaro EG, Caravello O, Scapellato PG, Stambulian M, Vidal GI, Loggia V, et al. ",Rosuvastatin for the treatment of dyslipidemia in HIV‐infected patients receiving highly active antiretroviral therapy. Preliminary experience]. Spanish], Enfermedades Infecciosas y Microbiologia Clinica ,2008,26,    ,['citation-journal']," Bottaro EG, Caravello O, Scapellato PG, Stambulian M, Vidal GI, Loggia V, et al. Rosuvastatin for the treatment of dyslipidemia in HIV‐infected patients receiving highly active antiretroviral therapy. Preliminary experience]. Spanish].  Enfermedades Infecciosas y Microbiologia Clinica 2008;26(6):325‐9. [MEDLINE: 18588813]CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/18588813', 'https://scholar.google.com/scholar_lookup?title=Rosuvastatin+for+the+treatment+of+dyslipidemia+in+HIV‐infected+patients+receiving+highly+active+antiretroviral+therapy.+Preliminary+experience].+Spanish]+&author=EG+Bottaro&author=O+Caravello&author=PG+Scapellato&author=M+Stambulian&author=GI+Vidal&author=V+Loggia&publication_year=2008&hl=en']",18588813,, Bottaro 2008 {published data only}  ,excluded,CD010254-bbs2-0112, Confounding factor: anti retroviral drugs for the treatment of HIV inappropriate outcomes median per cent change from baseline  ,,,,,,,18588813
CD010254-bib-0221,"Burmeister JE, Mittersteiner DR, Campos BM. ",Rosuvastatin in hemodialysis: Short‐term effects on lipids and C‐reactive protein, Journal of Nephrology ,2009,22,    ,['citation-journal']," Burmeister JE, Mittersteiner DR, Campos BM. Rosuvastatin in hemodialysis: Short‐term effects on lipids and C‐reactive protein.  Journal of Nephrology 2009;22(1):83‐9. [MEDLINE: 19229822]CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/19229822', 'https://scholar.google.com/scholar_lookup?title=Rosuvastatin+in+hemodialysis:+Short‐term+effects+on+lipids+and+C‐reactive+protein&author=JE+Burmeister&author=DR+Mittersteiner&author=BM+Campos&publication_year=2009&hl=en']",19229822,, Burmeister 2009 {published data only}  ,excluded,CD010254-bbs2-0113, Confounding factor: haemodialysis ,,19229822,,,,,19229822
CD010254-bib-0222,"Calza L, Manfredi R, Colangeli V, Pocaterra D, Pavoni M, Chiodo F. ","Rosuvastatin, pravastatin, and atorvastatin for the treatment of hyper‐cholesterolaemia in HIV‐infected patients receiving protease inhibitors",,2008,,    ,['citation-other']," Calza L, Manfredi R, Colangeli V, Pocaterra D, Pavoni M, Chiodo F. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hyper‐cholesterolaemia in HIV‐infected patients receiving protease inhibitors. Current HIV Research. Bentham Science Publishers B.V. (P.O. Box 294, Bussum 1400 AG, Netherlands), 2008; Vol. 6, issue 6:572‐8. [EMBASE: 2009079366]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Rosuvastatin,+pravastatin,+and+atorvastatin+for+the+treatment+of+hyper‐cholesterolaemia+in+HIV‐infected+patients+receiving+protease+inhibitors+&author=L+Calza&author=R+Manfredi&author=V+Colangeli&author=D+Pocaterra&author=M+Pavoni&author=F+Chiodo&publication_year=2008&hl=en']",,, Calza 2008 {published data only}  ,excluded,CD010254-bbs2-0114, Confounding factor: anti retroviral drugs for the treatment of HIV ,,,,,,,
CD010254-bib-0223,"Calza L, Trapani F, Bartoletti M, Manfredi R, Colangeli V, Borderi M, et al. ",Statin therapy decreases serum levels of high‐sensitivity C‐reactive protein and tumor necrosis factor‐ in HIV‐infected patients treated with ritonavir‐boosted protease inhibitors, HIV Clinical Trials ,2012,13,    ,['citation-journal']," Calza L, Trapani F, Bartoletti M, Manfredi R, Colangeli V, Borderi M, et al. Statin therapy decreases serum levels of high‐sensitivity C‐reactive protein and tumor necrosis factor‐ in HIV‐infected patients treated with ritonavir‐boosted protease inhibitors.  HIV Clinical Trials 2012;13(3):153‐61. [MEDLINE: 22592095]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1310/hct1303-153', 'https://www.ncbi.nlm.nih.gov/pubmed/22592095', 'https://scholar.google.com/scholar_lookup?title=Statin+therapy+decreases+serum+levels+of+high‐sensitivity+C‐reactive+protein+and+tumor+necrosis+factor‐+in+HIV‐infected+patients+treated+with+ritonavir‐boosted+protease+inhibitors+&author=L+Calza&author=F+Trapani&author=M+Bartoletti&author=R+Manfredi&author=V+Colangeli&author=M+Borderi&publication_year=2012&hl=en']",22592095,https://doi.org/10.1310/hct1303-153, Calza 2012 {published data only}  ,excluded,CD010254-bbs2-0115, Confounding factor: anti retroviral drugs for the treatment of HIV ,,,22592095,49,,,22592095
CD010254-bib-0224,"Calza L, Manfredi R, Colangeli V, Trapani FF, Salvadori C, Magistrelli E, et al. ",Two‐year treatment with rosuvastatin reduces carotid intima‐media thickness in HIV type 1‐infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk, AIDS Research & Human Retroviruses ,2013,29,    ,['citation-journal']," Calza L, Manfredi R, Colangeli V, Trapani FF, Salvadori C, Magistrelli E, et al. Two‐year treatment with rosuvastatin reduces carotid intima‐media thickness in HIV type 1‐infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk.  AIDS Research & Human Retroviruses 2013;29(3):547‐56. [MEDLINE: 23098891]CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1089/aid.2012.0015', 'https://scholar.google.com/scholar_lookup?title=Two‐year+treatment+with+rosuvastatin+reduces+carotid+intima‐media+thickness+in+HIV+type+1‐infected+patients+receiving+highly+active+antiretroviral+therapy+with+asymptomatic+atherosclerosis+and+moderate+cardiovascular+risk+&author=L+Calza&author=R+Manfredi&author=V+Colangeli&author=FF+Trapani&author=C+Salvadori&author=E+Magistrelli&publication_year=2013&hl=en']",,https://doi.org/10.1089/aid.2012.0015, Calza 2013 {published data only}  ,excluded,CD010254-bbs2-0116, Confounding factor: anti retroviral drugs for the treatment of HIV ,,23098891,23098891,40,,,23098891
CD010254-bib-0225,Kos Pharmaceuticals. ,Comparative efficacy evaluation of lipids when treated with niaspan & statin or other lipid‐modifying therapies‐COMPELL,,2006,,    ,['citation-other'], Kos Pharmaceuticals. Comparative efficacy evaluation of lipids when treated with niaspan & statin or other lipid‐modifying therapies‐COMPELL. http://clinical‐trials.findthedata.org/l/43529/Comparative‐Efficacy‐Evaluation‐of‐Lipids‐When‐Treated‐With‐Niaspan‐and‐Statin‐or‐Other‐Lipid‐Modifying‐Therapies‐COMPELL2006. [Study code NCT00079638]CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Comparative+efficacy+evaluation+of+lipids+when+treated+with+niaspan+&+statin+or+other+lipid‐modifying+therapies‐COMPELL+&author=Pharmaceuticals+Kos&publication_year=2006&hl=en']",,, COMPELL 2007 {published data only}  ,excluded,CD010254-bbs2-0117, Titrated dose sequential data ,15163282,,,,,,15163282
CD010254-bib-0226,"McKenney JM, Jones PH, Bays HE, Knopp RH, Kashyap ML, Ruoff GE, et al. ",Comparative effects on lipid levels of combination therapy with a statin and extended‐release niacin or ezetimibe versus a statin alone (the COMPELL study), Atherosclerosis ,2007,192,    ,['citation-journal']," McKenney JM, Jones PH, Bays HE, Knopp RH, Kashyap ML, Ruoff GE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended‐release niacin or ezetimibe versus a statin alone (the COMPELL study).  Atherosclerosis 2007;192(2):432‐7. [MEDLINE: 17239888]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.atherosclerosis.2006.11.037', 'https://www.ncbi.nlm.nih.gov/pubmed/17239888', 'https://scholar.google.com/scholar_lookup?title=Comparative+effects+on+lipid+levels+of+combination+therapy+with+a+statin+and+extended‐release+niacin+or+ezetimibe+versus+a+statin+alone+(the+COMPELL+study)+&author=JM+McKenney&author=PH+Jones&author=HE+Bays&author=RH+Knopp&author=ML+Kashyap&author=GE+Ruoff&publication_year=2007&hl=en']",17239888,https://doi.org/10.1016/j.atherosclerosis.2006.11.037, COMPELL 2007 {published data only}  ,excluded,CD010254-bbs2-0117, Titrated dose sequential data ,,,17239888,153,,,17239888
CD010254-bib-0227,"Binbrek AS, Elis A. ","Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: A randomized, open‐label, parallel‐group, multicenter study (DISCOVERY Alpha study)", Current Therapeutic Research ‐ Clinical and Experimental ,2006,67,    ,['citation-journal']," Binbrek AS, Elis A. Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: A randomized, open‐label, parallel‐group, multicenter study (DISCOVERY Alpha study).  Current Therapeutic Research ‐ Clinical and Experimental 2006;67(1):21. [EMBASE: 2006376830]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.curtheres.2006.02.005', 'https://www.ncbi.nlm.nih.gov/pubmed/24936119', 'https://scholar.google.com/scholar_lookup?title=Rosuvastatin+versus+atorvastatin+in+achieving+lipid+goals+in+patients+at+high+risk+for+cardiovascular+disease+in+clinical+practice:+A+randomized,+open‐label,+parallel‐group,+multicenter+study+(DISCOVERY+Alpha+study)+&author=AS+Binbrek&author=A+Elis&publication_year=2006&hl=en']",24936119,https://doi.org/10.1016/j.curtheres.2006.02.005, DISCOVERY‐Alpha 2006 {published data only}  ,excluded,CD010254-bbs2-0118, 447/1002 (44.6%) participants were not included in the efficacy analysis high incomplete outcome bias  ,24936119,24936119,24936119,25,https://doi.org/10.1016/j.curtheres.2006.02.005,,24936119
CD010254-bib-0228,"Domingos H, Cunha RV, Paniago AM, Souza AS, Rodrigues RL, Domingos JA, et al. ",Rosuvastatin and ciprofibrate in the treatment of dyslipidemia in patients with HIV, Arquivos Brasileiros de Cardiologia ,2012,99,    ,['citation-journal']," Domingos H, Cunha RV, Paniago AM, Souza AS, Rodrigues RL, Domingos JA, et al. Rosuvastatin and ciprofibrate in the treatment of dyslipidemia in patients with HIV.  Arquivos Brasileiros de Cardiologia 2012;99(5):997‐1007. [MEDLINE: 23108642]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1590/S0066-782X2012005000096', 'https://www.ncbi.nlm.nih.gov/pubmed/23108642', 'https://scholar.google.com/scholar_lookup?title=Rosuvastatin+and+ciprofibrate+in+the+treatment+of+dyslipidemia+in+patients+with+HIV&author=H+Domingos&author=RV+Cunha&author=AM+Paniago&author=AS+Souza&author=RL+Rodrigues&author=JA+Domingos&publication_year=2012&hl=en']",23108642,https://doi.org/10.1590/S0066-782X2012005000096, Domingos 2012 {published data only}  ,excluded,CD010254-bbs2-0119, Confounding factor: anti retroviral drugs for the treatment of HIV ,,23108642,23108642,5,https://www.scielo.br/j/abc/a/ZC8Jr3QbCFDN6JJHfzJkrnm/?lang=en&format=pdf,,23108642
CD010254-bib-0229,"Fonseca FAH, Ruiz A, Cardona‐Munoz EG, Silva JM, Fuenmayor N, Marotti M, et al. ",The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL‐C Value‐‐an Evaluation of Rosuvastatin therapY compared with atorvastatin, Current Medical Research and Opinion ,2005,21,    ,['citation-journal']," Fonseca FAH, Ruiz A, Cardona‐Munoz EG, Silva JM, Fuenmayor N, Marotti M, et al. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL‐C Value‐‐an Evaluation of Rosuvastatin therapY compared with atorvastatin.  Current Medical Research and Opinion 2005;21(8):1307‐15. [MEDLINE: 16083541]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1185/030079905X56529', 'https://www.ncbi.nlm.nih.gov/pubmed/16083541', 'https://scholar.google.com/scholar_lookup?title=The+DISCOVERY+PENTA+study:+a+DIrect+Statin+COmparison+of+LDL‐C+Value‐‐an+Evaluation+of+Rosuvastatin+therapY+compared+with+atorvastatin+&author=FAH+Fonseca&author=A+Ruiz&author=EG+Cardona‐Munoz&author=JM+Silva&author=N+Fuenmayor&author=M+Marotti&publication_year=2005&hl=en']",16083541,https://doi.org/10.1185/030079905X56529, Fonseca 2005 {published data only}  ,excluded,CD010254-bbs2-0120, Data from statin‐naive patients and switched patients were combined. No baseline dietary washout stabilization period for at least 3 weeks was performed for the switched patients  ,,16083541,16083541,33,,,16083541
CD010254-bib-0230,"Gadarla M, Kearns AK, Thompson PD. ",Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins, American Journal of Cardiology ,2008,101,    ,['citation-journal']," Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins.  American Journal of Cardiology 2008;101(12):1747‐8. [MEDLINE: 18549851]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.amjcard.2008.02.061', 'https://www.ncbi.nlm.nih.gov/pubmed/18549851', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+rosuvastatin+(5+mg+and+10+mg)+twice+a+week+in+patients+intolerant+to+daily+statins+&author=M+Gadarla&author=AK+Kearns&author=PD+Thompson&publication_year=2008&hl=en']",18549851,https://doi.org/10.1016/j.amjcard.2008.02.061, Gadarla 2008 {published data only}  ,excluded,CD010254-bbs2-0121, Some participants were receiving confounding drugs ,18549851,18549851,18549851,79,,,18549851
CD010254-bib-0231,"Gliozzi M, Walker R, Muscoli S, Vitale C, Gratteri S, Carresi C, et al. ","Bergamot polyphenolic fraction enhances rosuvastatin‐induced effect on LDL‐cholesterol, LOX‐1 expression and protein kinase B phosphorylation in patients with hyperlipidemia", International journal of cardiology ,2013,170,    ,['citation-journal']," Gliozzi M, Walker R, Muscoli S, Vitale C, Gratteri S, Carresi C, et al. Bergamot polyphenolic fraction enhances rosuvastatin‐induced effect on LDL‐cholesterol, LOX‐1 expression and protein kinase B phosphorylation in patients with hyperlipidemia.  International journal of cardiology 2013;170:140‐5. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ijcard.2013.08.125', 'https://www.ncbi.nlm.nih.gov/pubmed/24239156', 'https://scholar.google.com/scholar_lookup?title=Bergamot+polyphenolic+fraction+enhances+rosuvastatin‐induced+effect+on+LDL‐cholesterol,+LOX‐1+expression+and+protein+kinase+B+phosphorylation+in+patients+with+hyperlipidemia+&author=M+Gliozzi&author=R+Walker&author=S+Muscoli&author=C+Vitale&author=S+Gratteri&author=C+Carresi&publication_year=2013&hl=en']",24239156,https://doi.org/10.1016/j.ijcard.2013.08.125, Gliozzi 2013 {published data only}  ,excluded,CD010254-bbs2-0122, length of washout period not recorded ,,24239156,24239156,109,,,24239156
CD010254-bib-0232,"Goldberg AC, Bittner V, Pepine CJ, Kelly MT, Thakker K, Setze CM, et al. ",Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia, American Journal of Cardiology ,2011,107,    ,['citation-journal']," Goldberg AC, Bittner V, Pepine CJ, Kelly MT, Thakker K, Setze CM, et al. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.  American Journal of Cardiology 2011;107(6):898‐905. [MEDLINE: 21247520]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.amjcard.2010.11.009', 'https://www.ncbi.nlm.nih.gov/pubmed/21247520', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+fenofibric+acid+plus+statins+on+multiple+lipid+parameters+and+its+safety+in+women+with+mixed+dyslipidemia+&author=AC+Goldberg&author=V+Bittner&author=CJ+Pepine&author=MT+Kelly&author=K+Thakker&author=CM+Setze&publication_year=2011&hl=en']",21247520,https://doi.org/10.1016/j.amjcard.2010.11.009, Goldberg 2011 {published data only}  ,excluded,CD010254-bbs2-0123, No dose of rosuvastatin reported ,,21247520,21247520,8,,,21247520
CD010254-bib-0233,"Johns KW, Bennett MT, Bondy GP. ",Are HIV positive patients resistant to statin therapy?,,2007,,    ,['citation-other']," Johns KW, Bennett MT, Bondy GP. Are HIV positive patients resistant to statin therapy?. Lipids in Health and Disease2007; Vol. 6:27. [MEDLINE: 17958912]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Are+HIV+positive+patients+resistant+to+statin+therapy?&author=KW+Johns&author=MT+Bennett&author=GP+Bondy&publication_year=2007&hl=en']",,, Johns 2007 {published data only}  ,excluded,CD010254-bbs2-0124, Confounding factor: anti retroviral drugs for the treatment of HIV ,17958912,,,,,,17958912
CD010254-bib-0234,Jyoti N. ,Comparative evaluation of atorvastatin and rosuvastatin in patients of dyslipidemia, JK Practitioner ,2008,15,    ,['citation-journal'], Jyoti N. Comparative evaluation of atorvastatin and rosuvastatin in patients of dyslipidemia.  JK Practitioner 2008;15(1‐4):27‐35. [EMBASE: 2009190395]CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Comparative+evaluation+of+atorvastatin+and+rosuvastatin+in+patients+of+dyslipidemia&author=N+Jyoti&publication_year=2008&hl=en']",,, Jyoti 2008 {published data only}  ,excluded,CD010254-bbs2-0125, Not available via interlibrary loan ,,,,,,,
CD010254-bib-0235,"Katabami T, Murakami M, Kobayashi S, Matsui T, Ujihara M, Takagi S, et al. ",Efficacy of low‐dose rosuvastatin in patients with type 2 diabetes and hypo high‐density lipoprotein cholesterolaemia, Journal of International Medical Research ,2014,42,    ,['citation-journal']," Katabami T, Murakami M, Kobayashi S, Matsui T, Ujihara M, Takagi S, et al. Efficacy of low‐dose rosuvastatin in patients with type 2 diabetes and hypo high‐density lipoprotein cholesterolaemia.  Journal of International Medical Research 2014;42:457‐67. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1177/0300060513507648', 'https://www.ncbi.nlm.nih.gov/pubmed/24595147', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+low‐dose+rosuvastatin+in+patients+with+type+2+diabetes+and+hypo+high‐density+lipoprotein+cholesterolaemia+&author=T+Katabami&author=M+Murakami&author=S+Kobayashi&author=T+Matsui&author=M+Ujihara&author=S+Takagi&publication_year=2014&hl=en']",24595147,https://doi.org/10.1177/0300060513507648, Katabami 2014 {published data only}  ,excluded,CD010254-bbs2-0126, length of washout period not recorded ,,24595147,24595147,6,https://journals.sagepub.com/doi/pdf/10.1177/0300060513507648,,24595147
CD010254-bib-0236,"Khan M A, Murti K, Grover V, Lal K, Singh D, Das P, et al. ",Atorvastatin vs rosuvastatin; Fenofibrate as an add on: An exploratory study, International Journal of Pharmacy and Pharmaceutical Sciences ,2014,6,    ,['citation-journal']," Khan M A, Murti K, Grover V, Lal K, Singh D, Das P, et al. Atorvastatin vs rosuvastatin; Fenofibrate as an add on: An exploratory study.  International Journal of Pharmacy and Pharmaceutical Sciences 2014;6:493‐8. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Atorvastatin+vs+rosuvastatin;+Fenofibrate+as+an+add+on:+An+exploratory+study&author=MA+Khan&author=K+Murti&author=V+Grover&author=K+Lal&author=D+Singh&author=P+Das&publication_year=2014&hl=en']",,, Khan 2014 {published data only}  ,excluded,CD010254-bbs2-0127, length of washout period not recorded ,,,,,,,
CD010254-bib-0237,"Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW. ",Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers,,2008,,    ,['citation-other']," Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. Journal of Acquired Immune Deficiency Syndromes2008; Vol. 47, issue 5:570‐8. [MEDLINE: 18176327]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Drug/drug+interaction+between+lopinavir/ritonavir+and+rosuvastatin+in+healthy+volunteers&author=JJ+Kiser&author=JG+Gerber&author=JA+Predhomme&author=P+Wolfe&author=DM+Flynn&author=DW+Hoody&publication_year=2008&hl=en']",,, Kiser 2008 {published data only}  ,excluded,CD010254-bbs2-0128, Confounding factor: participants are receiving protease inhibitors for the treatment of HIV  ,18176327,,,,,,18176327
CD010254-bib-0238,"Li R‐F, Yi G‐Z, Liu Z‐H. ",Efficacy of rosuvastatin in the treatment of early diabetic nephropathy,,2012,,    ,['citation-other']," Li R‐F, Yi G‐Z, Liu Z‐H. Efficacy of rosuvastatin in the treatment of early diabetic nephropathy. Chinese Journal of New Drugs. Chinese Journal of New Drugs Co. Ltd. (Floor 8. Lunyang Building No.6 Beisanhuan Zhonglu, Xicheng District, Beijing 100120, China), 2012; Vol. 21, issue 3:298. [EMBASE: 2012227641]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+rosuvastatin+in+the+treatment+of+early+diabetic+nephropathy&author=R‐F+Li&author=G‐Z+Yi&author=Z‐H+Liu&publication_year=2012&hl=en']",,, Li 2012a {published data only}  ,excluded,CD010254-bbs2-0129, LDL‐C values are incorrect from the Friedewald formula all values are suspect ,,,,,,,
CD010254-bib-0239,"Li Bo, Liu Wei Wei, Wo Jin Shan. ",Effects of rosuvastatin on apolipoprotein b/apolipoprotein a1 in patients with metabolic syndrome, Shiyong Yixue Zazhi ,2012,28,    ,['citation-journal']," Li Bo, Liu Wei Wei, Wo Jin Shan. Effects of rosuvastatin on apolipoprotein b/apolipoprotein a1 in patients with metabolic syndrome.  Shiyong Yixue Zazhi 2012;28(7):1181‐3. [CENTRAL: CN‐00866854 NEW]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effects+of+rosuvastatin+on+apolipoprotein+b/apolipoprotein+a1+in+patients+with+metabolic+syndrome+&author=Bo+Li&author=Wei+LiuWei&author=Shan+WoJin&publication_year=2012&hl=en']",,, Li 2012b {published data only}  ,excluded,CD010254-bbs2-0130, LDL‐C values are incorrect from the Friedewald formula all values are suspect ,,,,,,,
CD010254-bib-0240,"Polis AB, Abate N, Catapano AL, Ballantyne CM, Davidson MH, Smugar SS, et al. ","Low‐density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category", Metabolic Syndrome and Related Disorders ,2009,7,    ,['citation-journal']," Polis AB, Abate N, Catapano AL, Ballantyne CM, Davidson MH, Smugar SS, et al. Low‐density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.  Metabolic Syndrome and Related Disorders 2009;7(6):601‐10. [MEDLINE: 19929597]CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/19929597', 'https://scholar.google.com/scholar_lookup?title=Low‐density+lipoprotein+cholesterol+reduction+and+goal+achievement+with+ezetimibe/simvastatin+versus+atorvastatin+or+rosuvastatin+in+patients+with+diabetes,+metabolic+syndrome,+or+neither+disease,+stratified+by+National+Cholesterol+Education+Program+risk+category+&author=AB+Polis&author=N+Abate&author=AL+Catapano&author=CM+Ballantyne&author=MH+Davidson&author=SS+Smugar&publication_year=2009&hl=en']",19929597,, Polis 2009 {published data only}  ,excluded,CD010254-bbs2-0131, Pooled data across all statin doses ,,,,,,,19929597
CD010254-bib-0241,"Puccetti L, Santilli F, Pasqui AL, Lattanzio S, Liani R, Ciani F, et al. ",Effects of atorvastatin and rosuvastatin on thromboxane‐dependent platelet activation and oxidative stress in hypercholesterolemia, Atherosclerosis ,2011,214,    ,['citation-journal']," Puccetti L, Santilli F, Pasqui AL, Lattanzio S, Liani R, Ciani F, et al. Effects of atorvastatin and rosuvastatin on thromboxane‐dependent platelet activation and oxidative stress in hypercholesterolemia.  Atherosclerosis 2011;214(1):122‐8. [MEDLINE: 21056418]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.atherosclerosis.2010.10.006', 'https://www.ncbi.nlm.nih.gov/pubmed/21056418', 'https://scholar.google.com/scholar_lookup?title=Effects+of+atorvastatin+and+rosuvastatin+on+thromboxane‐dependent+platelet+activation+and+oxidative+stress+in+hypercholesterolemia+&author=L+Puccetti&author=F+Santilli&author=AL+Pasqui&author=S+Lattanzio&author=R+Liani&author=F+Ciani&publication_year=2011&hl=en']",21056418,https://doi.org/10.1016/j.atherosclerosis.2010.10.006, Puccetti 2011 {published data only}  ,excluded,CD010254-bbs2-0132," Inappropriate outcomes, median per cent change ",,21056418,21056418,82,,,21056418
CD010254-bib-0242,"Riccioni G, Scotti L, Di Ilio E, Bucciarelli V, D'Orazio N, Aceto A, et al. ",Rosuvastatin effect on intima media thickness in adult vs elderly patients, Frontiers in Bioscience ,2012,4,    ,['citation-journal']," Riccioni G, Scotti L, Di Ilio E, Bucciarelli V, D'Orazio N, Aceto A, et al. Rosuvastatin effect on intima media thickness in adult vs elderly patients.  Frontiers in Bioscience 2012;4:2718‐21. [MEDLINE: 22652672]CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Rosuvastatin+effect+on+intima+media+thickness+in+adult+vs+elderly+patients&author=G+Riccioni&author=L+Scotti&author=E+Ilio&author=V+Bucciarelli&author=N+D'Orazio&author=A+Aceto&publication_year=2012&hl=en""]",,, Riccioni 2012 {published data only}  ,excluded,CD010254-bbs2-0133, Article is not available via interlibrary loan ,,,,,,,
CD010254-bib-0243,"Rossi M, Carpi A, Di Maria C, Franzoni F, Galetta F, Santoro G. ",Skin blood flow motion and microvascular reactivity investigation in hypercholesterolemic patients without clinically manifest arterial diseases, Physiological Research / Academia Scientiarum Bohemoslovaca ,2009,58,    ,['citation-journal']," Rossi M, Carpi A, Di Maria C, Franzoni F, Galetta F, Santoro G. Skin blood flow motion and microvascular reactivity investigation in hypercholesterolemic patients without clinically manifest arterial diseases.  Physiological Research / Academia Scientiarum Bohemoslovaca 2009;58(1):39‐47. [MEDLINE: 18198995]CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/18198995', 'https://scholar.google.com/scholar_lookup?title=Skin+blood+flow+motion+and+microvascular+reactivity+investigation+in+hypercholesterolemic+patients+without+clinically+manifest+arterial+diseases+&author=M+Rossi&author=A+Carpi&author=C+Maria&author=F+Franzoni&author=F+Galetta&author=G+Santoro&publication_year=2009&hl=en']",18198995,, Rossi 2009 {published data only}  ,excluded,CD010254-bbs2-0134, 4/15 (26.6%) participants were not included in the efficacy analysis high incomplete outcome bias  ,,,,,,,18198995
CD010254-bib-0244,"Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, et al. ","Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double‐blind study"," American Journal of Cardiovascular Drugs : drugs, devices, and other interventions ",2010,10,    ,['citation-journal']," Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, et al. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double‐blind study.  American Journal of Cardiovascular Drugs : drugs, devices, and other interventions 2010;10(3):175‐86. [MEDLINE: 20524719]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2165/11533430-000000000-00000', 'https://www.ncbi.nlm.nih.gov/pubmed/20524719', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+rosuvastatin+and+fenofibric+acid+combination+therapy+versus+simvastatin+monotherapy+in+patients+with+hypercholesterolemia+and+hypertriglyceridemia:+a+randomized,+double‐blind+study+&author=EM+Roth&author=JM+McKenney&author=MT+Kelly&author=CM+Setze&author=DM+Carlson&author=A+Gold&publication_year=2010&hl=en']",20524719,https://doi.org/10.2165/11533430-000000000-00000, Roth 2010 {published data only}  ,excluded,CD010254-bbs2-0135, Rosuvastatin fenofibrate combination ,,20524719,20524719,25,,,20524719
CD010254-bib-0245,"Talavera JO, Martinez G, Cervantes JL, Marin JA, Rodriguez‐Briones I, Gonzalez JG, et al. ","A double‐blind, double‐dummy, randomized, placebo‐controlled trial to evaluate the effect of statin therapy on triglyceride levels in Mexican hypertriglyceridemic patients", Current Medical Research & Opinion ,2013,29,    ,['citation-journal']," Talavera JO, Martinez G, Cervantes JL, Marin JA, Rodriguez‐Briones I, Gonzalez JG, et al. A double‐blind, double‐dummy, randomized, placebo‐controlled trial to evaluate the effect of statin therapy on triglyceride levels in Mexican hypertriglyceridemic patients.  Current Medical Research & Opinion 2013;29(4):379‐86. [MEDLINE: 23323877]CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1185/03007995.2013.766590', 'https://scholar.google.com/scholar_lookup?title=A+double‐blind,+double‐dummy,+randomized,+placebo‐controlled+trial+to+evaluate+the+effect+of+statin+therapy+on+triglyceride+levels+in+Mexican+hypertriglyceridemic+patients+&author=JO+Talavera&author=G+Martinez&author=JL+Cervantes&author=JA+Marin&author=I+Rodriguez‐Briones&author=JG+Gonzalez&publication_year=2013&hl=en']",,https://doi.org/10.1185/03007995.2013.766590, Talavera 2013 {published data only}  ,excluded,CD010254-bbs2-0136, Median per cent change was reported ,,,23323877,10,,,23323877
CD010254-bib-0246,"Van Der Lee, Sankatsing R, Schippers E, Vogel M, Fatkenheuer G, Van Der V, et al. ",Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV‐infected patients, Antiviral Therapy ,2007,12,    ,['citation-journal']," Van Der Lee, Sankatsing R, Schippers E, Vogel M, Fatkenheuer G, Van Der V, et al. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV‐infected patients.  Antiviral Therapy 2007;12(7):1127‐32. [MEDLINE: 18018771]CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/18018771', 'https://scholar.google.com/scholar_lookup?title=Pharmacokinetics+and+pharmacodynamics+of+combined+use+of+lopinavir/ritonavir+and+rosuvastatin+in+HIV‐infected+patients+&author=+Lee&author=R+Sankatsing&author=E+Schippers&author=M+Vogel&author=G+Fatkenheuer&author=+V&publication_year=2007&hl=en']",18018771,," Van Der Lee, 2007 {published data only}  ",excluded,CD010254-bbs2-0137, Confounding factor: participants received protease inhibitors for the treatment of HIV  ,,18018771,,,,,18018771
CD010254-bib-0247,"Van Der Lee, Sankatsing R, Schippers E, Vogel M, Rockstroh J, Fatkenheuer G, et al. ",Pharmacokinetics and pharmacodynamics of simultaneous use of lopinavir + ritonavir and rosuvastatin, Pharmaceutisch Weekblad ,2008,143,    ,['citation-journal']," Van Der Lee, Sankatsing R, Schippers E, Vogel M, Rockstroh J, Fatkenheuer G, et al. Pharmacokinetics and pharmacodynamics of simultaneous use of lopinavir + ritonavir and rosuvastatin.  Pharmaceutisch Weekblad 2008;143(7):42‐5. [EMBASE: 2008103375]CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Pharmacokinetics+and+pharmacodynamics+of+simultaneous+use+of+lopinavir+++ritonavir+and+rosuvastatin+&author=+Lee&author=R+Sankatsing&author=E+Schippers&author=M+Vogel&author=J+Rockstroh&author=G+Fatkenheuer&publication_year=2008&hl=en']",,," Van Der Lee, 2008 {published data only}  ",excluded,CD010254-bbs2-0138, Confounding factor: participants received protease inhibitors for the treatment of HIV  ,,,,,,,
CD010254-bib-0248,"Yun KH, Shin SN, Ko JS, Rhee SJ, Kim NH, Oh SK, et al. ",Rosuvastatin‐induced high‐density lipoprotein changes in patients who underwent percutaneous coronary intervention for non‐ST‐segment elevation acute coronary syndrome, Journal of Cardiology ,2012,60,    ,['citation-journal']," Yun KH, Shin SN, Ko JS, Rhee SJ, Kim NH, Oh SK, et al. Rosuvastatin‐induced high‐density lipoprotein changes in patients who underwent percutaneous coronary intervention for non‐ST‐segment elevation acute coronary syndrome.  Journal of Cardiology 2012;60(5):383‐8. [MEDLINE: 22884684]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.jjcc.2012.07.008', 'https://www.ncbi.nlm.nih.gov/pubmed/22884684', 'https://scholar.google.com/scholar_lookup?title=Rosuvastatin‐induced+high‐density+lipoprotein+changes+in+patients+who+underwent+percutaneous+coronary+intervention+for+non‐ST‐segment+elevation+acute+coronary+syndrome+&author=KH+Yun&author=SN+Shin&author=JS+Ko&author=SJ+Rhee&author=NH+Kim&author=SK+Oh&publication_year=2012&hl=en']",22884684,https://doi.org/10.1016/j.jjcc.2012.07.008, Yun 2012 {published data only}  ,excluded,CD010254-bbs2-0139, 167/723 (23%) participants were not included in the efficacy analysis; high incomplete outcome bias  ,,22884684,22884684,10,http://www.journal-of-cardiology.com/article/S0914508712001347/pdf,,22884684
CD010254-bib-0279,"Adams SP, Tsang M, Wright JM. ",Lipid lowering efficacy of atorvastatin, Cochrane Database of Systematic Reviews ,2012,,    ,['citation-journal']," Adams SP, Tsang M, Wright JM. Lipid lowering efficacy of atorvastatin.  Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008226.pub2]    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Lipid+lowering+efficacy+of+atorvastatin&author=SP+Adams&author=M+Tsang&author=JM+Wright&publication_year=2012&hl=en'],,, Adams 2012a ,additional,CD010254-bbs2-0170,,29508377,,,,,,29508377
CD010254-bib-0280,Bandolier. ,Cholesterol lowering with statins,,2004,,    ,['citation-other'], Bandolier. Cholesterol lowering with statins. Bandolier2004:121‐2.    Google Scholar     ,['https://scholar.google.com/scholar_lookup?title=Cholesterol+lowering+with+statins&author=+Bandolier&publication_year=2004&hl=en'],,, Bandolier 2004 ,additional,CD010254-bbs2-0171,,,,,,,,
CD010254-bib-0281,"Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM, Ridker PM, Kastelein JJ. ","Association of LDL cholesterol, non–HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta‐analysis", JAMA ,2012,307,    ,['citation-journal']," Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM, Ridker PM, Kastelein JJ. Association of LDL cholesterol, non–HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta‐analysis.  JAMA 2012;307(12):1302‐9. [MEDLINE: 22453571]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/jama.2012.366', 'https://www.ncbi.nlm.nih.gov/pubmed/22453571', 'https://scholar.google.com/scholar_lookup?title=Association+of+LDL+cholesterol,+non–HDL+cholesterol,+and+apolipoprotein+B+levels+with+risk+of+cardiovascular+events+among+patients+treated+with+statins:+a+meta‐analysis+&author=SM+Boekholdt&author=BJ+Arsenault&author=S+Mora&author=TR+Pedersen&author=JC+LaRosa&author=PJ+Nestel&author=RJ+Simes&author=P+Durrington&author=GA+Hitman&author=KM+Welch&author=DA+DeMicco&author=AH+Zwinderman&author=MB+Clearfield&author=JR+Downs&author=AM+Tonkin&author=HM+Colhoun&author=AM+Gotto&author=PM+Ridker&author=JJ+Kastelein&publication_year=2012&hl=en']",22453571,https://doi.org/10.1001/jama.2012.366, Boekholdt 2012 ,additional,CD010254-bbs2-0172,,22453571,,22453571,731,,,22453571
CD010254-bib-0282,Centers for Disease Control and Prevention (CDC). ,"Million hearts: strategies to reduce the prevalence of leading cardiovascular disease risk factors‐‐United States, 2011", MMWR ‐ Morbidity & Mortality Weekly Report ,2011,60,(36):1248‐51. [MEDLINE: 21918495]   ,['citation-journal']," Centers for Disease Control and Prevention (CDC). Million hearts: strategies to reduce the prevalence of leading cardiovascular disease risk factors‐‐United States, 2011.  MMWR ‐ Morbidity & Mortality Weekly Report 2011;60(36):1248‐51. [MEDLINE: 21918495]    ",[],,, CDC 2011 ,additional,CD010254-bbs2-0173,,21918495,,,,,,21918495
CD010254-bib-0283,"Choumerianou DM, Dedoussis GV. ",Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background,,2005,,    ,['citation-other']," Choumerianou DM, Dedoussis GV. Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background. Clinical Chemistry & Laboratory Medicine. Germany: Department of Science of Dietetics‐Nutrition, Harokopio University of Athens, Greece., 2005; Vol. 43, issue 8:793‐801. [MEDLINE: 16201887]    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Familial+hypercholesterolemia+and+response+to+statin+therapy+according+to+LDLR+genetic+background+&author=DM+Choumerianou&author=GV+Dedoussis&publication_year=2005&hl=en'],,, Choumerianou 2005 ,additional,CD010254-bbs2-0174,,16201887,,,,,,16201887
CD010254-bib-0284,,"Highlights of Prescribing Information, 2015",,2015,,.   ,['citation-other']," Highlights of Prescribing Information, 2015. https://www.astrazeneca.ca/content/dam/az‐ca/downloads/productinformation/CRESTOR%20‐%20Product‐Monograph.pdf2015.    ",[],,, Crestor Prescribing Information 2015 ,additional,CD010254-bbs2-0175,,41622770,,,,,,41622770
CD010254-bib-0285,"Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists' (CTT) Collaborators. ","Efficacy and safety of cholesterol‐lowering treatment: prospective meta‐analysis of data from 90,056 participants in 14 randomised trials of statins", Lancet ,2005,366,    ,['citation-journal']," Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol‐lowering treatment: prospective meta‐analysis of data from 90,056 participants in 14 randomised trials of statins.  Lancet 2005;366(9493):1267‐78. [MEDLINE: 16214597]    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/16214597', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+cholesterol‐lowering+treatment:+prospective+meta‐analysis+of+data+from+90,056+participants+in+14+randomised+trials+of+statins+&author=C+Baigent&author=A+Keech&author=PM+Kearney&author=L+Blackwell&author=G+Buck&author=C+Pollicino&author=A+Kirby&author=T+Sourjina&author=R+Peto&author=R+Collins&author=R+Simes&publication_year=2005&hl=en']",16214597,, CTT 2005 ,additional,CD010254-bbs2-0176,,16214597,16214597,,,,,16214597
CD010254-bib-0286,"Edwards JE, Moore RA. ","Statins in hypercholesterolaemia: a dose‐specific meta‐analysis of lipid changes in randomised, double blind trials", BMC Family Practice ,2003,4,    ,['citation-journal']," Edwards JE, Moore RA. Statins in hypercholesterolaemia: a dose‐specific meta‐analysis of lipid changes in randomised, double blind trials.  BMC Family Practice 2003;4:18. [MEDLINE: 14969594]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1186/1471-2296-4-18', 'https://www.ncbi.nlm.nih.gov/pubmed/14969594', 'https://scholar.google.com/scholar_lookup?title=Statins+in+hypercholesterolaemia:+a+dose‐specific+meta‐analysis+of+lipid+changes+in+randomised,+double+blind+trials+&author=JE+Edwards&author=RA+Moore&publication_year=2003&hl=en']",14969594,https://doi.org/10.1186/1471-2296-4-18, Edwards 2003 ,additional,CD010254-bbs2-0177,,14969594,14969594,14969594,170,https://bmcprimcare.biomedcentral.com/track/pdf/10.1186/1471-2296-4-18,,14969594
CD010254-bib-0287,"Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. ",Imputing missing standard deviations in meta‐analyses can provide accurate results, Journal of Clinical Epidemiology ,2006,59,    ,['citation-journal']," Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results.  Journal of Clinical Epidemiology 2006;59(1):7‐10. [MEDLINE: 16360555]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.jclinepi.2005.06.006', 'https://www.ncbi.nlm.nih.gov/pubmed/16360555', 'https://scholar.google.com/scholar_lookup?title=Imputing+missing+standard+deviations+in+meta‐analyses+can+provide+accurate+results&author=TA+Furukawa&author=C+Barbui&author=A+Cipriani&author=P+Brambilla&author=N+Watanabe&publication_year=2006&hl=en']",16360555,https://doi.org/10.1016/j.jclinepi.2005.06.006, Furukawa 2006 ,additional,CD010254-bbs2-0178,,16360555,,16360555,1339,,,16360555
CD010254-bib-0288,"Gaw A, Packard CJ, Shepherd J. ",,Statins : the HMG CoA Reductase Inhibitors in Perspective,2000,,. [ISBN 1853174688]   ,['citation-book']," Gaw A, Packard CJ, Shepherd J. Statins : the HMG CoA Reductase Inhibitors in Perspective. London, England: Martin Dunitz Ltd, 2000. [ISBN 1853174688]    ",[],,, Gaw 2000 ,additional,CD010254-bbs2-0179,,21956727,,,,,,21956727
CD010254-bib-0289,"Goodman LS,  Brunton LL,  Chabner B,  Knollmann BC. ",,Goodman & Gilman's Pharmacological Basis of Therapeutics,2011,,. [ISBN: 9780071624428]   ,['citation-book']," Goodman LS,  Brunton LL,  Chabner B,  Knollmann BC. Goodman & Gilman's Pharmacological Basis of Therapeutics. 12th Edition. New York: McGraw‐Hill, 2011. [ISBN: 9780071624428]    ",[],,, Goodman 2011 ,additional,CD010254-bbs2-0180,,,,,,,,
CD010254-bib-0290,"Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, Coordinating Committee of the National Cholesterol Education Program. ",Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, Journal of the American College of Cardiology ,2004,44,    ,['citation-journal']," Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.  Journal of the American College of Cardiology 2004;44(3):720‐32. [MEDLINE: 15358046]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.jacc.2004.07.001', 'https://www.ncbi.nlm.nih.gov/pubmed/15358046', 'https://scholar.google.com/scholar_lookup?title=Implications+of+recent+clinical+trials+for+the+National+Cholesterol+Education+Program+Adult+Treatment+Panel+III+Guidelines+&author=SM+Grundy&author=JI+Cleeman&author=CN+Merz&author=HB+Brewer&author=LT+Clark&author=DB+Hunninghake&author=RC+Pasternak&author=SC+Smith&author=NJ+Stone&publication_year=2004&hl=en']",15358046,https://doi.org/10.1016/j.jacc.2004.07.001, Grundy 2004 ,additional,CD010254-bbs2-0181,,15358046,16755211,,,,,15358046
CD010254-bib-0291,"Heran BS, Wong MMY, Heran IK, Wright JM. ",Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension, Cochrane Database of Systematic Reviews ,2008,,    ,['citation-journal']," Heran BS, Wong MMY, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension.  Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003823.pub2]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD003823.pub2', 'https://scholar.google.com/scholar_lookup?title=Blood+pressure+lowering+efficacy+of+angiotensin+converting+enzyme+(ACE)+inhibitors+for+primary+hypertension+&author=BS+Heran&author=MMY+Wong&author=IK+Heran&author=JM+Wright&publication_year=2008&hl=en']",,https://doi.org/10.1002/14651858.CD003823.pub2, Heran 2008 ,additional,CD010254-bbs2-0182,,,,18843651,168,https://europepmc.org/articles/pmc7156914?pdf=render,,18843651
CD010254-bib-0292,"Higgins JP, Thompson SG. ",Quantifying heterogeneity in a meta‐analysis, Statistics in Medicine ,2002,21,    ,['citation-journal']," Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis.  Statistics in Medicine 2002;21(11):1539‐58. [MEDLINE: 12111919]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1002/sim.1186', 'https://www.ncbi.nlm.nih.gov/pubmed/12111919', 'https://scholar.google.com/scholar_lookup?title=Quantifying+heterogeneity+in+a+meta‐analysis&author=JP+Higgins&author=SG+Thompson&publication_year=2002&hl=en']",12111919,https://doi.org/10.1002/sim.1186, Higgins 2002 ,additional,CD010254-bbs2-0183,,,,12111919,31525,,,12111919
CD010254-bib-0293,"Higgins JPT, Altman DG, Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. ",,"Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions  Version 5.1.0 (updated March 2011)",2011,,.   ,['citation-book']," Higgins JPT, Altman DG, Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions  Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org, 2011.    ",[],,, Higgins 2011 ,additional,CD010254-bbs2-0184,,,,,,,,
CD010254-bib-0294,"Kellick KA, Burns K, Mcandrew E, Haberl E, Hook N, Ellis AK. ",Focus on atorvastatin: An HMG‐CoA reductase inhibitor for lowering both elevated LDL cholesterol and triglycerides in hypercholesterolemic patients, Formulary ,1997,32,    ,['citation-journal']," Kellick KA, Burns K, Mcandrew E, Haberl E, Hook N, Ellis AK. Focus on atorvastatin: An HMG‐CoA reductase inhibitor for lowering both elevated LDL cholesterol and triglycerides in hypercholesterolemic patients.  Formulary 1997;32(4):352‐63. [EMBASE: 27183679]    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Focus+on+atorvastatin:+An+HMG‐CoA+reductase+inhibitor+for+lowering+both+elevated+LDL+cholesterol+and+triglycerides+in+hypercholesterolemic+patients+&author=KA+Kellick&author=K+Burns&author=E+Mcandrew&author=E+Haberl&author=N+Hook&author=AK+Ellis&publication_year=1997&hl=en'],,, Kellick 1997 ,additional,CD010254-bbs2-0185,,,,,,,,
CD010254-bib-0295,"Kreatsoulas C, Anand SS. ",The impact of social determinants on cardiovascular disease, Canadian Journal of Cardiology ,2010,26,    ,['citation-journal']," Kreatsoulas C, Anand SS. The impact of social determinants on cardiovascular disease.  Canadian Journal of Cardiology 2010;26(Suppl C):8C‐13C. [MEDLINE: 20847985]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0828-282X(10)71075-8', 'https://www.ncbi.nlm.nih.gov/pubmed/20847985', 'https://scholar.google.com/scholar_lookup?title=The\xa0impact\xa0of\xa0social\xa0determinants\xa0on\xa0cardiovascular\xa0disease&author=C+Kreatsoulas&author=SS+Anand&publication_year=2010&hl=en']",20847985,https://doi.org/10.1016/S0828-282X(10)71075-8, Kreatsoulas 2010 ,additional,CD010254-bbs2-0186,,20847985,,20847985,226,https://europepmc.org/articles/pmc2949987?pdf=render,,20847985
CD010254-bib-0296,"Law MR, Wald NJ, Rudnicka AR. ","Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta‐analysis", BMJ ,2003,326,    ,['citation-journal']," Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta‐analysis.  BMJ 2003;326(7404):1423. [MEDLINE: 12829554]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.326.7404.1423', 'https://www.ncbi.nlm.nih.gov/pubmed/12829554', 'https://scholar.google.com/scholar_lookup?title=Quantifying+effect+of+statins+on+low+density+lipoprotein+cholesterol,+ischaemic+heart+disease,+and+stroke:+systematic+review+and+meta‐analysis+&author=MR+Law&author=NJ+Wald&author=AR+Rudnicka&publication_year=2003&hl=en']",12829554,https://doi.org/10.1136/bmj.326.7404.1423, Law 2003 ,additional,CD010254-bbs2-0187,,12829554,,12829554,1842,https://www.bmj.com/content/bmj/326/7404/1423.full.pdf,,12829554
CD010254-bib-0297,"Liao JK, Laufs U. ",Pleiotropic effects of statins, Annual Review of Pharmacology and Toxicology ,2005,45,    ,['citation-journal']," Liao JK, Laufs U. Pleiotropic effects of statins.  Annual Review of Pharmacology and Toxicology 2005;45:89‐118. [MEDLINE: 15822172]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1146/annurev.pharmtox.45.120403.095748', 'https://www.ncbi.nlm.nih.gov/pubmed/15822172', 'https://scholar.google.com/scholar_lookup?title=Pleiotropic+effects+of+statins&author=JK+Liao&author=U+Laufs&publication_year=2005&hl=en']",15822172,https://doi.org/10.1146/annurev.pharmtox.45.120403.095748, Liao 2005 ,additional,CD010254-bbs2-0188,,28057795,,15822172,1142,https://europepmc.org/articles/pmc2694580?pdf=render,,15822172
CD010254-bib-0298,"Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. ","Primary prevention of cardiovascular mortality and events with statin treatments: a network meta‐analysis involving more than 65,000 patients", Journal of the American College of Cardiology ,2008,52,    ,['citation-journal']," Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta‐analysis involving more than 65,000 patients.  Journal of the American College of Cardiology 2008;52(22):1769‐81. [MEDLINE: 19022156]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.jacc.2008.08.039', 'https://www.ncbi.nlm.nih.gov/pubmed/19022156', 'https://scholar.google.com/scholar_lookup?title=Primary+prevention+of+cardiovascular+mortality+and+events+with+statin+treatments:+a+network+meta‐analysis+involving+more+than+65,000+patients+&author=EJ+Mills&author=B+Rachlis&author=P+Wu&author=PJ+Devereaux&author=P+Arora&author=D+Perri&publication_year=2008&hl=en']",19022156,https://doi.org/10.1016/j.jacc.2008.08.039, Mills 2008 ,additional,CD010254-bbs2-0189,,19022156,19022156,19022156,449,https://doi.org/10.1016/j.jacc.2008.08.039,,19022156
CD010254-bib-0299,Moghadasian MH. ,Clinical pharmacology of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors, Life Sciences ,1999,65,    ,['citation-journal'], Moghadasian MH. Clinical pharmacology of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors.  Life Sciences 1999;65(13):1329‐37. [MEDLINE: 10503952]    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.1016/S0024-3205(99)00199-X', 'https://www.ncbi.nlm.nih.gov/pubmed/10503952', 'https://scholar.google.com/scholar_lookup?title=Clinical+pharmacology+of+3‐hydroxy‐3‐methylglutaryl+coenzyme+A+reductase+inhibitors&author=MH+Moghadasian&publication_year=1999&hl=en']",10503952,https://doi.org/10.1016/S0024-3205(99)00199-X, Moghadasian 1999 ,additional,CD010254-bbs2-0190,,10503952,,10503952,134,,,10503952
CD010254-bib-0300,"Roger VL, Go AS, Lloyd‐Jones DM, Adams RJ, Berry JD, Brown TM, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. ",Heart disease and stroke statistics ‐‐ 2011 update: a report from the American Heart Association, Circulation ,2011,123,    ,['citation-journal']," Roger VL, Go AS, Lloyd‐Jones DM, Adams RJ, Berry JD, Brown TM, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics ‐‐ 2011 update: a report from the American Heart Association.  Circulation 2011;123(4):e18‐e209. [MEDLINE: 21160056]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1161/CIR.0b013e3182009701', 'https://www.ncbi.nlm.nih.gov/pubmed/21160056', 'https://scholar.google.com/scholar_lookup?title=Heart+disease+and+stroke+statistics+‐‐+2011+update:+a+report+from+the+American+Heart+Association+&author=VL+Roger&author=AS+Go&author=DM+Lloyd‐Jones&author=RJ+Adams&author=JD+Berry&author=TM+Brown&publication_year=2011&hl=en']",21160056,https://doi.org/10.1161/CIR.0b013e3182009701, Roger 2011 ,additional,CD010254-bbs2-0191,,,,21160056,5274,https://europepmc.org/articles/pmc4418670?pdf=render,,21160056
CD010254-bib-0301,"Schaefer EJ, McNamara JR, Tayler T, Daly JA, Gleason JL, Seman LJ, Ferrari A, Rubenstein JJ. ","Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects", American Journal of Cardiology ,2004,93,    ,['citation-journal']," Schaefer EJ, McNamara JR, Tayler T, Daly JA, Gleason JL, Seman LJ, Ferrari A, Rubenstein JJ. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.  American Journal of Cardiology 2004;93(1):31‐9. [MEDLINE: 14697462]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.amjcard.2003.09.008', 'https://www.ncbi.nlm.nih.gov/pubmed/14697462', 'https://scholar.google.com/scholar_lookup?title=Comparisons+of+effects+of+statins+(atorvastatin,+fluvastatin,+lovastatin,+pravastatin,+and+simvastatin)+on+fasting+and+postprandial+lipoproteins+in+patients+with+coronary+heart+disease+versus+control+subjects+&author=EJ+Schaefer&author=JR+McNamara&author=T+Tayler&author=JA+Daly&author=JL+Gleason&author=LJ+Seman&author=A+Ferrari&author=JJ+Rubenstein&publication_year=2004&hl=en']",14697462,https://doi.org/10.1016/j.amjcard.2003.09.008, Schaefer 2004 ,additional,CD010254-bbs2-0192,,14697462,14697462,14697462,149,,,14697462
CD010254-bib-0302,"Schectman G, Hiatt J. ",Dose‐response characteristics of cholesterol‐lowering drug therapies: implications for treatment, Annals of Internal Medicine ,1996,125,    ,['citation-journal']," Schectman G, Hiatt J. Dose‐response characteristics of cholesterol‐lowering drug therapies: implications for treatment.  Annals of Internal Medicine 1996;125(12):990‐1000. [MEDLINE: 8967711]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.7326/0003-4819-125-12-199612150-00011', 'https://www.ncbi.nlm.nih.gov/pubmed/8967711', 'https://scholar.google.com/scholar_lookup?title=Dose‐response+characteristics+of+cholesterol‐lowering+drug+therapies:+implications+for+treatment+&author=G+Schectman&author=J+Hiatt&publication_year=1996&hl=en']",8967711,https://doi.org/10.7326/0003-4819-125-12-199612150-00011, Schectman 1996 ,additional,CD010254-bbs2-0193,,8967711,,8967711,92,,,8967711
CD010254-bib-0303,"Smith MEB, Lee NJ, Haney E, Carson S. ","Drug Class Review HMG‐CoA Reductase Inhibitors (Statins) and Fixed‐dose Combination Products Containing a Statin. Final Report Update 5, 2009",,,,. www.ncbi.nlm.nih.gov/books/NBK47273/pdf/TOC.pdf (last accessed 8 November 2012).   ,['citation-other']," Smith MEB, Lee NJ, Haney E, Carson S. Drug Class Review HMG‐CoA Reductase Inhibitors (Statins) and Fixed‐dose Combination Products Containing a Statin. Final Report Update 5, 2009. www.ncbi.nlm.nih.gov/books/NBK47273/pdf/TOC.pdf (last accessed 8 November 2012).    ",[],,, Smith 2009 ,additional,CD010254-bbs2-0194,,21089253,,,,,,21089253
CD010254-bib-0304,"Sterne JAC, Egger M, Moher D on behalf of the Cochrane Bias Methods Group (editors). ",,"Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention",2011,,.   ,['citation-book']," Sterne JAC, Egger M, Moher D on behalf of the Cochrane Bias Methods Group (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org, 2011.    ",[],,, Sterne 2011 ,additional,CD010254-bbs2-0195,,,,,,,,
CD010254-bib-0305,"Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, Ward K, Ebrahim S. ",Statins for the primary prevention of cardiovascular disease, Cochrane Database of Systematic Reviews ,2013,,    ,['citation-journal']," Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease.  Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD004816.pub5]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD009217.pub2', 'https://scholar.google.com/scholar_lookup?title=Statins+for+the+primary+prevention+of+cardiovascular+disease&author=F+Taylor&author=MD+Huffman&author=AF+Macedo&author=THM+Moore&author=M+Burke&author=G+DaveySmith&author=K+Ward&author=S+Ebrahim&publication_year=2013&hl=en']",,https://doi.org/10.1002/14651858.CD009217.pub2, Taylor 2013 ,additional,CD010254-bbs2-0196,,23440795,,24026890,30,https://researchonline.lshtm.ac.uk/id/eprint/12666/1/Hooper_et_al-2003-The_Cochrane_library.pdf,,24026890
CD010254-bib-0306,"Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB, Banerjee P, Milos PM, Myrand SP, Paulauskis J, Milad MA, Sasiela WJ. ",An association study of 43 SNPs in 16 candidate genes with atorvastatin response, Pharmacogenomics Journal ,2005,5,    ,['citation-journal']," Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB, Banerjee P, Milos PM, Myrand SP, Paulauskis J, Milad MA, Sasiela WJ. An association study of 43 SNPs in 16 candidate genes with atorvastatin response.  Pharmacogenomics Journal 2005;5(6):352‐8. [MEDLINE: 16103896]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1038/sj.tpj.6500328', 'https://www.ncbi.nlm.nih.gov/pubmed/16103896', 'https://scholar.google.com/scholar_lookup?title=An+association+study+of+43+SNPs+in+16+candidate+genes+with+atorvastatin+response&author=JF+Thompson&author=M+Man&author=KJ+Johnson&author=LS+Wood&author=ME+Lira&author=DB+Lloyd&author=P+Banerjee&author=PM+Milos&author=SP+Myrand&author=J+Paulauskis&author=MA+Milad&author=WJ+Sasiela&publication_year=2005&hl=en']",16103896,https://doi.org/10.1038/sj.tpj.6500328, Thompson 2005 ,additional,CD010254-bbs2-0197,,16103896,16103896,16103896,201,,,16103896
CD010254-bib-0307,"Tsang MB, Adams SP, Jauca C, Wright JM. ",In Some Systematic Reviews Placebos May Not Be Necessary: An Example From a Statin Dose‐Response Study,,2002,,    ,['citation-other']," Tsang MB, Adams SP, Jauca C, Wright JM. In Some Systematic Reviews Placebos May Not Be Necessary: An Example From a Statin Dose‐Response Study. 10th Cochrane Colloquium Abstracts; 2002 31 Jul‐3 Aug; Stavanger, Norway. 2002:Poster 29.    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=In+Some+Systematic+Reviews+Placebos+May+Not+Be+Necessary:+An+Example+From+a+Statin+Dose‐Response+Study+&author=MB+Tsang&author=SP+Adams&author=C+Jauca&author=JM+Wright&publication_year=2002&hl=en'],,, Tsang 2002 ,additional,CD010254-bbs2-0198,,,,,,,,
CD010254-bib-0308,"Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N. ",A systematic review and economic evaluation of statins for the prevention of coronary events, Health Technology Assessment ,2007,11,    ,['citation-journal']," Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N. A systematic review and economic evaluation of statins for the prevention of coronary events.  Health Technology Assessment 2007;11(14):1‐160, iii‐iv. [MEDLINE: 17408535]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.3310/hta11140', 'https://www.ncbi.nlm.nih.gov/pubmed/17408535', 'https://scholar.google.com/scholar_lookup?title=A+systematic+review+and+economic+evaluation+of+statins+for+the+prevention+of+coronary+events+&author=S+Ward&author=M+LloydJones&author=A+Pandor&author=M+Holmes&author=R+Ara&author=A+Ryan&author=W+Yeo&author=N+Payne&publication_year=2007&hl=en']",17408535,https://doi.org/10.3310/hta11140, Ward 2007 ,additional,CD010254-bbs2-0199,,17408535,,17408535,561,https://njl-admin.nihr.ac.uk/document/download/2001468,,17408535
CD010254-bib-0249,"Abid Shah M, Suleman S, Hussain Munir A. ",Comparative efficacy and safety profile of 5 MG rosuvastatin versus 10 MG rosuvastatin in patients with ischemic heart disease, Journal of Medical Sciences (Peshawar) ,2013,21,    ,['citation-journal']," Abid Shah M, Suleman S, Hussain Munir A. Comparative efficacy and safety profile of 5 MG rosuvastatin versus 10 MG rosuvastatin in patients with ischemic heart disease.  Journal of Medical Sciences (Peshawar) 2013;21:35‐9. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Comparative+efficacy+and+safety+profile+of+5+MG+rosuvastatin+versus+10+MG+rosuvastatin+in+patients+with+ischemic+heart+disease+&author=M+AbidShah&author=S+Suleman&author=A+HussainMunir&publication_year=2013&hl=en']",,, Abid 2013 {published data only}  ,awaiting_assessment,CD010254-bbs2-0140,,,,,,,,
CD010254-bib-0250,"Anagnostis P, Adamidou F, Slavakis A, Polyzos SA, Selalmatzidou D, Panagiotou A, et al. ",Comparative effect of atorvastatin and rosuvastatin on 25‐hydroxy‐Vitamin D levels in non‐diabetic patients with Dyslipidaemia: A prospective randomized open‐label pilot study, Open Cardiovascular Medicine Journal ,2014,8,    ,['citation-journal']," Anagnostis P, Adamidou F, Slavakis A, Polyzos SA, Selalmatzidou D, Panagiotou A, et al. Comparative effect of atorvastatin and rosuvastatin on 25‐hydroxy‐Vitamin D levels in non‐diabetic patients with Dyslipidaemia: A prospective randomized open‐label pilot study.  Open Cardiovascular Medicine Journal 2014;8:55‐60. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2174/1874192401408010055', 'https://www.ncbi.nlm.nih.gov/pubmed/25110531', 'https://scholar.google.com/scholar_lookup?title=Comparative+effect+of+atorvastatin+and+rosuvastatin+on+25‐hydroxy‐Vitamin+D+levels+in+non‐diabetic+patients+with+Dyslipidaemia:+A+prospective+randomized+open‐label+pilot+study+&author=P+Anagnostis&author=F+Adamidou&author=A+Slavakis&author=SA+Polyzos&author=D+Selalmatzidou&author=A+Panagiotou&publication_year=2014&hl=en']",25110531,https://doi.org/10.2174/1874192401408010055, Anagnostis 2014 {published data only}  ,awaiting_assessment,CD010254-bbs2-0141,,,25110531,25110531,27,https://opencardiovascularmedicinejournal.com/VOLUME/8/PAGE/55/PDF/,,25110531
CD010254-bib-0251,Arshad AR. ,Comparison of low‐dose rosuvastatin with atorvastatin in lipid‐lowering efficacy and safety in a high‐risk Pakistani cohort: An open‐label randomized trial,,2014,,    ,['citation-other'], Arshad AR. Comparison of low‐dose rosuvastatin with atorvastatin in lipid‐lowering efficacy and safety in a high‐risk Pakistani cohort: An open‐label randomized trial. Journal of Lipids2014. CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+low‐dose+rosuvastatin+with+atorvastatin+in+lipid‐lowering+efficacy+and+safety+in+a+high‐risk+Pakistani+cohort:+An+open‐label+randomized+trial+&author=AR+Arshad&publication_year=2014&hl=en']",,, Arshad 2014 {published data only}  ,awaiting_assessment,CD010254-bbs2-0142,,,,,,,,
CD010254-bib-0252,"Ballantyne CM, Hoogeveen RC, Raya JL, Cain VA, Palmer MK, Karlson BW, et al. ","Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high‐risk patients: Results of the GRAVITY randomized study", Atherosclerosis ,2014,232,    ,['citation-journal']," Ballantyne CM, Hoogeveen RC, Raya JL, Cain VA, Palmer MK, Karlson BW, et al. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high‐risk patients: Results of the GRAVITY randomized study.  Atherosclerosis 2014;232:86‐93. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.atherosclerosis.2013.10.022', 'https://www.ncbi.nlm.nih.gov/pubmed/24401221', 'https://scholar.google.com/scholar_lookup?title=Efficacy,+safety+and+effect+on+biomarkers+related+to+cholesterol+and+lipoprotein+metabolism+of+rosuvastatin+10+or+20+mg+plus+ezetimibe+10+mg+vs.+simvastatin+40+or+80+mg+plus+ezetimibe+10+mg+in+high‐risk+patients:+Results+of+the+GRAVITY+randomized+study+&author=CM+Ballantyne&author=RC+Hoogeveen&author=JL+Raya&author=VA+Cain&author=MK+Palmer&author=BW+Karlson&publication_year=2014&hl=en']",24401221,https://doi.org/10.1016/j.atherosclerosis.2013.10.022, Ballantyne 2014 {published data only}  ,awaiting_assessment,CD010254-bbs2-0143,,,,,,,,24401221
CD010254-bib-0253,"Capoulade R, Clavel MA, Dumesnil JG, Chan KL, Teo KK, Tam JW, et al. ",Insulin resistance and LVH progression in patients with calcific aortic stenosis: A substudy of the ASTRONOMER trial, JACC: Cardiovascular Imaging ,2013,6,    ,['citation-journal']," Capoulade R, Clavel MA, Dumesnil JG, Chan KL, Teo KK, Tam JW, et al. Insulin resistance and LVH progression in patients with calcific aortic stenosis: A substudy of the ASTRONOMER trial.  JACC: Cardiovascular Imaging 2013;6:165‐74. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/23489530', 'https://scholar.google.com/scholar_lookup?title=Insulin+resistance+and+LVH+progression+in+patients+with+calcific+aortic+stenosis:+A+substudy+of+the+ASTRONOMER+trial+&author=R+Capoulade&author=MA+Clavel&author=JG+Dumesnil&author=KL+Chan&author=KK+Teo&author=JW+Tam&publication_year=2013&hl=en']",23489530,, Capoulade 2013 {published data only}  ,awaiting_assessment,CD010254-bbs2-0144,,,23489530,,,,,23489530
CD010254-bib-0254,"Capoulade R, Cote N, Mathieu P, Chan KL, Clavel MA, Dumesnil JG, et al. ",Circulating levels of matrix gla protein and progression of aortic stenosis: a substudy of the Aortic Stenosis Progression Observation: Measuring Effects of rosuvastatin (ASTRONOMER) trial, Canadian Journal of Cardiology ,2014,30,    ,['citation-journal']," Capoulade R, Cote N, Mathieu P, Chan KL, Clavel MA, Dumesnil JG, et al. Circulating levels of matrix gla protein and progression of aortic stenosis: a substudy of the Aortic Stenosis Progression Observation: Measuring Effects of rosuvastatin (ASTRONOMER) trial.  Canadian Journal of Cardiology 2014;30:1088‐95. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.cjca.2014.03.025', 'https://www.ncbi.nlm.nih.gov/pubmed/25015689', 'https://scholar.google.com/scholar_lookup?title=Circulating+levels+of+matrix+gla+protein+and+progression+of+aortic+stenosis:+a+substudy+of+the+Aortic+Stenosis+Progression+Observation:+Measuring+Effects+of+rosuvastatin+(ASTRONOMER)+trial+&author=R+Capoulade&author=N+Cote&author=P+Mathieu&author=KL+Chan&author=MA+Clavel&author=JG+Dumesnil&publication_year=2014&hl=en']",25015689,https://doi.org/10.1016/j.cjca.2014.03.025, Capoulade 2014 {published data only}  ,awaiting_assessment,CD010254-bbs2-0145,,,25015689,,,,,25015689
CD010254-bib-0255,"Daida H, Nohara R, Hata M, Kaku K, Kawamori R, Kishimoto J, et al. ",Can intensive lipid‐lowering therapy improve the carotid Intima‐media thickness in Japanese subjects under primary prevention for cardiovascular disease?: The JART and JART extension subanalysis, Journal of Atherosclerosis and Thrombosis ,2014,21,    ,['citation-journal']," Daida H, Nohara R, Hata M, Kaku K, Kawamori R, Kishimoto J, et al. Can intensive lipid‐lowering therapy improve the carotid Intima‐media thickness in Japanese subjects under primary prevention for cardiovascular disease?: The JART and JART extension subanalysis.  Journal of Atherosclerosis and Thrombosis 2014;21:739‐54. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.5551/jat.19109', 'https://www.ncbi.nlm.nih.gov/pubmed/24953046', 'https://scholar.google.com/scholar_lookup?title=Can+intensive+lipid‐lowering+therapy+improve+the+carotid+Intima‐media+thickness+in+Japanese+subjects+under+primary+prevention+for+cardiovascular+disease?:+The+JART+and+JART+extension+subanalysis+&author=H+Daida&author=R+Nohara&author=M+Hata&author=K+Kaku&author=R+Kawamori&author=J+Kishimoto&publication_year=2014&hl=en']",24953046,https://doi.org/10.5551/jat.19109, Daida 2014 {published data only}  ,awaiting_assessment,CD010254-bbs2-0146,,,24953046,,,,,24953046
CD010254-bib-0256,"Davidson MH, Phillips AK, Kling D, Maki KC. ",Addition of omega‐3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia, Expert Review of Cardiovascular Therapy ,2014,12,    ,['citation-journal']," Davidson MH, Phillips AK, Kling D, Maki KC. Addition of omega‐3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia.  Expert Review of Cardiovascular Therapy 2014;12:1045‐54. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1586/14779072.2014.942640', 'https://www.ncbi.nlm.nih.gov/pubmed/25089906', 'https://scholar.google.com/scholar_lookup?title=Addition+of+omega‐3+carboxylic+acids+to+statin+therapy+in+patients+with+persistent+hypertriglyceridemia+&author=MH+Davidson&author=AK+Phillips&author=D+Kling&author=KC+Maki&publication_year=2014&hl=en']",25089906,https://doi.org/10.1586/14779072.2014.942640, Davidson 2014 {published data only}  ,awaiting_assessment,CD010254-bbs2-0147,,25089906,,,,,,25089906
CD010254-bib-0257,"Deguchi I, Horiuchi Y, Hayashi T, Sehara Y, Kato Y, Ohe Y, et al. ",Effects of Rosuvastatin on Serum Lipids and Arteriosclerosis in Dyslipidemic Patients with Cerebral Infarction, Journal of Stroke & Cerebrovascular Diseases ,2014,23,    ,['citation-journal']," Deguchi I, Horiuchi Y, Hayashi T, Sehara Y, Kato Y, Ohe Y, et al. Effects of Rosuvastatin on Serum Lipids and Arteriosclerosis in Dyslipidemic Patients with Cerebral Infarction.  Journal of Stroke & Cerebrovascular Diseases 2014;23:2007‐11. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.02.028', 'https://scholar.google.com/scholar_lookup?title=Effects+of+Rosuvastatin+on+Serum+Lipids+and+Arteriosclerosis+in+Dyslipidemic+Patients+with+Cerebral+Infarction+&author=I+Deguchi&author=Y+Horiuchi&author=T+Hayashi&author=Y+Sehara&author=Y+Kato&author=Y+Ohe&publication_year=2014&hl=en']",,https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.02.028, Deguchi 2014 {published data only}  ,awaiting_assessment,CD010254-bbs2-0148,,,25066602,25066602,8,,,25066602
CD010254-bib-0258,"Florentin M, Liberopoulos EN, Rizos CV, Kei AA, Liamis G, Kostapanos MS, et al. ",Colesevelam plus rosuvastatin 5mg/day versus rosuvastatin 10mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose, Metabolic Syndrome & Related Disorders ,2013,11,    ,['citation-journal']," Florentin M, Liberopoulos EN, Rizos CV, Kei AA, Liamis G, Kostapanos MS, et al. Colesevelam plus rosuvastatin 5mg/day versus rosuvastatin 10mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose.  Metabolic Syndrome & Related Disorders 2013;11:152‐6. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1089/met.2012.0103', 'https://scholar.google.com/scholar_lookup?title=Colesevelam+plus+rosuvastatin+5mg/day+versus+rosuvastatin+10mg/day+alone+on+markers+of+insulin+resistance+in+patients+with+hypercholesterolemia+and+impaired+fasting+glucose+&author=M+Florentin&author=EN+Liberopoulos&author=CV+Rizos&author=AA+Kei&author=G+Liamis&author=MS+Kostapanos&publication_year=2013&hl=en']",,https://doi.org/10.1089/met.2012.0103, Florentin 2013a {published data only}  ,awaiting_assessment,CD010254-bbs2-0149,,,,23170931,15,,,23170931
CD010254-bib-0259,"Graziano R, Scotti L, Di Ilio E, Bucciarelli V, D'Orazio N, Aceto A, et al. ",Rosuvastatin effect on intima media thickness in adult vs elderly patients, Frontiers in Bioscience ‐ Elite ,2012,4 E,    ,['citation-journal']," Graziano R, Scotti L, Di Ilio E, Bucciarelli V, D'Orazio N, Aceto A, et al. Rosuvastatin effect on intima media thickness in adult vs elderly patients.  Frontiers in Bioscience ‐ Elite 2012;4 E:2618‐21. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.2741/e577', ""https://scholar.google.com/scholar_lookup?title=Rosuvastatin+effect+on+intima+media+thickness+in+adult+vs+elderly+patients&author=R+Graziano&author=L+Scotti&author=E+Ilio&author=V+Bucciarelli&author=N+D'Orazio&author=A+Aceto&publication_year=2012&hl=en""]",,https://doi.org/10.2741/e577, Graziano 2012 {published data only}  ,awaiting_assessment,CD010254-bbs2-0150,,,,22652672,1,,,22652672
CD010254-bib-0260,"Jing S, Sun NL, Li XY, Hua Q, Wang L, Li Z Q, et al. ",Efficacy and safety of rosuvastatin in the treatment of hypercholesterolemia. [Chinese],,2013,,    ,['citation-other']," Jing S, Sun NL, Li XY, Hua Q, Wang L, Li Z Q, et al. Efficacy and safety of rosuvastatin in the treatment of hypercholesterolemia. [Chinese]. Chinese Journal of New Drugs2013; Vol. 22:937‐940+960. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+rosuvastatin+in+the+treatment+of+hypercholesterolemia.+[Chinese]&author=S+Jing&author=NL+Sun&author=XY+Li&author=Q+Hua&author=L+Wang&author=ZQ+Li&publication_year=2013&hl=en']",,, Jing 2013a {published data only}  ,awaiting_assessment,CD010254-bbs2-0151,,,,,,,,
CD010254-bib-0261,"Kim W, Hong MJ, Woo JS, Kang WY, Hwang SH, Kim W. ","Rosuvastatin does not affect fasting glucose, insulin resistance, or adiponectin in patients with mild to moderate hypertension",,2013,,    ,['citation-other']," Kim W, Hong MJ, Woo JS, Kang WY, Hwang SH, Kim W. Rosuvastatin does not affect fasting glucose, insulin resistance, or adiponectin in patients with mild to moderate hypertension. Chonnam Medical Journal2013; Vol. 49:31‐7. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Rosuvastatin+does+not+affect+fasting+glucose,+insulin+resistance,+or+adiponectin+in+patients+with+mild+to+moderate+hypertension+&author=W+Kim&author=MJ+Hong&author=JS+Woo&author=WY+Kang&author=SH+Hwang&author=W+Kim&publication_year=2013&hl=en']",,, Kim 2013a {published data only}  ,awaiting_assessment,CD010254-bbs2-0152,,,,,,,,
CD010254-bib-0262,"Koh KK, Quon MJ, Sakuma I, Han SH, Choi H, Lee K, et al. ",Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients, International Journal of Cardiology ,2013,166,    ,['citation-journal']," Koh KK, Quon MJ, Sakuma I, Han SH, Choi H, Lee K, et al. Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients.  International Journal of Cardiology 2013;166:509‐15. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ijcard.2011.11.028', 'https://www.ncbi.nlm.nih.gov/pubmed/22204857', 'https://scholar.google.com/scholar_lookup?title=Differential+metabolic+effects+of+rosuvastatin+and+pravastatin+in+hypercholesterolemic+patients+&author=KK+Koh&author=MJ+Quon&author=I+Sakuma&author=SH+Han&author=H+Choi&author=K+Lee&publication_year=2013&hl=en']",22204857,https://doi.org/10.1016/j.ijcard.2011.11.028, Koh 2013a {published data only}  ,awaiting_assessment,CD010254-bbs2-0153,,,22204857,,,,,22204857
CD010254-bib-0263,"Kouvelos GN, Arnaoutoglou EM, Matsagkas MI, Kostara C, Gartzonika C, Bairaktari ET, et al. ",Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study, Journal of Cardiovascular Pharmacology and Therapeutics ,2013,18,    ,['citation-journal']," Kouvelos GN, Arnaoutoglou EM, Matsagkas MI, Kostara C, Gartzonika C, Bairaktari ET, et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study.  Journal of Cardiovascular Pharmacology and Therapeutics 2013;18:5‐12. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1177/1074248412445506', 'https://www.ncbi.nlm.nih.gov/pubmed/22573476', 'https://scholar.google.com/scholar_lookup?title=Effects+of+rosuvastatin+with+or+without+ezetimibe+on+clinical+outcomes+in+patients+undergoing+elective+vascular+surgery:+results+of+a+pilot+study+&author=GN+Kouvelos&author=EM+Arnaoutoglou&author=MI+Matsagkas&author=C+Kostara&author=C+Gartzonika&author=ET+Bairaktari&publication_year=2013&hl=en']",22573476,https://doi.org/10.1177/1074248412445506, Kouvelos 2013 {published data only}  ,awaiting_assessment,CD010254-bbs2-0154,,,,22573476,33,,,22573476
CD010254-bib-0264,"Kurtoglu E, Balta S, Sincer I, Altas Y, Atas H, Yilmaz M, et al. ",Comparision of effects of rosuvastatin versus atorvastatin treatment on plasma levels of asymmetric dimethylarginine in patients with hyperlipidemia having coronary artery disease, Angiology ,2014,65,    ,['citation-journal']," Kurtoglu E, Balta S, Sincer I, Altas Y, Atas H, Yilmaz M, et al. Comparision of effects of rosuvastatin versus atorvastatin treatment on plasma levels of asymmetric dimethylarginine in patients with hyperlipidemia having coronary artery disease.  Angiology 2014;65:788‐93. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1177/0003319713507333', 'https://www.ncbi.nlm.nih.gov/pubmed/24163120', 'https://scholar.google.com/scholar_lookup?title=Comparision+of+effects+of+rosuvastatin+versus+atorvastatin+treatment+on+plasma+levels+of+asymmetric+dimethylarginine+in+patients+with+hyperlipidemia+having+coronary+artery+disease+&author=E+Kurtoglu&author=S+Balta&author=I+Sincer&author=Y+Altas&author=H+Atas&author=M+Yilmaz&publication_year=2014&hl=en']",24163120,https://doi.org/10.1177/0003319713507333, Kurtoglu 2014 {published data only}  ,awaiting_assessment,CD010254-bbs2-0155,,,24163120,24163120,15,,,24163120
CD010254-bib-0265,"Lee HK, Hu M, Lui SS, Ho CS, Wong CK, Tomlinson B. ","Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients", Pharmacogenomics ,2013,14,    ,['citation-journal']," Lee HK, Hu M, Lui SS, Ho CS, Wong CK, Tomlinson B. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.  Pharmacogenomics 2013;14:1283‐94. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2217/pgs.13.115', 'https://www.ncbi.nlm.nih.gov/pubmed/23930675', 'https://scholar.google.com/scholar_lookup?title=Effects+of+polymorphisms+in+ABCG2,+SLCO1B1,+SLC10A1+and+CYP2C9/19+on+plasma+concentrations+of+rosuvastatin+and+lipid+response+in+Chinese+patients+&author=HK+Lee&author=M+Hu&author=SS+Lui&author=CS+Ho&author=CK+Wong&author=B+Tomlinson&publication_year=2013&hl=en']",23930675,https://doi.org/10.2217/pgs.13.115, Lee 2013 {published data only}  ,awaiting_assessment,CD010254-bbs2-0156,,23930675,23930675,23930675,100,,,23930675
CD010254-bib-0266,"Liberopoulos EN, Moutzouri E, Rizos CV, Barkas F, Liamis G, Elisaf MS. ","Effects of manidipine plus rosuvastatin versus olmesartan plus rosuvastatin on markers of insulin resistance in patients with impaired fasting glucose, hypertension, and mixed dyslipidemia", Journal of Cardiovascular Pharmacology & Therapeutics ,2013,18,    ,['citation-journal']," Liberopoulos EN, Moutzouri E, Rizos CV, Barkas F, Liamis G, Elisaf MS. Effects of manidipine plus rosuvastatin versus olmesartan plus rosuvastatin on markers of insulin resistance in patients with impaired fasting glucose, hypertension, and mixed dyslipidemia.  Journal of Cardiovascular Pharmacology & Therapeutics 2013;18:113‐8. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1177/1074248412463611', 'https://scholar.google.com/scholar_lookup?title=Effects+of+manidipine+plus+rosuvastatin+versus+olmesartan+plus+rosuvastatin+on+markers+of+insulin+resistance+in+patients+with+impaired+fasting+glucose,+hypertension,+and+mixed+dyslipidemia+&author=EN+Liberopoulos&author=E+Moutzouri&author=CV+Rizos&author=F+Barkas&author=G+Liamis&author=MS+Elisaf&publication_year=2013&hl=en']",,https://doi.org/10.1177/1074248412463611, Liberopoulos 2013a {published data only}  ,awaiting_assessment,CD010254-bbs2-0157,,23113965,23113965,23113965,7,https://journals.sagepub.com/doi/pdf/10.1177/1074248412463611,,23113965
CD010254-bib-0267,"McGuire TR, Kalil AC, Dobesh PP, Klepser DG, Olsen KM. ",Anti‐inflammatory effects of rosuvastatin in healthy subjects: A prospective longitudinal study, Current Pharmaceutical Design ,2014,20,    ,['citation-journal']," McGuire TR, Kalil AC, Dobesh PP, Klepser DG, Olsen KM. Anti‐inflammatory effects of rosuvastatin in healthy subjects: A prospective longitudinal study.  Current Pharmaceutical Design 2014;20:1156‐60. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2174/1381612820666140127163313', 'https://www.ncbi.nlm.nih.gov/pubmed/24467235', 'https://scholar.google.com/scholar_lookup?title=Anti‐inflammatory+effects+of+rosuvastatin+in+healthy+subjects:+A+prospective+longitudinal+study+&author=TR+McGuire&author=AC+Kalil&author=PP+Dobesh&author=DG+Klepser&author=KM+Olsen&publication_year=2014&hl=en']",24467235,https://doi.org/10.2174/1381612820666140127163313, McGuire 2014 {published data only}  ,awaiting_assessment,CD010254-bbs2-0158,,24467235,24467235,24467235,14,,,24467235
CD010254-bib-0268,"Mori H, Okada Y, Tanaka Y. ","Effects of pravastatin, atorvastatin, and rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia",,2013,,    ,['citation-other']," Mori H, Okada Y, Tanaka Y. Effects of pravastatin, atorvastatin, and rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia. Diabetology International2013; Vol. 4:117‐25. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effects+of+pravastatin,+atorvastatin,+and+rosuvastatin+in+patients+with+type+2+diabetes+mellitus+and+hypercholesterolemia+&author=H+Mori&author=Y+Okada&author=Y+Tanaka&publication_year=2013&hl=en']",,, Mori 2013a {published data only}  ,awaiting_assessment,CD010254-bbs2-0159,,,,,,,,
CD010254-bib-0269,"Moutzouri E, Liberopoulos EN, Tellis CC, Milionis HJ, Tselepis AD, Elisaf MS. ",Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia, Atherosclerosis ,2013,231,    ,['citation-journal']," Moutzouri E, Liberopoulos EN, Tellis CC, Milionis HJ, Tselepis AD, Elisaf MS. Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia.  Atherosclerosis 2013;231:8‐14. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.atherosclerosis.2013.08.013', 'https://www.ncbi.nlm.nih.gov/pubmed/24125402', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+the+effect+of+simvastatin+versus+simvastatin/ezetimibe+versus+rosuvastatin+on+markers+of+inflammation+and+oxidative+stress+in+subjects+with+hypercholesterolemia+&author=E+Moutzouri&author=EN+Liberopoulos&author=CC+Tellis&author=HJ+Milionis&author=AD+Tselepis&author=MS+Elisaf&publication_year=2013&hl=en']",24125402,https://doi.org/10.1016/j.atherosclerosis.2013.08.013, Moutzouri 2013 {published data only}  ,awaiting_assessment,CD010254-bbs2-0160,,,,24125402,50,,,24125402
CD010254-bib-0270,"Nohara R, Daida H, Hata M, Kaku K, Kawamori R, Kishimoto J, et al. ",Effect of long‐term intensive lipid‐lowering therapy with rosuvastatin on progression of carotid intima‐media thickness‐‐Justification for Atherosclerosis Regression Treatment (JART) extension study, Circulation Journal ,2013,77,    ,['citation-journal']," Nohara R, Daida H, Hata M, Kaku K, Kawamori R, Kishimoto J, et al. Effect of long‐term intensive lipid‐lowering therapy with rosuvastatin on progression of carotid intima‐media thickness‐‐Justification for Atherosclerosis Regression Treatment (JART) extension study.  Circulation Journal 2013;77:1526‐33. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1253/circj.CJ-12-1149', 'https://www.ncbi.nlm.nih.gov/pubmed/23486191', 'https://scholar.google.com/scholar_lookup?title=Effect+of+long‐term+intensive+lipid‐lowering+therapy+with+rosuvastatin+on+progression+of+carotid+intima‐media+thickness‐‐Justification+for+Atherosclerosis+Regression+Treatment+(JART)+extension+study+&author=R+Nohara&author=H+Daida&author=M+Hata&author=K+Kaku&author=R+Kawamori&author=J+Kishimoto&publication_year=2013&hl=en']",23486191,https://doi.org/10.1253/circj.CJ-12-1149, Nohara 2013 {published data only}  ,awaiting_assessment,CD010254-bbs2-0161,,,23486191,23486191,30,https://www.jstage.jst.go.jp/article/circj/77/6/77_CJ-12-1149/_pdf,,23486191
CD010254-bib-0271,"Sharma A, Joshi PH, Rinehart S, Thakker KM, Lele A, Voros S. ","Baseline very low‐density lipoprotein cholesterol is associated with the magnitude of triglyceride lowering on statins, fenofibric acid, or their combination in patients with mixed dyslipidemia", Journal of Cardiovascular Translational Research ,2014,7,    ,['citation-journal']," Sharma A, Joshi PH, Rinehart S, Thakker KM, Lele A, Voros S. Baseline very low‐density lipoprotein cholesterol is associated with the magnitude of triglyceride lowering on statins, fenofibric acid, or their combination in patients with mixed dyslipidemia.  Journal of Cardiovascular Translational Research 2014;7:465‐74. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1007/s12265-014-9559-3', 'https://www.ncbi.nlm.nih.gov/pubmed/24723075', 'https://scholar.google.com/scholar_lookup?title=Baseline+very+low‐density+lipoprotein+cholesterol+is+associated+with+the+magnitude+of+triglyceride+lowering+on+statins,+fenofibric+acid,+or+their+combination+in+patients+with+mixed+dyslipidemia+&author=A+Sharma&author=PH+Joshi&author=S+Rinehart&author=KM+Thakker&author=A+Lele&author=S+Voros&publication_year=2014&hl=en']",24723075,https://doi.org/10.1007/s12265-014-9559-3, Sharma 2014 {published data only}  ,awaiting_assessment,CD010254-bbs2-0162,,24723075,,24723075,16,,,24723075
CD010254-bib-0272,"Takase B, Hattori H, Tanaka Y, Nagata M, Ishihara M. ",Anti‐sympathetic action enhances statin's pleiotropic effects: The combined effect of rosuvastatin and atenolol on endothelial function, International Angiology ,2014,33,    ,['citation-journal']," Takase B, Hattori H, Tanaka Y, Nagata M, Ishihara M. Anti‐sympathetic action enhances statin's pleiotropic effects: The combined effect of rosuvastatin and atenolol on endothelial function.  International Angiology 2014;33:27‐34. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/24452083', ""https://scholar.google.com/scholar_lookup?title=Anti‐sympathetic+action+enhances+statin's+pleiotropic+effects:+The+combined+effect+of+rosuvastatin+and+atenolol+on+endothelial+function+&author=B+Takase&author=H+Hattori&author=Y+Tanaka&author=M+Nagata&author=M+Ishihara&publication_year=2014&hl=en""]",24452083,, Takase 2014 {published data only}  ,awaiting_assessment,CD010254-bbs2-0163,,24452083,24452083,,,,,24452083
CD010254-bib-0273,"Wang P, Liu Y, Wang Z, Zhao N, Ye H, Ren L. ",Effects of rosuvastatin on arterial stiffness in hyperlipidemia patients. [Chinese], National Medical Journal of China ,2014,94,    ,['citation-journal']," Wang P, Liu Y, Wang Z, Zhao N, Ye H, Ren L. Effects of rosuvastatin on arterial stiffness in hyperlipidemia patients. [Chinese].  National Medical Journal of China 2014;94:2452‐4. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/25400055', 'https://scholar.google.com/scholar_lookup?title=Effects+of+rosuvastatin+on+arterial+stiffness+in+hyperlipidemia+patients.+[Chinese]&author=P+Wang&author=Y+Liu&author=Z+Wang&author=N+Zhao&author=H+Ye&author=L+Ren&publication_year=2014&hl=en']",25400055,, Wang 2014 {published data only}  ,awaiting_assessment,CD010254-bbs2-0164,,,,,,,,25400055
CD010254-bib-0274,"Weinstein DL, Williams LA, Carlson DM, Kelly MT, Burns KM, Setze CM, et al. ","A randomized, double‐blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.[Erratum appears in Clin Ther. 2013 Nov;35(11):1862]", Clinical therapeutics ,2013,35,    ,['citation-journal']," Weinstein DL, Williams LA, Carlson DM, Kelly MT, Burns KM, Setze CM, et al. A randomized, double‐blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.[Erratum appears in Clin Ther. 2013 Nov;35(11):1862].  Clinical therapeutics 2013;35:1186‐98. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.clinthera.2013.06.013', 'https://www.ncbi.nlm.nih.gov/pubmed/23891363', 'https://scholar.google.com/scholar_lookup?title=A+randomized,+double‐blind+study+of+fenofibric+acid+plus+rosuvastatin+compared+with+rosuvastatin+alone+in+stage+3+chronic+kidney+disease.[Erratum+appears+in+Clin+Ther.+2013+Nov;35(11):1862]+&author=DL+Weinstein&author=LA+Williams&author=DM+Carlson&author=MT+Kelly&author=KM+Burns&author=CM+Setze&publication_year=2013&hl=en']",23891363,https://doi.org/10.1016/j.clinthera.2013.06.013, Weinstein 2013a {published data only}  ,awaiting_assessment,CD010254-bbs2-0165,,,,23891363,11,,,23891363
CD010254-bib-0275,"Wu H, Han YL, Wang XZ, Li Y, Xu K, Li J, et al. ",Effects of short‐term rosuvastatin therapy on heart and kidney function in patients with acute coronary syndrome combining diabetes mellitus and concomitant chronic kidney disease. [Chinese], Medical Journal of Chinese People's Liberation Army ,2014,39,    ,['citation-journal']," Wu H, Han YL, Wang XZ, Li Y, Xu K, Li J, et al. Effects of short‐term rosuvastatin therapy on heart and kidney function in patients with acute coronary syndrome combining diabetes mellitus and concomitant chronic kidney disease. [Chinese].  Medical Journal of Chinese People's Liberation Army 2014;39:546‐52. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effects+of+short‐term+rosuvastatin+therapy+on+heart+and+kidney+function+in+patients+with+acute+coronary+syndrome+combining+diabetes+mellitus+and+concomitant+chronic+kidney+disease.+[Chinese]+&author=H+Wu&author=YL+Han&author=XZ+Wang&author=Y+Li&author=K+Xu&author=J+Li&publication_year=2014&hl=en']",,, Wu 2014 {published data only}  ,awaiting_assessment,CD010254-bbs2-0166,,,,,,,,
CD010254-bib-0276,"Yamazaki T, Nohara R, Daida H, Hata M, Kaku K, Kawamori R, et al. ",Intensive Lipid‐Lowering Therapy for Slowing Progression as Well as Inducing Regression of Atherosclerosis in Japanese Patients Subanalysis of the JART Study, International Heart Journal ,2013,54,    ,['citation-journal']," Yamazaki T, Nohara R, Daida H, Hata M, Kaku K, Kawamori R, et al. Intensive Lipid‐Lowering Therapy for Slowing Progression as Well as Inducing Regression of Atherosclerosis in Japanese Patients Subanalysis of the JART Study.  International Heart Journal 2013;54:33‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1536/ihj.54.33', 'https://www.ncbi.nlm.nih.gov/pubmed/23428922', 'https://scholar.google.com/scholar_lookup?title=Intensive+Lipid‐Lowering+Therapy+for+Slowing+Progression+as+Well+as+Inducing+Regression+of+Atherosclerosis+in+Japanese+Patients+Subanalysis+of+the+JART+Study+&author=T+Yamazaki&author=R+Nohara&author=H+Daida&author=M+Hata&author=K+Kaku&author=R+Kawamori&publication_year=2013&hl=en']",23428922,https://doi.org/10.1536/ihj.54.33, Yamazaki 2013 {published data only}  ,awaiting_assessment,CD010254-bbs2-0167,,,23428922,23428922,25,https://www.jstage.jst.go.jp/article/ihj/54/1/54_33/_pdf,,23428922
CD010254-bib-0277,"Yogo M, Sasaki M, Ayaori M, Kihara T, Sato H, Takiguchi S, et al. ",Intensive lipid lowering therapy with titrated rosuvastatin yields greater atherosclerotic aortic plaque regression: Serial magnetic resonance imaging observations from RAPID study, Atherosclerosis ,2014,232,    ,['citation-journal']," Yogo M, Sasaki M, Ayaori M, Kihara T, Sato H, Takiguchi S, et al. Intensive lipid lowering therapy with titrated rosuvastatin yields greater atherosclerotic aortic plaque regression: Serial magnetic resonance imaging observations from RAPID study.  Atherosclerosis 2014;232:31‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.atherosclerosis.2013.10.007', 'https://www.ncbi.nlm.nih.gov/pubmed/24401214', 'https://scholar.google.com/scholar_lookup?title=Intensive+lipid+lowering+therapy+with+titrated+rosuvastatin+yields+greater+atherosclerotic+aortic+plaque+regression:+Serial+magnetic+resonance+imaging+observations+from+RAPID+study+&author=M+Yogo&author=M+Sasaki&author=M+Ayaori&author=T+Kihara&author=H+Sato&author=S+Takiguchi&publication_year=2014&hl=en']",24401214,https://doi.org/10.1016/j.atherosclerosis.2013.10.007, Yogo 2014 {published data only}  ,awaiting_assessment,CD010254-bbs2-0168,,,24401214,24401214,23,,,24401214
CD010254-bib-0278,"Yokoi H, Nohara R, Daida H, Hata M, Kaku K, Kawamori R, et al. ",Change in carotid intima‐media thickness in a high‐risk group of patients by intensive lipid‐lowering therapy with rosuvastatin: subanalysis of the JART study, International Heart Journal ,2014,55,    ,['citation-journal']," Yokoi H, Nohara R, Daida H, Hata M, Kaku K, Kawamori R, et al. Change in carotid intima‐media thickness in a high‐risk group of patients by intensive lipid‐lowering therapy with rosuvastatin: subanalysis of the JART study.  International Heart Journal 2014;55:146‐52. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1536/ihj.13-216', 'https://www.ncbi.nlm.nih.gov/pubmed/24632963', 'https://scholar.google.com/scholar_lookup?title=Change+in+carotid+intima‐media+thickness+in+a+high‐risk+group+of+patients+by+intensive+lipid‐lowering+therapy+with+rosuvastatin:+subanalysis+of+the+JART+study+&author=H+Yokoi&author=R+Nohara&author=H+Daida&author=M+Hata&author=K+Kaku&author=R+Kawamori&publication_year=2014&hl=en']",24632963,https://doi.org/10.1536/ihj.13-216, Yokoi 2014 {published data only}  ,awaiting_assessment,CD010254-bbs2-0169,,,,24632963,21,https://www.jstage.jst.go.jp/article/ihj/55/2/55_13-216/_pdf,,24632963
CD010254-bib-0309,"Adams SP, Wright JM. ",Lipid lowering efficacy of rosuvastatin, Cochrane Database of Systematic Reviews ,2012,,    ,['citation-journal']," Adams SP, Wright JM. Lipid lowering efficacy of rosuvastatin.  Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD010254]    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Lipid+lowering+efficacy+of+rosuvastatin&author=SP+Adams&author=JM+Wright&publication_year=2012&hl=en'],,, Adams 2012b ,other_versions,CD010254-bbs2-0200,,37721222,,,,,,37721222
